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1. Air conduction hearing
Vibrating	particles	of	a	medium	such	as	air	produces	sound.	Vibration	of	air	molecules	
causes	other	nearby	air	particles	to	vibrate	as	well,	resulting	in	sound	propagation.	At	
room	temperature	 the	 speed	of	 sound	 in	dry	air	 is	 343	m/s.	 Sound	vibrations	are	
represented	by	a	longitudinal	wave	(sinus)	of	which	its	frequency	and	amplitude	are	
the	most	important	characteristics.	The	frequency	is	the	number	of	vibration	cycles	
per second, expressed in Hertz (Hz), which determines the pitch of the sound. The 
amplitude is the maximum displacement, which determines the intensity of the 
sound, expressed in decibels (dB). The human ear transforms airborne sound into 
nerve	signals	that	are	transmitted	by	the	auditory	nerve	to	the	auditory	system	of	the	
brain. We consider three components of the ear: the outer ear, the middle ear, and 
the inner ear, as illustrated by Figure 1.
The outer ear is composed of the pinna and the external auditory canal. These two 




tympanic membrane, then through the incus to the stapes. The stapes is connected 




the	higher	acoustical	 impedance	of	fluid	 compared	 to	air,	 a	 lot	of	acoustic	energy	
would	 be	 lost	 if	 the	 airborne	 sound	 directly	 stimulated	 the	 oval	 window.	 This	
emphasizes the important role of the middle ear as an impedance transformer. First, 
this	 is	effected	by	the	area	ratio	between	the	tympanic	membrane	and	the	stapes	
footplate;	as	the	tympanic	membrane	is	about	20	times	larger	than	the	footplate,	the	
force per unit area is 20 dB higher on the footplate than on the tympanic membrane. 
Second,	 the	 lever	 function	of	 the	malleus-incus	 joint	 as	 a	 result	 of	 a	difference	 in	
length	of	articulating	parts	results	in	less	movement	but	more	force.	The	fluid	motion	
in the inner ear then travels as a longitudinal wave through the cochlea, the snail-
shell-formed	portion	of	the	inner	ear,	where	this	motion	is	transformed	into	nerve	
signals.	 The	 cochlea	 consists	of	 three	 rolled-up	 compartments:	 the	 scala	 vestibuli,	
scala media, and scala tympani (see Figure 2).





















the apex of the cochlea (helicotrema). The middle channel is the scala media, 
separated	 from	the	scala	vestibuli	by	Reissner’s	membrane	 (vestibular	membrane)	














2. Bone conduction hearing
In	addition	to	hearing	by	means	of	airborne	sound	(air	conduction,	AC),	sound	can	
also	 be	 perceived	 by	 bone	 conduction	 (BC)	 through	 vibrations	 of	 the	 skull.	 After	





to	BC	of	 sound	 is	 still	 not	 clear.	 Extensive	 research	by	 Tonndorf2 has led to seven 
possible	 contributing	 factors	 in	 BC	 hearing.	 Stenfelt	 and	Goode3 elaborated these 
theories	 and	 provided	 an	 updated	 review	 of	 the	 four	 most	 significant	 factors	
contributing	to	BC	hearing,	which	are	discussed	below	based	on	that	overview.
2.1. Sound radiated in the external auditory canal
Vibration	of	the	skull	as	a	consequence	of	BC	stimulation	causes	the	skull	to	radiate	
sound	 in	 the	air.	 Likewise,	 radiation	by	 the	external	auditory	 canal	walls	produces	
sound in the ear canal. This sound is picked up by the tympanic membrane and 
transmitted	to	the	cochlea	the	same	way	as	AC	sound.	This	effect	is	only	significant	
when the entrance of the ear canal is blocked and it dominates BC hearing for lower 
frequencies	(0.4-1.2	kHz),	however	only	if	the	middle	ear	works	properly.
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2.2. Middle ear ossicle inertia
The middle ear ossicles are suspended in the middle ear cavity by several ligaments, 
muscle tendons, and the tympanic membrane. From a mechanical viewpoint, these 
ligaments and tendons act as springs, holding the ossicles in place. When the skull 




2.3. Inertia of the cochlear fluid
The	incompressible	cochlear	fluid	is	subject	to	inertial	forces	when	the	skull	vibrates	
due	to	BC	stimulation.	Flow	of	this	fluid	through	the	cochlea	is	allowed	by	compliance	
of the oval and round window and results in a movement from one membrane to the 
other,	stimulating	the	basilar	membrane.	Fluid	inertia	is	considered	to	be	the	most	
important	contributor	to	BC	hearing,	especially	in	frequencies	below	4	kHz.







Hearing loss can be divided into three types: sensorineural hearing loss (SNHL), 
conductive	 hearing	 loss	 (CHL),	 and	 mixed	 hearing	 loss	 (MHL).	 SNHL	 is	 caused	 by	
dysfunction	 of	 the	 inner	 ear,	 the	 vestibulocochlear	 nerve,	 or	 central	 processing	
centers	of	the	brain.	CHL	is	caused	by	dysfunction	or	absence	of	outer	and/or	middle	
ear	 structures	 and	 function,	 resulting	 in	 interruption	 of	 the	 physiological	 sound	
conduction	pathway	from	the	outside	to	the	inner	ear.	MHL	is	defined	as	a	combination	 
of both SNHL and CHL. Furthermore, each type of hearing loss can either be of 
congenital	origin	or	can	be	acquired	at	any	moment	during	 life.	The	extent	of	 the	

























from	 the	 previous	 paragraphs	 that	 patients	with	 CHL	 or	MHL	 and	 relatively	 good	
cochlear	 function	 may	 benefit	 from	 hearing	 amplification	 that	 applies	 BC	 sound	
transmission.	Bone	conduction	devices	 (BCDs)	are	also	an	option	 for	patients	who	
cannot	 use	 conventional	 air	 conduction	 hearing	 aids	 (ACHAs)	 due	 to	 chronic	 ear	
infections	caused	by	the	blocking	of	the	external	ear	canal	by	the	inevitable	earmold	
of	 such	 devices.	 Also	 for	 patients	with	 aural	 atresia	 or	microtia,	which	 implies	 an	
aberrance or absence of the external auditory canal, pinna and/or middle ear ossicles, 
yet,	usually	a	good	cochlear	function,	a	BCD	provides	a	resolution.
4.1. History of bone conduction devices
Berger4 and Mudry and Tjellström5 provided elaborate historical overviews of the 
development	of	BCDs	through	the	ages.	 It	has	at	 least	been	known	since	Antiquity	
that hearing is also possible through BC of sound. This concept was further studied 
during	the	Renaissance,	through	stimulation	at	the	teeth.	This	led	to	the	first	BCDs	
that were applied to the teeth in the 19th	 century.	When	 conductive	 hearing	 loss	
began	 being	 formally	 diagnosed	 and	 the	 carbon	 microphone	 and	 the	 magnetic	
receiver (or earphone) were developed at the beginning of the 20th	century,	the	first	
BCDs that were applied at the mastoid bone on a steel headband were developed. 





by the drawbacks of these “old-fashioned” transcutaneous (i.e., BC through intact skin) 
BCDs	worn	on	headbands	or	eyeglasses,	such	as	soft	tissue	irritation	due	to	pressure,	poor	
quality	of	the	transmitted	sound,	and	unfavorable	cosmetics,	Tjellström,	Håkansson,	






implanted with the system in 1977. From that moment on a lot of research has been 
conducted.	Benefit	from	an	audiological	point	of	view	was	established.9 It was studied 
that	 the	 percutaneous	 application	 of	 BC	 should	 theoretically	 be	 10–20	 dB	 more	
18
effective	in	terms	of	amplification	than	transcutaneous	application.10	After	promising	
outcomes	 of	 the	 first	 ten	 years	 of	 clinical	 application	 of	 the	 BAHA	 under	 strict	
conditions,11	it	became	commercially	available.	In	1988,	the	first	patient	in	our	clinic	
was implanted with the system by Cremers. In the past 27 years, this has resulted in 
over	1600	patients	receiving	treatment	by	means	of	a	percutaneously	applied	BCD	in	
Nijmegen.
Over the last decades, the BAHA has become increasingly applied in a growing 
number of clinics all over the world. More than 150.000 people from all over the 
world	have	been	treated	with	this	hearing	solution.	Nowadays,	the	term	“BAHA”	is	
not accepted terminology anymore for these kind of percutaneously applied BCDs, 
due to copyright reasons, as it refers to the Baha system marketed by Cochlear Bone 
Anchored	Solutions	AB	 (Mölnlycke,	Sweden).	Another	company	developed	 its	own	
percutaneous	BCD	system	more	recently:	the	Ponto	system	was	released	by	Oticon	
Medical AB (Askim, Sweden) in 2009. Therefore, the terminology used in this thesis is 
bone-anchored	hearing	implant	(BAHI)	when	referring	specifically	to	the	implant	and	
bone	conduction	device	(BCD)	when	referring	specifically	to	the	sound	processor.




Figure 3  The three components of the BAHA system: the implant, the 
percutaneous	abutment,	and	the	vibrating	sound	processor.	Specifically,	 




















between ACHAs, percutaneous BCDs, and transcutaneous BCDs showed resemblance 
in	 mean	 functional	 gains,	 which	 was	 reported	 to	 be	 highly	 individual,11 however, 
better	 speech	 recognition	 in	 noise	 and	 subjective	 benefit	 were	 reported	 for	 the	
percutaneous BCDs.9,11,12	These	results	were	confirmed	and	even	enhanced,	as	both	
audiological	 and	 subjective	 benefit	 of	 a	 percutaneous	 BCD	 compared	 to	 an	ACHA	
were found.13,14	 Percutaneous	 BCDs	were	 found	 to	 be	more	 effective	 than	 ACHA’s	
when	the	conductive	component	of	the	total	hearing	loss	exceeds	25	to	30	dB,14 which 
was later reported to be somewhat higher, i.e., 35 dB.15	Indications	for	the	application	
of percutaneous BCDs have expanded,16	which	will	be	discussed	in	the	next	section.
4.2.1. Unilateral or bilateral application in bilateral hearing loss?
It	has	 long	been	argued	that	binaural	application	of	any	BCD	may	not	be	effective,	
because	 the	 intracranial	 attenuation	of	 skull	 vibrations	 in	decibels	 is	 so	 small	 that	
even	one	BCD	will	stimulate	both	cochleae	almost	to	the	same	extent.	However,	in	
the	1990s,	bilateral	application	of	percutaneous	BCDs	in	patients	with	bilateral	CHL	





was	 confirmed	 by	 research	 from	 our	 center18-20 and by researchers from other 
centers.21,22	 Consequently,	 bilateral	 application	was	 advised	 in	 a	 position	paper	 by	
experts on BCDs.23	Bilateral	application	was	also	studied	specifically	in	children	with	
bilateral	CHL	and	MHL	(also	termed	CMHL),	which	revealed	subjective	benefit24 and 
better	binaural	processing	 skills	 compared	 to	unilateral	 application.25	A	 systematic	
review	of	all	available	literature	on	bilateral	application	of	BCDs	for	bilateral	CMHL	
concluded	clear	benefits,	except	if	bone	conduction	thresholds	are	quite	asymmetric;	
then bilateral BCDs will likely not confer advantages associated with binaural hearing, 
such	as	localization	and	improved	speech	perception	in	noise.26	Despite	all	positive	
results,	bilateral	application	of	BCDs	still	provides	a	subject	of	discussion	for	a	few	
skeptics.27 Based on the previous, bilateral implants are placed simultaneously in our 
center,	so	patients	benefit	optimally	from	bilateral	application	of	their	BCDs.	





with	 congenital	 unilateral	 CHL.	 These	 findings	 were	 later	 corroborated	 by	 other	
studies.29,30	All	of	these	studies	found	that	several	patients	with	unilateral	CHL	showed	
remarkably	good	binaural	processing	skills	while	only	effectively	using	one	ear.	These	
findings	 were	 more	 distinct	 in	 patients	 with	 congenital	 compared	 to	 acquired	
unilateral CHL. Agterberg et al.31,32	 supported	 these	 results,	 finding	 improvement	
after	 BCD	 fitting	 in	 sound	 localization	 in	 patients	 with	 acquired	 unilateral	 CHL	 in	
contrast	 to	patients	with	congenital	unilateral	CHL.	The	 long-term	compliance	and	




BCDs	 were	 found	 to	 have	 its	 merits	 as	 a	 contralateral	 routing	 of	 signal	 (CROS)	
device.33-37	To	achieve	this	CROS	function,	the	BAHI	is	implanted	at	the	side	of	the	deaf	
ear.	This	application	does	not	rehabilitate	the	affected	ear,	as	this	 is	dysfunctional,	
but relies on the transmission of the sounds that are received by the BCD through BC 
to	 the	 normal	 functioning	 contralateral	 cochlea.	 Therefore,	 stereophonic	 hearing,	
vital	in	sound	localization	and	discrimination	of	speech	in	noise,	will	not	be	achieved.	
Nevertheless,	some	patients	with	SSD	appeared	to	be	able	to	 localize	sound	using	
monaural cues to some extent in a recent study.38	The	main	objective	of	the	CROS	




















that	 concluded	 that	 speech	 perception	 in	 noise	 and	 sound	 localization	 were	 not	
improved	 by	 the	 BCD	 CROS,	 while	 subjective	 benefit	 was	 assessed	 on	 speech	
communication.39	Therefore,	implantation	of	a	BAHI	for	SSD	should	only	be	considered	
in	motivated	patients	with	specific	listening	demands	imposed	by	their	lifestyle	and	
working environment that have experienced an extended trial period with a powerful 
enough BCD on a headband, which is known to be 5–20 dB inferior to the percutaneous 
application	 on	 the	 BAHI.40	 Varying	 percentages	 of	 patients	with	 SSD	 choosing	 for	
implantation	after	a	headband	trial	have	been	reported:	ranging	from	20%	to	63%.41-45 
These	choices	were	mostly	based	on	subjective	benefit,	as	no	significant	predictive	
factors	 could	 be	 identified.	 Recently,	 long-term	 satisfaction	 (mean	 50	 months	 of	
percutaneous	BCD	use)	was	investigated	in	44	patients	with	SSD.46 The majority of 




4.3. Evolution of sound processors
The	first	four	years	after	Tjellström	implanted	the	first	patient	with	a	percutaneous	
implant,	a	modified	Oticon	bone	conductor	was	applied	as	a	sound	processor.	The	
first	 specifically	 designed	 prototype	 of	 the	 single	 housing	 BAHA	 was	 successfully	
tested	by	Håkansson	on	a	patient	in	1981.9 Its successor, the BAHA HC200, was the 
first	sound	processor	to	become	commercially	available	in	1987.	This	processor	was	
reported	superior	to	conventional	BCDs	on	headbands	or	eyeglasses	and	comparable	
to	 the	 outcome	 of	 ACHAs	 available	 at	 that	 time	 in	 patients	 with	 CMHL	 with	 a	
sensorineural threshold of less than 45 dB,47	which	confirmed	the	initial	indications	
for	implantation	with	the	device.	For	patients	suffering	from	sensorineural	thresholds	
up to 60 dB, the more powerful “super-bass” HC220 was advocated.48	The	difference	
between the HC200 and HC220 was that the HC220 consisted of a body-worn device 
consisting	of	the	microphone	and	amplifier	that	is	connected	to	the	ear-level	vibrating	
transducer,	 while	 the	 HC200	 contained	 the	 microphone,	 amplifier,	 and	 vibrating	
transducer together in the ear-level device. The successor of the HC200, the HC300, 
which was later marketed as the Baha Classic, was released in 1991 and provided 
similar technical performance.49 In 1993, the Baha Cordelle, also a body-worn device, 
was released as the more powerful successor of the HC220.50 In 2000, the Baha 
Compact	was	introduced,	which	was	smaller	in	size	than	the	Classic	to	provide	better	
cosmetic	 appearance.	 Both	 devices	were	 able	 to	 close	 the	 air-bone	 gap,	 i.e.,	 fully	
rehabilitate a CHL. However, because the maximum output of the Compact was lower 
than	the	Classic,	this	device	was	only	advised	in	patients	with	a	mild	sensorineural	
component of their hearing loss, not exceeding 25-30 dB.23,51 The Classic was suitable 
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for	patients	with	a	SNHL	component	up	to	35	dB.23 The Cordelle provides favorable 





situations.52	 The	 Intenso,	 successor	 of	 the	 Classic	 in	 2007,	 provided	 substantially	
higher maximum output than the Divino.53 In 2009, the Divino was replaced by the 
BP100 (later renamed to Baha 3), which provided improved speech understanding in 
noise	and	better	hearing	thresholds	in	the	higher	frequencies	together	with	subjective	
benefit.54 The BP110 (later renamed to Baha 3 Power), which succeeded the Intenso, 
had	an	additional	advantage	for	speech	 in	noise.55	These	Baha	3	generation	sound	
processors have advanced signal processing technologies and provide more 
configuration	options	for	audiologists	due	to	dedicated	fitting	software.56,57
	 In	2009,	Oticon	Medical	AB	released	its	first	bone-conduction	hearing	system.	
The	first	 sound	processors	were	 the	Ponto	Pro	and	 the	more	powerfull	Ponto	Pro	
Power.	According	to	the	manufacturer,	the	Ponto	Pro	could	be	fitted	in	patients	with	
a SNHL component up to 45 dB, compared to 55 dB for the Ponto Pro Power. In a 
comparison	between	the	Ponto	Pro	and	the	Baha	BP100,	the	Ponto	Pro	yielded	better	
hearing	 results	 and	 subjective	 benefit,	 and	 was	 therefore	 the	 preferred	 sound	
processor	 in	 eight	 out	 of	 twelve	 patients	 in	 the	 test	 population.58 The Ponto Pro 
Power	was	 found	 superior	 to	 the	Baha	 Intenso,	 however,	 this	 difference	 is	 largely	
based	on	the	effectiveness	of	digital	techniques	(Ponto	Pro	Power)	relative	to	analog	
techniques	 (Baha	 Intenso).59 A comparison between the Ponto Pro Power and the 
Baha 3 Power would have been more valid in terms of a comparison between both 
manufacturers’	power	device.
	 The	 latest	generation	of	 sound	processors,	 the	Baha	4	and	5,	and	Ponto	Plus,	
have recently been introduced. However, there have not been any published data on 
these sound processors yet.
	 Besides	the	technical	evolution	of	the	sound	processors	that	resulted	in	favorable	
audiological performance, the appearance of the casing changed to become as 
inconspicuous as possible. Sizes were reduced and the casings are available in a variety 
of	colors	to	match	the	patient’s	hair	or	other	personal	preferences.
5. Implant surgery






















lead	 to	a	firmly	attached	 implant	with	minimal	 soft	tissue	 irritation	around	 it.	 The	
following paragraphs will discuss these factors. 
5.1. Osseointegration and implant surgery
In	the	early	1960s,	Brånemark	and	coworkers8 discovered that implanted screw-shaped 
titanium	chambers	that	were	used	for	long-term	in	vivo	microscopic	studies	of	bone	






in	Figure	5	(originally	published	by	Brånemark8), which are addressed in the following 
paragraph).	To	implant	a	screw-like	titanium	foreign	body	in	human	bone	tissue,	first	
a hole needs to be drilled in the bone. Obviously, this bone site cannot be made 





bone (2). Unavoidably, some surrounding bone will be damaged by thermal and 
mechanical trauma (3). During a healing period in which the implant remains unloaded 
with the abutment and/or device, hematoma transforms into new bone through 
callus	formation	(6).	Damaged	bone,	which	also	heals,	undergoes	revascularization,	
demineralization	and	remineralization.	After	this	healing	period,	vital	bone	tissue	is	in	
Figure 5  Schematic	representation	of	osseointegration.	The	numbers	within	the	
figure	are	explained	in	the	text	of	paragraph	5.1.	(Figure	originally	published	by	Brånemark8)
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close	 contact	 with	 the	 fixture	 surface,	 without	 any	 other	 intermediate	 tissue	 (8).	
Brånemark	defined	osseointegration	as	a	direct	structural	and	functional	connection	
between ordered living bone and the surface of a load-carrying implant.
	 Osseointegration	was	and	is	an	extensively	investigated	phenomenon.	In	2007,	




anchorage	 for	 different	 prostheses.	 Other	 metals	 as	 vanadium,	 tantalum,	 certain	
ceramics,	aluminum	hydroxide,	and	hydroxyapatite	are	also	known	to	integrate	into	
the bone to a certain degree. Second, the macrostructure of the implant has 
importance	for	the	 integration:	a	screw-shaped	implant	often	shows	good	primary	
stability,	 whereas	 a	 cone-shaped	 implant	 might	 be	 lost	 because	 of	 initial	 micro	
movements and hence poor stability. Third, the microstructure of the implant is also 
known	 to	 affect	osseointegration.	Numerous	 types	of	 implant	 surfaces	have	been	
studied	 in	 dental	 implantology,	 with	 different	 outcomes.61-63 This has led to an 
interesting	 remark	 by	 three	 leading	 investigators	 in	 dental	 implantology:	 “Today,	
osseo	integration	is	a	term	regarded	as	synonymous	with	clinical	success.	This	is	an	
unfortunate	misconception.	New	implant	surfaces	and	designs	are	being	produced	
and marketed at a rapid rate. What was once a careful protocol dominated by science 
and	clinical	 records	 is	 today	 replaced	by	a	 ‘car	model’	attitude	 that	 is	not	entirely	
sound. What is overlooked is the risk of secondary failures, which with some designs 
have been a common, if unwanted, result of challenging the limits of biology.”64 




who have been irradiated or who sustained burns will have an altered texture of bone 
that will reduce the capacity to integrate implants.66	Fifth,	the	surgical	technique	is	of	
major	 importance.	 It	 is	 necessary	 that	 surgery	 should	 be	 non-traumatic,	 without	
causing	 the	 drilling	 temperature	 to	 rise	 by	more	 than	 a	 few	 degrees.	 The	 fixture	
should	only	be	handled	by	titanium	 instruments	and	never	 touched	by	 the	gloved	
hand.	 It	 is	 further	 recommended	 that	 the	 surgical	 field	 should	 be	protected	 from	
fibers,	powder	and	other	substances	that	might	hinder	osseointegration.67 Finally, the 
load	 of	 the	 implant	 should	 preferably	 be	 in	 the	 longitudinal	 direction.	 Thus	 it	 is	
important	to	avoid	rotational	or	cantilever	forces	once	the	implant	has	integrated.	If	




















5.2. Soft tissue handling technique
Besides	a	firmly	anchored	implant,	the	abutment	should	be	tolerated	well	by	the	soft	
tissue	of	the	scalp	to	result	in	a	secure	and	stable	base	for	the	BCD.	Several	incisions	
and	 subcutaneous	 tissue	 handling	 techniques	 have	 been	 proposed	 over	 years.	
Initially,	 a	 two-stage	 surgical	 technique	 was	 advocated.68 First, the implant was 
installed	by	elevating	the	skin	with	periosteum	through	a	curved	incision,	which	was	
closed for three tot six months. Second, the implant was exposed to connect the 
abutment	to	the	implant,	after	which	a	free	skin	graft	was	used	to	establish	a	hair-free	
zone	 around	 the	 skin	 penetration	 site.	 Due	 to	 high	 occurrence	 of	 partial	 necrosis	




speed-up	 this	 technique,	 a	 dermatome	 was	 introduced	 for	 skin	 thinning.70 The 
outcome of skin-healing using the dermatome was reported to be at least as good as 
the	U-flaps	created	by	long-experienced	BAHI	surgeons.71
 In our center, a one-stage surgical procedure was developed to be used with a 





Long-term	 follow-up	 on	 BAHIs	 showed	high	 success	 rates	 and	 patient	 satisfaction	
that	 outweigh	 risks	 and	 complications.	 Intraoperative	 complications	 are	 rare	 and	
generally	mild;	mostly	these	concern	bleeding	from	the	scalp,	muscle	tissue,	or	emissary	
veins,	or	lesions	of	the	dura.	Postoperative	complications	can	be	roughly	divided	into	
bone	 complications	 and	 soft	tissue	 complications.	 These	will	 be	 considered	 in	 the	
following paragraphs.
5.3.1. Implant survival
Survival	 figures	 of	 BAHI	 are	well	 known,	 as	 there	 have	 been	 published	 numerous	
retrospective	studies	on	BAHI	populations,	with	largely	varying	population	sizes	and	
follow-up	 times.	 Most	 of	 these	 studies	 have	 been	 reviewed	 in	 a	 meta-analysis	
covering 2,310 implants,76	revealing	implant	loss	of	1.6%	to	17.4%	in	adult	and	mixed	
populations	 and	 0.0%	 to	 25%	 in	 pediatric	 patients.	 The	 largest	 retrospective	
case-series to date,77	which	was	studied	in	our	center,	presented	implant	loss	in	8.3%	
of	 1,132	 implants,	 with	 a	 higher	 percentage	 of	 implant	 loss	 in	 children	 (15.2%)	
compared	to	adults	(7.3%).	Various	risk	factors	for	implant	loss	have	been	proposed,	
but	only	radiation	therapy78 and type 2 diabetes mellitus79 have been reported to be 
26
Figure 6  The	simplified	Nijmegen	one-stage	linear	incision	surgical	technique.	 
[A]	Determination	of	implantation	location.	[B] Exposure of the periosteum.  
[C]	Drilling	procedure	and	placement	of	the	implant	under	saline	irrigation.	 
[D]	Area	of	subcutaneous	tissue	reduction.	[E]	Subcutaneous	tissue	reduction	
procedure. [F]	Healing	cap	and	position	of	suction. (Figure originially published by  






















for new implant designs to achieve higher implant stability and survival rates. Important 
variables in the design are the shape of the implant and abutment and their surface 
properties	or	coatings.	Two	new	BAHI	designs	are	studied	in	chapter	2.2	and	2.4	of	
this thesis.










2. redness and moist;
3.	 granulation	tissue;
4.	 extensive	soft	tissue	reaction	requiring	removal	of	abutment	or	implant.	
In	 our	 center,	 we	 consider	 Holgers	 grade	 0	 and	 1	 as	 no	 indication	 for	 treatment.	
Holgers	grade	2	is	treated	with	local	steroid	and	antibiotic	ointment.	Holgers	grade	3	
is	also	treated	locally	and	systemically	with	antibiotics.	Sometimes	replacement	of	a	
longer	 abutment	 or	 limited	 surgery	 is	 necessary.	 Holgers	 grade	 4	 often	 results	 in	
implant	loss	or	at	least	removal	of	the	abutment.	It	is	known	from	retrospective	data	
that	the	 incidence	of	adverse	skin	reactions	(Holgers	grade	2	or	higher)	 is	 16.1%	to	
38.1%,76	which	 is	 remarkably	 lower	 in	our	 center:	 in	4.6%	of	all	 follow-up	visits	 an	
adverse	skin	reaction	is	observed.77	This	difference	is	remarkable	and	may	possibly	 
be	 attributed	 to	 the	 specialized	 BAHI	 care	 team	 in	 our	 center.	 Furthermore,	 the	









transducer (called SmartPeg).84 RFA results in the more clinically useful Implant 
Stability	Quotient	(ISQ).	RFA	was	 introduced	as	an	objective	technique	to	measure	
BAHI stability when abutments that supported coupling for SmartPegs became 
available.	The	application	and	interpretation,	as	well	as	the	exact	clinical	value,	are	
not	yet	 fully	understood	 in	BAHI	 research	or	daily	practice.	Therefore,	 chapter	 1.2	
discusses RFA by reviewing the studies it has been used in up to date and provides 
guidelines	for	use	and	reporting.





Furthermore,	new	developments	 such	as	 transcutaneous	 coupling	and	active	 implants	
have been introduced recently. 
6.1. Implant and abutment design
Since	the	commercial	 introduction	of	the	BAHA	until	2009,	there	was	only	a	single	
implant	system	available,	the	machined	titanium	flange	fixture,	which	was	obviously	
subject	 to	 some	 evolutions	 over	 time.	 This	 system	 has	 been	marketed	 by	 several	
companies and is currently known as the Cochlear Baha system (Cochlear Bone 
Anchored	Solutions	AB,	Mölnycke,	Sweden).	The	outcomes	of	these	implants	are	well	
known,	as	reported	in	paragraph	5.3.	In	2009,	Oticon’s	Ponto	system	(Oticon	Medical	




was	 good	 (Holgers	 grade	 1	 in	 18.1%	of	 visits	 and	Holgers	 grade	2	 in	4.3%	of	 visits;	 
no higher Holgers grades were observed).
 A new implant design was commercially introduced in 2010, the Baha BI300, 
with a wider diameter, small-sized threads at the implant neck, and a moderately 
rough	 surface	on	 the	 intraosseous	portion	of	 the	 implant.	Also	 the	abutment	had	
evolved:	 the	 initial	 5.5-mm	 conically	 shaped	 abutment	 was	 changed	 to	 a	 6-mm	
rounded, apically converging design. This implant and abutment were found superior 
to	 the	 previous	 generation	 flange	 fixture	 in	 a	 six-month	 multicenter	 randomized	
controlled	clinical	 trial	 in	 terms	of	 ISQ	and	soft	tissue	tolerability.86 The three-year 
























chapter 2.4 six-month data of a randomized controlled clinical trial comparing the 
Ponto	wide	implant	with	the	previous	generation	implant	are	presented.
	 As	a	result	of	these	higher	initial	ISQ	values	of	the	wide	implants	and	the	increasing	
trends in ISQ, earlier loading the BAHI with the BCD was studied. Nevertheless, also 
for the previous 3.75-mm-diameter implants, early loading has been reported.77 This 
concept	was	mostly	stimulated	by	dental	research	where	earlier	(and	even	immediate)	
loading	protocols	are	common	practice.88	Promising,	yet,	relatively	short-term	outcomes	
have been reported on early loading of 4.5-mm-diameter BAHI at four,89 three,90 and 
two weeks.91 The outcomes of early loading at three weeks with a three-year follow-up 
are presented in chapter 2.3 of this thesis.
 The abutment design is arguably the most important implant related factor for 
soft	tissue	tolerability,	as	this	is	the	actual	percutaneous	part	of	the	system.	Besides	
the recent change in abutment design from conical to concave, which has been 
mentioned	earlier,	different	abutment	lengths	have	been	introduced.	The	first	longer	
8.5-mm conical abutment was introduced in 2003. This longer abutment provided a 
solution	for	patients	with	frequent	soft	tissue	related	problems	such	as	Holgers	grade	2	 
(or	higher)	skin	reactions	and	soft	tissue	overgrowth,	as	well	as	patients	with	a	thick	
scalp92,93	and	preserved	them	from	further	surgical	interventions.93 Not only was scalp 
thickness found to correlate with body mass index,94	obese	patients	(body	mass	index	
>	30)	are	more	prone	to	have	soft	tissue	complications	resulting	 in	partial	or	 total	
overgrowth of skin over the abutment.95	Ethnic	disparity	in	soft	tissue	complications	
has	been	 reported:	patients	with	dark	skin	experience	significantly	more	keloid	or	
hypertrophic	scar	formation	compared	to	patients	with	lighter	skin.96 Longer abutments 
could	be	specifically	beneficial	in	surgery	of	patients	with	a	thick	scalp	or	a	tendency	
to hypertrophic scarring. Currently, the Baha BA300 abutment is available in 6, 9, and 
12 mm and the Ponto abutment in 6, 9, 12, and 14 mm. Increasing the abutment 
lengths was considered safe due to the higher implant stability and survival of wide 
implants.
 The availability of these longer abutments allowed surgeons to further evolve 
the	linear	incision	technique	to	a	technique	without	subcutaneous	tissue	thinning.97 
Besides	 this	 technique	 being	 quicker	 and	 the	 outcomes	 are	 reported	 to	 be	more	
cosmetically	pleasing,98,99	 fewer	and	 less	severe	subcutaneous	tissue	 infections	are	
expected	to	be	encountered,	healing	time	is	faster,	and	numbness	and	pain	around	
the	implant	are	minimized	compared	to	the	U-flap	and	dermatome	techniques.99,100 
Obviously,	a	 comparison	between	 this	 technique	and	 the	 linear	 incision	 technique	
30
with	subcutaneous	tissue	reduction	would	be	of	even	more	interest,	as	that	technique	
is	already	known	to	be	superior	to	the	U-flap	and	dermatome	techniques.75 An even 
more	limited	subcutaneous	tissue	handling	technique	using	a	biopsy	punch	to	only	
remove	skin	and	underlying	soft	tissue	at	the	proposed	implant	site	has	recently	been	
presented,101-103	 which	 compared	 positively	 to	 the	 dermatome	 and	 linear	 incision	
technique	in	surgery	time,	while	the	complication	rates	did	not	differ	between	the	
two	techniques.102,103	However,	some	remarks	about	this	punch	technique	could	be	
raised.	 Due	 to	 limited	 exposure	 of	 the	 skull,	 it	 is	more	 difficult	 to	 determine	 the	




surgery	using	 ‘exposing’	 techniques	 is	 required	before	 switching	 to	 this	 technique	
with	limited	visibility.	Furthermore,	it	will	be	interesting	to	see	if	there	is	an	additional	




the	 subcutaneous	 tissue,	 immobilization	 of	 the	 skin	 surrounding	 the	 implant	 was	




6.2. Percutaneous or transcutaneous coupling
Although	it	has	been	established	that	percutaneous	coupling	of	a	BCD	is	more	effective	
than transcutaneous coupling,10	 the	 concept	 remained	attractive,	 as	 an	 intact	 skin	
could	be	considered	 to	be	cosmetically	more	appealing	and	potentially	diminishes	
skin	reactions.
 In 1986, Hough and co-workers107	 introduced	 the	 temporal	 bone	 stimulator,	 a	
transcutaneous	BCD	with	magnetic	coupling,	later	marketed	as	the	Xomed	Audiant.	
However, due to the limited gain and output of the Audiant,108 non-use because of 
insufficient	amplification	in	combination	with	skin	issues	was	observed	in	several	study	
groups that were implanted with the device.109-111	As	a	result	of	these	disappointing	
outcomes, the device was withdrawn from the market.
 More recently, a new transcutaneous BCD, the Otomag system, was developed 
by Siegert and co-workers.112 This device, later marketed as the Sophono Alpha 1 
(Sophono,	 Inc.,	Boulder,	Colorado),	consists	of	double	 implanted	magnets	 in	a	titanium	





















system is studied in more detail in chapter 3 of this thesis.





percutaneous	 application	was	 found	 superior.114 Another study found that hearing 
Figure 7  The Sophono Alpha 2 system, a passive transcutaneous BCD.  
(Figure courtesy of Sophono, Inc.)





6.3. Passive or active implants





of these BCDs can be located more closely to the cochlea.116,117	The	first	commercially	
available	active	transcutaneous	BCD	on	the	market,	the	Bonebridge	(MED-EL	Corporation,	
Innsbruck, Austria), was introduced in 2013.118 It consists of an external audio processor 
without	 an	 actuator,	 magnetically	 coupled	 to	 the	 implanted	 receiver	 coil	 and	 actuator	
(vibrating	floating	mass	transducer)	(see	Figure	9).	A	preclinical	study	showed	similar,	yet	
slightly	less	favorable,	functional	performance	of	the	Bonebridge	compared	to	a	Baha	




Figure 9  The	BoneBridge	system,	an	active	transcutaneous	BCD.	 





















the	first	implantation	in	a	patient	was	reported	in	2014.122 Recently, the six-months 
outcomes	of	the	application	of	the	BCI	in	the	first	six	patients	were	reported.123 No 
soft	 tissue	 complications	 were	 observed	 and	 significantly	 improved	 audiometric	
outcomes	were	measured.	Audiometric	 results	 and	 the	 subjective	outcome	compared	
positively	 to	 a	 Ponto	 Pro	 Power	 on	 a	 headband.	 Up	 to	 date,	 the	 BCI	 is	 not	 yet	
commercially	 available,	 however,	 a	 partnership	 with	 Oticon	Medical	 was	 recently	
announced.
7. Scope of this thesis
The	current	thesis	roughly	has	two	scopes.	First,	the	investigation	of	clinical	safety	




research, but has been applied in BAHI research since a few years. Because of lack of 
standardization,	RFA	outcomes	have	been	diversely	reported.	Therefore,	reporting	
standards are established in this paragraph.
 Chapter 2 covers several implantology studies. In chapter 2.1, comorbidity factors 
that	could	be	identified	as	risk	factors	for	implant	complications	are	descibed.	Chapter	
2.2 reports the three-year results of the Baha BI300 implant compared to the 
preceding	 Baha	 flange	 fixture	 in	 a	 randomized	 controlled	 clinical	 trial.	 Three-year	
outcome of early loading of the BI300 implant with the sound processor at three 
weeks	 after	 implantation	 is	 reported	 in	 chapter	 2.3.	 Finally,	 in	 chapter	 2.4,	 the	
Figure 10  The	Bone	Conduction	Implant,	an	active	transcutaneous	BCD.
(Figure originally published by Reinfeldt et al.124)
34
six-months results of a randomized controlled clinical trial comparing the Ponto wide 
implant with the preceding Ponto implant are described.
Chapter 3 reports on the Sophono Alpha 1 and 2 devices. In chapter 3.1, this 
transcutaneous	BCD	is	compared	to	its	percutaneous	alternative	in	terms	of	clinical	
outcomes	 and	audiometric	 results.	 These	 results	 are	 completed	with	 an	objective	
between the BCDs using a skull simulator. Chapter 3.2 presents prolonged follow-up 
and	a	 comparison	of	 sound	 localization	abilities	between	 the	 transcutaneous	BCD	
users and percutaneous BCD users.
	 Chapter	 4	 presents	 long-term	 follow-up	 in	 patients	who	 received	 a	 percutaneous	 
BCD	for	extended	 indications.	 In	chapter	4.1,	 the	compliance	and	satisfaction	with	
their	percutaneous	BCD	is	analyzed	in	patients	with	single-sided	sensorineural	deafness.	
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APPLICATION AND INTERPRETATION 
OF RESONANCE FREQUENCY 
ANALYSIS IN AUDITORY  
OSSEOINTEGRATED IMPLANTS






reviewing the currently published literature.









grated	 implants	and	might	have	potential	as	a	clinically	 relevant	 tool	 for	assessing	
implant stability. Due to the heterogeneous data that have been reported to date, the 
following	guidelines	for	standardization	of	application	and	reporting	were	established.	
The implant and abutment type and length as well as the type of SmartPeg used 
should always be stated. Stand-alone absolute ISQ values should not be interpreted 
individually.	ISQ	values	are	most	meaningful	as	a	trend	in	an	individual	patient	or	a	
population	 over	 time.	 No	 conclusions	 should	 be	 based	 on	 individual	 ISQ	 values.	
Standardized	time	points	 for	RFA	 in	 research	 should	be	determined	prospectively,	
with	surgery	as	a	baseline.	After	abutment	replacement,	individual	ISQ	trends	from	
baseline	cannot	be	interpreted	anymore	if	the	abutments	differ	in	length.
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intraorally applied to support a full bridge in the lower jaw. Furthermore, since 1977, 
roughly the same implant type has been used percutaneously in the temporal bone, 
allowing	firm	attachment	of	a	sound	processor	for	bone	conduction	hearing.2
	 Primary	fixation	is	a	prerequisite	for	the	osseointegration	process	and	relies	on	
mechanical engagement of an implant in the surrounding bone. It is expected that 
implant	stability	may	decrease	slightly	during	the	initial	period	following	implantation,	
as the mechanical stability is gradually replaced by secondary biological stability, 
provided	 by	 newly	 formed	 bone	 as	 osseointegration	 occurs	 during	 early	 wound	
healing.3














analysis (RFA) was introduced by Meredith et al.6 to clinically test implant stability in 
a	 non-destructive	 manner.	 RFA	 is	 essentially	 a	 bending	 test	 of	 the	 bone-implant	





into	 the	more	 clinically	useful	 Implant	 Stability	Quotient	 (ISQ)	 scale,	which	 ranges	
from 1 to 100 (Figure 1). The higher the ISQ, the more stable the implant. Measurements 
are	 conducted	 in	 two	 perpendicular	 directions,	 which	 result	 in	 two	 different	 ISQ	
values: ISQ High and ISQ Low.
 Most of what is known on implant stability as measured by RFA was discovered 












both as a parameter in research and as a clinical tool. In order to apply RFA in clinical 
studies	 in	 a	 consistent	 and	 replicable	manner,	 standardization	 of	 the	way	 data	 is	
reported	is	vital	to	assure	correct	interpretations	and	comparability	of	studies.	For	














































become a useful tool.
Methods
Definition of products
The current review describes RFA applied in auditory osseointegrated implants and 
abutments,	 such	 as	 the	 Baha	 system	 from	 Cochlear	 Bone	 Anchored	 Solutions	 AB	
(Mölnlycke,	Sweden)	or	the	Ponto	system	from	Oticon	Medical	AB	(Askim,	Sweden).	
The SmartPegs and the handheld electronic analysis device, the Osstell ISQ 
instrument, are manufactured by Osstell AB (Göteborg, Sweden).
Literature search
PubMed, Embase, and The Cochrane Library were searched on December 7th, 2014 for 
clinical	studies	reporting	on	RFA	of	auditory	osseointegrated	implants.	To	be	included	
in the current review of the available literature, studies had to appear in a peer- 
reviewed	journal	written	in	the	English,	German,	or	Dutch	language.	A	systematic	search	




Of all studies judged suitable from the abstract, the full text was read.
Results
Seventeen studies were found to report outcome of RFA in auditory osseointegrated 
implants.10-26 Two studies were pre-clinical18,24	and	were	therefore	left	out	of	further	
analysis	 in	 the	 current	 study.	 Two	 other	 clinical	 studies	 were	 excluded.	 The	 first	
because a previous type of (wired) transducer, other than the currently used 
SmartPegs,	was	applied	and	there	was	no	ISQ	scale	at	that	time.15 The second because 
the short-term data of that study are also reported in a long-term follow-up study.11
Table 1 provides an overview of all 13 included studies. Of these studies, two were 
prospective	randomized	controlled	clinical	 investigations.16,22 All other studies were 
prospective	or	retrospective	case	series	or	cross-sectional	studies.





Table 1   Assessment	of	clinical	studies	reporting	on	RFA	in	auditory	 
osseointegrated implants. 
Authors Year Study  
design
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n.s. 3 weeks High AUC 68.1 
(SD ± 4.8)






2014 case series 4.5-mm 
moderately 
rough






(surgery; 1 week; 
within 3 months; 
3 to 6 months; at 
other follow-up; 
at loading)
n.s. 3–6 months 
(mean 3.5 
months)










20 4 mm 6 mm &  
9 mm
n.s. 54.6  
(range 25–71)
1 year standardized  
(10 days;  
6 weeks; 6,  
12 months)
55 6 weeks mean n.s. significant	
increase at 10 
days, dip at 7 
weeks,	significant	











49 4 mm 9 mm 49 n.s. for 
population	as	 
a whole
1 year standardized  
(0, 3, 7, 10 days; 
2, 3 weeks; 1, 3, 6, 
12 months)
55 2 weeks mean AUC 63.6 
(SD ± 6.3) & 















1 year standardized  
(1 week; 3, 6,  
12 months)
n.s. 4–6 weeks n.s. n.s. increase from 
‘onset’	(n.s.	
Whether surgery 
or 1 week) at 3,  
6, 12 months















5 3 mm n.s. 5 7.4 (3-11) 6 months
 
standardized 
(surgery; 1, 2 


























68 n.s. n.s. 88 54  
(range 16–84)
16 weeks standardized 
(surgery; 1, 4, 16 
weeks)
n.s. 4 weeks High n.s. minimal decrease 
at 1 week, 










































Table 1   Assessment	of	clinical	studies	reporting	on	RFA	in	auditory	 
osseointegrated implants. 
Authors Year Study  
design












ISQ High or 
Low






















































30 n.s. 6 mm 30 55.3  
(SD ± 12.3)
6 months standardized 
(surgery,  
10 days; 3, 6,  
12 weeks;  
6 months)
n.s. 3 weeks High AUC 68.1 
(SD ± 4.8)






2014 case series 4.5-mm 
moderately 
rough






(surgery; 1 week; 
within 3 months; 
3 to 6 months; at 
other follow-up; 
at loading)
n.s. 3–6 months 
(mean 3.5 
months)










20 4 mm 6 mm &  
9 mm
n.s. 54.6  
(range 25–71)
1 year standardized  
(10 days;  
6 weeks; 6,  
12 months)
55 6 weeks mean n.s. significant	
increase at 10 
days, dip at 7 
weeks,	significant	











49 4 mm 9 mm 49 n.s. for 
population	as	 
a whole
1 year standardized  
(0, 3, 7, 10 days; 
2, 3 weeks; 1, 3, 6, 
12 months)
55 2 weeks mean AUC 63.6 
(SD ± 6.3) & 















1 year standardized  
(1 week; 3, 6,  
12 months)
n.s. 4–6 weeks n.s. n.s. increase from 
‘onset’	(n.s.	
Whether surgery 
or 1 week) at 3,  
6, 12 months















5 3 mm n.s. 5 7.4 (3-11) 6 months
 
standardized 
(surgery; 1, 2 


























68 n.s. n.s. 88 54  
(range 16–84)
16 weeks standardized 
(surgery; 1, 4, 16 
weeks)
n.s. 4 weeks High n.s. minimal decrease 
at 1 week, 




Table 1  Continued.	
Authors Year Study  
design












ISQ High or 
Low











68 n.s. n.s. 88 54
(range 16–84)
16 weeks standardized 
(surgery; 1, 4,  
16 weeks)
n.s. 4 weeks High n.s. minimal decrease 
at 1 week, 










22 3 & 4 mm n.s. 30 9 
(range 2–16)
16 weeks standardized 
(surgery; 4,  
16 weeks)
n.s. 1–16 weeks 
(mean 6 
weeks)





















(surgery, 10 days; 
4, 6, 8, 12 weeks; 











dip at 10 days, 
increase	until	 
6 months, stable 
intil	2	years,	 










dip at 10 days, 
increase	until	 
6 months, stable 
at 1 years, slight 












Test: n.s. 10 n.s. n.s. 10 n.s. n.s. random follow-
up moment at 









































14 4 mm 8 mm 14 n.s. 1 month surgery, 1 week,  
1 month
n.s. n.s. mean n.s. increase at  











































Table 1  Continued.	
Authors Year Study  
design












ISQ High or 
Low











68 n.s. n.s. 88 54
(range 16–84)
16 weeks standardized 
(surgery; 1, 4,  
16 weeks)
n.s. 4 weeks High n.s. minimal decrease 
at 1 week, 










22 3 & 4 mm n.s. 30 9 
(range 2–16)
16 weeks standardized 
(surgery; 4,  
16 weeks)
n.s. 1–16 weeks 
(mean 6 
weeks)





















(surgery, 10 days; 
4, 6, 8, 12 weeks; 











dip at 10 days, 
increase	until	 
6 months, stable 
intil	2	years,	 










dip at 10 days, 
increase	until	 
6 months, stable 
at 1 years, slight 












Test: n.s. 10 n.s. n.s. 10 n.s. n.s. random follow-
up moment at 









































14 4 mm 8 mm 14 n.s. 1 month surgery, 1 week,  
1 month
n.s. n.s. mean n.s. increase at  










while others reported absolute ISQ values. Because of this heterogeneity, pooling of 
data and performing a meta-analysis was not possible.
Discussion




can be loaded safely with the sound processor without compromising the implant- 
bone	interface	and,	as	a	consequence,	risking	implant	loss.	Besides,	implant	stability	
is an important outcome measure in clinical research on new implant designs, expanded 
indications,	and	specific	patient	populations.	Therefore,	an	objective	and	non-invasive	
method for measuring implant stability is both of clinical relevance and an important 
tool in implant research. The current review evaluated the use of RFA as such a 
technique	in	auditory	osseointegrated	implants.	RFA	measurements	of	these	implants	
have only been possible for the last few years.






of RFA in auditory osseointegrated implants. 
 RFA has been widely applied in research on dental implants, which provides 
support to discuss the recently published RFA data in auditory osseointegrated 
implants. In dental implants, RFA outcome is reported to depend upon three main 
factors:	 first,	 the	 design	 of	 the	 transducer	 (i.e.,	 the	 SmartPeg)	 and	 the	 transduc-
er-to-implant	interface;	second,	the	stiffness	of	the	implant	interface	with	the	tissues	
and	surrounding	bone;	and,	third,	the	total	effective	height	of	the	transducer	above	
the marginal bone level.27	Because	of	these	different	factors,	researchers	have	still	
not been able to clearly assess absolute ISQ values for clinically stable dental implants; 
there	are	only	indicative	ranges	of	values	that	represent	stable	implants.27 In dental 
implantology, however, there is a much larger variety in implant and abutment 








































ISQ measurements was reported to be fair-to-good and the inter-observer variability 




 As ISQ values depend on more factors than solely the bone-implant contact (e.g., 
bone	quality,	whether	the	measurement	was	performed	at	the	implant	or	abutment	




ISQ values measured from the same implants with varying abutment lengths or 
measured	with	different	SmartPeg	types	cannot	be	interpreted	the	same	way.	Most	
studies	included	in	the	current	review	reported	the	course	of	ISQ	over	time	(see	Table	




	 ISQ	 is	 measured	 in	 two	 perpendicular	 directions,	 which	 generally	 yield	 two	
different	ISQ	values,	typically	varying	a	few	units.	This	difference	is	explained	by	the	
different	 bone	 characteristics	 in	 both	 directions.	 One	 of	 the	 vibrations	 is	 in	 the	
direction	where	the	implant	is	most	stable	and	the	other	vibration	is	in	the	direction	
where the implant is least stable.27	These	differences	are	larger	and	more	relevant	for	
dental	implants	than	in	implants	in	the	temporal	bone,	as	there	are	more	differences	
in	 anatomy	 in	 different	 directions	 of	 the	 mandible	 or	 maxilla	 compared	 to	 the	
temporal bone. Both the high and the low ISQ value can be argued to be of clinical 
significance	in	auditory	osseointegrated	implants	and	should	both	be	reported.	From	
Table 1, it is observed that not all authors specify whether ISQ High or Low is 
interpreted.10,17,21	Most	authors	reported	a	mean	ISQ	value.	Furthermore,	elaborating	
on	 the	first	 consideration,	 it	 could	be	postulated	 that	 if	not	absolute	values	but	a	
trend in ISQ values is interpreted, it is expected to be of less importance which of 
both values is used, as long as consistently ISQ High or Low is used.
	 The	timing	of	follow-up	measurements	is	important	to	consider	when	creating	a	
research	protocol	using	RFA.	Depending	on	the	study	objectives,	suitable	follow-up	
moments should be chosen. As a baseline, it is necessary to measure at surgery. The 
first	 follow-up	visit	at	which	 the	healing	cap	and	dressing	are	 removed	provides	a	
suitable	next	moment	to	perform	RFA,	as	 it	may	capture	any	problems	with	 initial	




and	osseointegration	 take	 place,	 e.g.,	 as	 carried	 out	 in	Nelissen	 et	 al.22 When the 
influence	of	a	loading	moment	is	studied,	RFA	should	specifically	be	conducted	right	
before	 loading	and	shortly	after	 (i.e.,	one	to	two	weeks	 following	 loading),	e.g.,	as	
carried out in Faber et al.12 or Høgsbro et al.16 Finally, RFA should ideally be measured 
yearly	post	implantation	to	observe	if	stability	is	maintained.
	 As	mentioned	before,	ISQ	values	measured	at	different	abutment	lengths	cannot	
be compared. The same applies to ISQ trends within the follow-up of a single implant 
if abutments are replaced during follow-up. Lower ISQ values are yielded with longer 
abutments, due to the increased distance between the SmartPeg and the bone level. 
Hence, if an abutment is replaced during follow-up, it is advisable to perform RFA 
before	and	after	abutment	replacement	to	establish	a	new	baseline	value	to	continue	
the	follow-up	of	the	ISQ	trend	in	that	specific	patient.	Absolute	ISQ	values	obtained	





at this moment. Nevertheless, it is clear that stand-alone, incidentally measured, ISQ 
values	provide	limited	information	on	implant	stability.	Clinical	use	should	focus	on	




clinical	 question	 raised.	 However,	 these	 recommendations	 are	 not	 scientifically	
supported,	 but	 rationally	 determined.	 Changes	 in	 individual	 ISQ	 trends	 could	 be	
indicative	of	implant	stability	failure.	Therefore,	we	would	like	to	encourage	clinicians	
who	 use	 RFA	 in	 clinical	 practice	 to	 perform	 this	 longitudinally	 and,	when	 implant	
failure is encountered, to report these cases in a standardized manner.

























































RFA at surgery should be established as a baseline. Depending on the research 
question,	follow-up	moments	may	vary.
5.	 After	 abutment	 replacement,	 individual	 ISQ	 trends	 from	 baseline	 cannot	 be	
interpreted	anymore	if	abutments	differ	in	length.	A	new	baseline	ISQ	value	should	 
be	established	after	replacement.
6. It is encouraged to present case-series of clinically unstable implants with 
baseline and event related ISQ values. With a large pool of such data, an individual 
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A RETROSPECTIVE COHORT STUDY 
ON THE INFLUENCE OF 
COMORBIDITY ON SOFT TISSUE 
REACTIONS, REVISION SURGERY, 









1,	 1988	 and	 December	 31,	 2007	 were	 approached	 to	 fill	 out	 a	 questionnaire	 on	
comorbidity	factors.	A	total	of	581	patients	with	669	implants	were	included	in	the	






In	 a	 multivariable	 analysis,	 skin	 disease	 and	 female	 gender	 were	 observed	 as	
independent	associative	factors,	with	an	adjusted	hazard	ratio	of	3.08	(1.32–7.16)	and	
0.56 (0.33–0.94). For revision surgery, female gender and cardiovascular disease 
were	identified	as	negative	risk	factors	in	a	univariable	analysis,	and	smoking	showed	
a	trend	toward	a	negative	risk,	with	hazard	ratios	of	0.15	(0.07–0.32),	0.07	(0.03–0.20),	




Conclusion |	 Retrospective	 analysis	 of	 comorbidity	 factors	 and	 clinical	 outcomes	
revealed	risk	factors	for	postoperative	complications	after	BAHI	surgery.
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on	the	influence	of	comorbidity	on	soft	tissue	reactions,	revision	surgery,	and	implant	




















































The percutaneous bone-anchored hearing implant (BAHI) was introduced in 1977 by 
Tjellström.1 For more than 35 years, it has been used successfully as a treatment for 






implants was proposed by Holgers et al. in 1988.3	 This	 classification	describes	five	
different	 degrees	 of	 soft	 tissue	 reactions.	 A	 Holgers	 grade	 2	 reaction	 or	 higher	 is	
generally	considered	as	an	adverse	reaction	in	need	of	treatment.	These	soft	tissue	
reactions	may	result	 in	more	serious	adverse	outcomes,	such	as	 implant	extrusion	




obesity	and	soft	tissue	complications	at	the	implant	site.8-10 Zeitler et al.11 analyzed the 
influence	of	other	comorbidity	factors	on	soft	tissue	reactions	in	BAHIs.	Their	study	
describes	an	increased	risk	of	skin-site	complications	for	African	American	patients,	




that	 diabetes	 mellitus	 and	 a	 history	 of	 cardiovascular	 disease	 are	 significant	 risk	
factors for peri-implant disease.12,13 Furthermore, dermatologic diseases such as 














potential	 local	 and	 systemic	 factors	 are	 mentioned	 in	 various	 studies;	 however,	
definite	evidence	is	often	lacking.
	 The	aim	of	the	current	retrospective	cohort	study	was	to	identify	the	influence	 
of	comorbidity	on	soft	tissue	reaction,	revision	surgery,	and	 implant	 loss	 in	a	 large	
population	 of	 patients	 with	 the	 same	 type	 of	 BAHI.	 Studies	 on	 wound	 healing	 in	
general	have	led	to	the	hypothesis	that	among	patients	with	relevant	comorbidities,	
peri-implant	 complications	might	be	higher	compared	with	healthy	adult	patients.	
Knowledge	 of	 these	 potential	 risk	 factors	 could	 be	 useful	 in	 patient	 counseling,	
selection	of	surgical	procedure,	and	postoperative	surgical	site	care.	We	retrospec-
tively	analyzed	a	consecutive	series	of	more	than	1,000	 implants	on	clinical	outcomes,	 
with	 emphasis	 on	 adverse	 events	 and	 potential	 risk	 factors.	 The	 same	 series	was	
previously analyzed by Dun et al.,4	focusing	on	age	differences	and	loading	time,	and	
by	Horstink	 et	 al.,18	 focusing	on	 the	 effect	 of	DM	on	 implant	 loss.	 For	 the	 current	










Surgical techniques and post-surgery protocol
The	original	 Tjellström	 skin	 graft	 technique19	was	used	 from	 1988	until	 1995,	 after	
which	the	Nijmegen	linear	incision	technique	with	tissue	reduction14,20 was implemented. 






status according to the Holgers grading system.





















































disease, hypertension, cardiovascular disease, or other comorbidity factors (not 
further	specified;	thyroid	disease	was	mentioned	as	an	example),	including	the	year	
of	 diagnosis.	 For	 the	 patients	 with	 missing	 information	 on	 the	 year	 of	 diagnosis,	
medical	 files	 were	 searched	 and	 the	 database	 was	 completed	 with	 this	 missing	
information.	Only	diagnoses	made	before	or	in	the	year	of	operation	were	used	for	
further	 analysis.	 An	 exception	was	made	 for	DM2,	where	 a	 separate	 analysis	was	
conducted	 for	patients	diagnosed	during	 follow-up,	as	was	also	 carried	out	 in	our	
previous analysis on largely the same series.18	Reanalysis	of	the	effects	of	DM2	was	
included	 in	 the	 current	 study,	 as	 the	 current	 study	 emphasizes	 on	 the	 relation	
between	DM2	and	 soft	tissue	 reactions	and	 revision	 surgery.	 In	addition,	a	 longer	
period	of	follow-up	was	available	for	implant	loss,	until	January	2013.
	 Furthermore,	 patients	 were	 asked	 for	 their	 height	 and	 weight,	 smoking	 and	
alcohol intake status, and any changes in these factors since BAHI surgery. Smoking 
was	handled	as	either	active	or	nonsmoker,	and	when	patients	stated	they	had	quit	
smoking the year before BAHI surgery, they were counted as nonsmokers. For alcohol, 
drinking	two	or	more	daily	units	reported	in	the	questionnaire	was	included	as	a	risk	
factor.	 Body	 mass	 index	 (BMI)	 was	 calculated	 for	 all	 patients,	 and	 changes	 since	
surgery	 were	 included	 in	 this	 calculation.	 In	 addition,	 data	 concerning	 age	 at	














	 To	 take	 into	 account	 the	 dependency	 of	 the	 observations,	 a	 random	 effects	
proportional	 hazards	model	 with	Weibull	 baseline	 hazard	 was	 performed	 for	 the	
time-to-event	data.	A	normal	distributed	frailty	was	incorporated	for	each	individual.	










	 For	each	time-to-event	analysis,	potential	 risk	 factors	 (p < 0.10) in univariable 





















soft	tissue	reaction,	with	a	hazard	rate	ratio	of	3.41	 (95%	CI	 1.45–8.01;	p = 0.005). 
The	presence	of	profound	learning	difficulties	resulted	in	a	hazard	ratio	of	3.42	(95%	
CI 1.03–11.39; p	=	0.045)	for	the	time	to	the	first	adverse	soft	tissue	reaction.	Female	
gender	resulted	in	a	hazard	rate	ratio	of	0.60	(95%	CI	0.35–1.03;	p = 0.062). The unadjusted 
hazard	ratios	for	all	risk	factors	with	95%	confidence	intervals	are	shown	in	Table	2	
and graphically displayed in Figure 1.
 When including comorbidity factors with a p-value	of	less	than	0.10	in	a	multivariable	
model,	the	hazard	ratios	only	changed	marginally.	For	gender,	the	hazard	ratio	was	




















































Table 1  Patient	characteristics	at	the	time	of	first	implantation.	
n %
Total patients 581 100%









> 30 80 13.8%
DM2 
DM2 31 5.4%















Currently > 2 units daily 78 13.4%

























































































































































































































































































































































































































































































































































































































































































































































































graphically displayed in Figure 3.
 When including comorbidity factors with a p-value	of	less	than	0.10	in	a	multivariable	
model,	virtually	the	same	hazard	ratios	were	seen,	except	for	cardiovascular	disease.	
For	female	gender,	the	hazard	ratio	was	0.14	(95%	CI	0.06–0.30;	p < 0.001), for cardio-
vascular	 disease	 0.95	 (95%	 CI	 0.41–2.18;	 p	 =	 0.897),	 and	 for	 smoking	 0.45	 (95%	 
CI 0.22–0.95; p = 0.036).
Figure 1  Influence	of	comorbidity	factors	on	the	time	to	the	first	adverse	soft	tissue	
reaction	(Holgers	score	≥	2).	Hazard	rate	ratio	±	95%	CI.	Random	effects	proportional	
hazards model: * p < 0.05. Ref: reference category.
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HRR time to ﬁrst adverse
soft tissue reaction
70
Figure 2  Influence	of	comorbidity	factors	on	the	number	of	adverse	soft	tissue	
reactions	during	observation	time	of	implants	(Holgers	score	≥	2).	Incidence	rate	
ratio	±	95%	CI.	Normal	random	effects	Poisson	regression	model:	*	p < 0.05.  
Ref: reference category.
Figure 3  Influence	of	comorbidity	factors	on	revision	surgery	(soft	tissue	revision	
and/or	abutment	replacement).	Hazard	rate	ratio	±	95%	CI.	Random	effects	
proportional	hazards	model:	*	p < 0.05. Ref: reference category.
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During	 follow-up,	 50	 of	 the	 669	 implants	 were	 lost	 (7.5%).	 In	 the	 first	 year	 after	




cardiovascular disease (HRR 2.10) and when during follow-up DM2 was present (HRR 
2.21).	The	unadjusted	hazard	ratios	for	all	risk	factors	with	95%	confidence	intervals	







as	a	risk	 factor	 for	 implant	 loss.	 In	addition,	 less	revision	surgery	was	necessary	 in	
female	patients	and	patients	with	cardiovascular	disease	in	a	univariable	analysis.	In	
multivariable	analysis,	 female	gender	and	smoking	were	 identified	as	negative	risk	
factors for revision surgery.
Figure 4  Influence	of	comorbidity	factors	on	implant	loss.	Hazard	rate	ratio	±	95%	
CI.	Random	effects	proportional	hazards	model:	*	p < 0.05. Ref: reference category.
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Comparison with other studies
Evaluation	of	clinical	outcomes	of	BAHI	surgery	has	been	extensively	reported	since	
the	 introduction	 of	 the	 system.	 Over	 the	 past	 years,	 several	 risk	 factors	 were	
evaluated,	mostly	in	small	populations	and	with	short	follow-up,	as	briefly	reviewed	
in	 the	 introduction	of	 this	manuscript.	 Younger	age,	profound	 learning	difficulties,	
obesity, tobacco use, diabetes mellitus, cardiovascular disease, ethnic background, 
and skin disease have all been discussed.4,14,15,21-23 In the current study, our BAHI 
database	was	evaluated	 for	all	 these	 factors	 combined.	Moreover,	 evaluation	was	
done not only with respect to implant loss, but also referring to revision surgery and 
soft	tissue	reactions,	which	are	more	difficult	outcome	parameters	to	interpret.	The	
current study is one of the largest series to date studying risk factors for these 
parameters.	Some	risk	factors	reported	elsewhere	can	be	confirmed	by	this	study,	
such	as	skin	disease	and	smoking.	The	negative	effect	of	smoking	on	implant	survival	




rate.	However,	 other	 risk	 factors	 previously	described	 could	not	be	 confirmed.	As	
stated	in	the	introduction,	Berenholtz	et	al.,8 Rebol,9 and Kraai et al.10	identified	high	
BMI	as	a	risk	factor	for	soft	tissue	problems,	explained	by	the	relation	between	body	










constraints,	 longer	 follow-up,	 and	 different	 statistical	 analysis	 could	 explain	 this	
discrepancy.
Strengths and limitations
The	 current	 study	 has	 several	 strengths.	 First	 of	 all,	 the	 population	 size	 and	 the	
duration	of	follow-up	lend	for	robust	conclusions.	The	response	rate	was	high,	with	
nearly	70%	of	all	our	patients	completing	the	questionnaire.	Moreover,	homogeneous	
exposure was achieved, because only one implant type was used and because in the 
majority	of	patients	the	same	surgical	technique	was	applied.	Additionally,	over	95%	























































incidences of, e.g., smoking and alcohol are comparable to numbers in the total Dutch 
population.31 Moreover, clinical outcomes were comparable to what was reported 
previously	 on	 largely	 the	 same	patient	 group.4 The somewhat higher incidence of 
implant loss and revisions in the current study are considered to be a result of the 
longer follow-up.





8.1%,	 was	 seen	 in	 the	 patient	 group	with	 profound	 learning	 difficulties	 versus	 no	
profound	learning	difficulties.	However,	in	a	multivariable	analysis	on	the	time	to	the	
first	 soft	 tissue	 reactions,	 hazard	 ratios	 for	 skin	 disease	 and	 profound	 learning	
difficulties	were	approximately	the	same	as	in	a	univariable	approach.
	 Obviously,	 the	 retrospective	 design	 of	 the	 current	 study	 has	 some	 inherent	
limitations.	 A	 questionnaire	 was	 used,	 in	 which	 patients	 were	 asked	 to	 report	
information	 on	 diagnosis	made	 in	 the	 past.	 Consequently,	 the	 data	might	 include	
some	 inaccuracies	as	a	 result	of	 this	 strategy.	Potential	 information	bias,	 resulting	
from measurement errors in recall of comorbidity factors are expected to result in an 
underestimation	of	associations	between	comorbidity	factors	and	complications.	All	
missing	 information	 in	 the	 questionnaires	 was	 completed	 by	 a	 search	 of	 patient	
charts.	Nevertheless,	this	study	design	still	depends	on	proper	clinical	documentation	
and an appropriate follow-up. The follow-up protocol in our center adheres to strict 
guidelines:	visits	are	planned	at	1	week,	3	weeks,	and	after	this	yearly.	During	all	visits,	




diseases	 was	 newly	 identified	 and	 negative	 risk	 factors	 for	 revision	 surgery	 were	
recognized.	 Furthermore,	 smoking	was	 identified	 as	 a	 risk	 factor	 for	 implant	 loss.	
These	factors	should	be	included	in	patient	counseling	and	selection	of	surgical	and	
postoperative	procedures.	Moreover,	the	current	results	could	be	used	as	a	reference	
for upcoming (long-term) clinical results of new implants and advances in surgical 
techniques,	 like	 the	 tissue	 preservation	 technique.	 Developments	 and	 expected	
74
improvements in bone-anchored hearing implants, abutments, and concomitant 
surgical	technique	could	be	compared	to	the	current	results.	The	current	study	adds	
important	data	to	what	is	available	to	date,	as	it	is	the	first	large	series	analysis	on	
comorbidity risk factors in BAHI surgery.
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LONG-TERM STABILITY,  
SURVIVAL, AND TOLERABILITY OF  
A NOVEL OSSEOINTEGRATED 
IMPLANT FOR BONE CONDUCTION 
HEARING
THREE-YEAR DATA FROM A  




Objective | To compare the three-year stability, survival, and tolerability of two osse-
ointegrated	implants	for	bone	conduction	hearing:	a	4.5-mm-diameter	wide	implant	
with a moderately roughened surface and a rounded 6-mm high abutment (test) and 
a 3.75-mm-diameter wide implant with an as-machined surface and a conically 














Conclusion |	This	clinical	 investigation	demonstrated	that	the	test	 implant	 is	more	
stable	 in	terms	of	 ISQ-values	and	provides	high	tolerability	 for	 the	soft	tissue.	The	
results	show	that	implant	loading	at	6	weeks	post	implantation	is	safe.
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In	 order	 to	 accomplish	 bone	 conduction	hearing	 amplification,	 percutaneous	 (i.e.,	
skin-penetrating)	or	transcutaneous	(i.e.,	through	intact	skin)	titanium	implants	can	
be	placed	in	the	temporal	bone	to	allow	attachment	of	a	vibrating	sound	processor.	
The	concept	of	titanium	temporal	bone	implants1 was adopted from dental research 
on	osseointegration,2	i.e.,	formation	of	a	direct	interface	between	an	implant	and	the	
surrounding	bone.	Primary	stability	is	a	prerequisite	for	subsequent	osseointegration	













 Aiming to improve treatment outcome and predictability, a new implant design 
was introduced in 2010.5 This new design was adapted from dental implantology, 
where wider diameter implant designs have been reported to increase implant 
stability6 and moderately roughened surfaces have been reported to increase the 
bone	response	after	implantation.7 In 2011, Dun et al.5	reported	the	first	short-term	
clinical outcome of the new implant with a wider diameter (4.5 mm), moderately 






	 Long-term	data	on	 stability,	 survival,	 and	 tolerability	 are	 important	 characteristics	 
of	an	implant	that	may	help	clinicians	in	guiding	patients’	choices.	The	current	study	
is	a	continuation	of	the	previously	reported	investigation5 and evaluates three-year 
outcomes	on	implant	stability	measured	by	ISQ,	implant	survival,	and	skin	reactions	






The test implant was the Cochlear Baha BI300 with BA300 abutment, while the 
previous	generation	as-machined	Cochlear	Baha	flange	fixture	with	conically	shaped	
abutment served as the control implant. Both implants are manufactured by Cochlear 
Bone	Anchored	Solutions	AB	(Mölnlycke,	Sweden)	and	have	been	elaborately	described	
previously.5 Figure 1 displays both implants.
In	the	current	prospective	multicenter	randomized	controlled	clinical	 investigation,	
77	 adult	 patients	 were	 consecutively	 included;	 42	 patients	 at	 Radboud	 university	
medical	 center	 (Nijmegen,	 The	Netherlands),	 18	 patients	 at	 Salford	 Royal	 Hospital	
(Salford,	United	Kingdom),	13	patients	at	Sahlgrenska	University	Hospital	(Göteborg,	
Sweden),	and	4	patients	at	Manchester	Royal	 Infirmary	(Manchester,	United	Kingdom).	
Exclusion criteria were bone thickness at the implant site of less than 4 mm and diseases 
or	 treatments	 at	 the	 time	 of	 inclusion	 known	 to	 compromise	 the	 bone	 quality	 at	 
the	 implant	 site,	 which	might	 be,	 but	 were	 not	 limited	 to,	 radiation	 therapy	 and	




The	 primary	 study	 objective	 was	 to	 demonstrate	 superiority	 of	 the	 test	 implant	
compared	to	the	control	implant	as	measured	by	ISQ.	The	secondary	objectives	were	
to	 compare	 implant	 survival,	 to	 compare	 tolerability	 as	 determined	 by	 soft	tissue	






















































and	 statistically	 significant	 difference	between	both	 implants,	 a	 power	 calculation	
was	 conducted.	 As	 this	 was	 the	 first	 clinical	 investigation	 that	 used	 resonance	
frequency	analysis	(RFA)	to	determine	the	stability	of	percutaneous	temporal	bone	
implants,	 the	 power	 calculation	 was	 based	 on	 estimates	 from	 non-clinical	 data.	
Estimated	ISQ	values	of	60	and	50	for	test	and	control	implants,	respectively,	and	a	
standard	deviation	(SD)	of	±	13	were	used	in	the	calculation.	With	an	implant	allocation	 






implantation.	 The	 implants	 and	 abutments	 were	 placed	 in	 a	 one-stage	 surgical	
procedure.	 Reduction	 of	 subcutaneous	 soft	 tissue	 around	 the	 abutment	 was	
performed	by	means	of	the	linear	incision	technique9	in	Nijmegen,	the	flap	technique10 









could not be conducted blinded. During these visits, the ISQ was measured by means 
of	 RFA	with	 the	Osstell	Mentor	 (Osstell	 AB,	 Göteborg,	 Sweden),	 an	 objective	 and	
non-invasive	technique.	RFA	relies	on	mimicking	the	clinical	load	and	direction	on	an	
implant,	which	provides	information	about	the	stiffness	of	the	implant–bone	interface.12 
The highest (ISQ High) and lowest (ISQ Low) value obtained from perpendicular 
measurements were recorded. The method of RFA has been described in detail 
elsewhere.5,12	 Furthermore,	 soft	tissue	 status	was	monitored	according	 to	Holgers’	
classification.8	All	clinical	findings	were	noted	in	standardized	data	recording	forms.
Data analysis
The	 trial	was	monitored	by	an	 independent	clinical	 contract	 research	organization	
(A+	Science	AB,	Stockholm,	Sweden)	and	data	management	and	statistical	analysis	




between the test implant group and the control implant group, Mann-Whitney U test 
was	 used	 for	 all	 continuous	 variables,	 Mantel-Haenszel	 χ2 test for all ordered 
categorical	variables,	Fisher’s	exact	test	for	dichotomous	variables,	and	χ2 test for all 
unordered categorical variables. Repeated measures analyses were performed on 
ISQ	 values	 over	 time.	Wilcoxon	 Signed	 Rank	 test	was	 used	 for	 comparison	within	
groups. A weighted average of ISQ during the period of baseline to 36 months was 
obtained	by	mean	area	under	the	curve	(AUC)	calculations	using	the	trapezoid	rule.	
The	mean	AUC	was	calculated	for	the	time	the	implant	was	in	function.	For	implants	










	 Five	patients	were	withdrawn	from	the	study.	 In	 two	patients	 this	was	due	to	
implant	loss	(test	implants).	For	one	patient,	a	protocol	deviation	was	discovered:	the	
bone	thickness	at	the	implant	site	was	less	than	4	mm	(control	implant).	Two	patients	





The mean AUC for ISQ High over three years was 71.5 (SD ± 2.2) for the test implants. 
The	control	 implants	displayed	a	statistically	significantly	 (p < 0.0001) lower mean 
AUC	for	ISQ	High	of	66.4	(SD	±	5.2).	A	statistically	significant	(p	<	0.0001)	difference	in	
mean AUC also applies to ISQ Low: 69.8 (SD ± 2.4) for the test implants compared to 
64.4 (SD ± 5.3) for the control implants. Furthermore, both mean ISQ High and Low 
were	 statistically	 significantly	 higher	 for	 the	 test	 implants	 than	 for	 the	 control	



















































	 Both	 implants	 showed	 a	 statistically	 significant	 decrease	 in	 ISQ	 at	 ten	 days	
post-surgery (test –1.7 ISQ, p = 0.0232; control –2.4 ISQ, p	=	0.0104).	Subsequently,	
for both implant types, ISQ increased up to six months. The control implant showed 
a stronger absolute mean change in ISQ from baseline at six months follow-up 
compared to the test implant (test 1.8 ISQ units, p = 0.0001; control 3.7 ISQ units, 
p	=	0.0010).	From	this	point,	ISQ	values	remained	more	or	less	stable	until	two	years	
post-surgery. In the period between two and three years post-surgery, there was a 
statistically	significant	decrease	in	ISQ	of	1.6	units	for	the	test	implants	(p = 0.0072) 
and	a	statistically	non-significant	decrease	of	2.5	ISQ	units	for	the	control	 implants	 
(p = 0.0640). For both implants, mean ISQ values at three-year follow-up were 
numerically higher than those recorded at baseline (test: baseline 70.0 and 36 months 
70.6; control: baseline 64.6 and 36 months 64.9).
Implant survival




medical	history	of	myocardial	 infarction	and	 type	2	diabetes	mellitus.	 The	 second	
Table 1  Patient	demographics	and	baseline	characteristics.	
Variable Test (n = 52) Control (n = 25) p-value
Sex, n	(%)
Male 23 (44.2) 15 (60.0)
Female 29 (55.8) 10 (40.0) 0.2925
Age, mean (SD), yr 55.5 (± 13.8) 61.7 (± 13.5) 0.0701
Smoking at baseline, n	(%)
No 46 (88.5) 22 (88.0)
Yes 6 (11.5) 3 (12.0) 1.0000
Indication	for	implant,	n	(%)
Conductive	HL 14 (26.9) 7 (28.0)
Mixed HL 20 (38.5) 13 (52.0)
SSD 17 (32.7) 4 (16.0)
Other 1 (1.9) 1 (4.0) 0.4110
HL: hearing loss. SSD: single sided deafness.
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implant	loss	was	an	elective	explantation	after	one	year	in	a	39-year-old	woman	because	






implants)	of	visits,	Holgers	2	 in	1.8%	(test	 implants)	and	8.4%	(control	 implants)	of	
visits.	 No	 Holgers	 grade	 3	 or	 4	were	 observed.	 Statistical	 comparison	 of	 the	 two	
treatment	groups	in	terms	of	maximum	Holgers	grades	over	all	visits	for	each	patient	
showed	significantly	different	skin	reaction	profiles	(p = 0.005). A Holgers grade 2 was 
reported	to	occur	in	more	patients	with	the	control	implant	than	in	patients	with	the	
test	implant:	48.0%	of	patients	with	the	control	implant	experienced	a	Holgers	grade	
2	 reaction	 at	 some	 point	 during	 the	 three-year	 follow-up	 compared	 to	 15.4%	 of	
patients	with	the	test	 implant.	The	percentages	of	clinically	relevant	skin	reactions	
were	comparable	in	the	different	centers.
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implant with a moderately rough surface and the 3.75-mm-diameter control implant 
with	 an	 as-machined	 surface.	 The	 abutment	 designs	 were	 also	 different	 for	 both	
implants	 (see	 Figure	 1).	 The	 current	 study	 presented	 a	 continuation	 of	 previously	
published	 six-months	 data	 involving	 the	 same	 patients.5	 Significantly	 higher	 ISQ	
values were measured for the test implant compared to the control implant during 






studies on the test implant have been published in recent years,5,13-17 all showing 
promising yet short-term results. Three of these studies reported outcomes in varied 
Figure 3  Soft	tissue	reactions	as	a	percentage	of	all	visits	per	follow-up	moment	 
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88
populations,	 including	 children,	 with	 relatively	 short	 follow-up	 time	 and	 smaller	
n-size.13,14,17	Two	other	studies,	with	larger	populations,	mainly	focused	on	timing	of	
sound	 processor	 fitting,15,16	 also	 with	 limited	 follow-up	 time.	 The	 most	 important	
weakness of the current study is the non-blinded follow-up. However, a blinded 
study-design was not possible, as the abutment is clearly visible to the clinician 
performing the follow-up.
	 In	the	present	investigation,	ISQ	values	were	statistically	significantly	higher	for	
the test implant compared to the control implant, both as a weighted average over 
the complete study period (AUC) and at each follow-up moment. An animal study 
that	compared	both	 implants,	also	 reported	significantly	higher	 ISQ	values	 for	 the	
test implant.18 The mean AUC for ISQ values over three years in the current study was 
higher for both implants than the mean AUC over six months,5	 indicating	the	early	
stability is maintained over a longer period. It is also notable that mean ISQ values at 
three	years	are	higher	than	those	at	baseline.	The	initial	drop	in	ISQ	in	the	current	
study has also been reported from another study on the test implant16 and in dental 
research19 and has been suggested to be caused by normal bone healing characteris-
tics	in	response	to	the	surgical	intervention.5	The	decrease	in	ISQ	after	two	years	that	
is observed for both implants did not correspond with a clinically observed instability 
of	 the	 implants.	A	possible	 explanation	 for	 the	decrease	 in	 ISQ	 could	be	marginal	
bone loss around the implant. In dental literature, marginal bone loss is reported to 
commence	 already	 in	 the	 first	 year	 after	 implantation,	 followed	 by	 an	 annual	
progression. It is concluded to be a complex phenomenon that relies on a wide variety 
of	factors	(e.g.,	implant	design	and	location)	that	is	not	yet	fully	understood.20 Also, it 
is	unclear	if	these	findings	are	relevant	for	the	application	of	implants	in	the	temporal	
bone.	It	is	assumed	that	marginal	bone	loss	around	dental	implants	is	reflected	by	a	
decrease in ISQ of about three ISQ units per mm bone loss.12 To the best of our 
knowledge, no reports on marginal bone loss around implants in the temporal bone 
have	 been	 published.	 Therefore,	 speculation	 remains	 whether	 the	 ISQ	 decrease	
found in the current results could be explained by marginal bone loss, and might be 
verified	by	means	of	radiologic	imaging.	Furthermore,	it	will	be	extremely	valuable	to	
follow	up	on	this	specific	group	of	controlled	patients	in	the	future	in	order	to	evaluate	
how implant stability evolves over the even longer term.
	 ISQ	 is	 influenced	by	various	 characteristics	of	 the	 implant,	 the	abutment,	 and	 
the	 individual	 patient,	 and	 is	 therefore	 an	 interesting	 subject	 to	 discussion.	 In	 a	
comprehensive review of dental literature, Sennerby and Meredith discuss the use of 
RFA	and	interpretation	of	ISQ.12	They	reported	that	ISQ	represents	the	stiffness	of	the	
bone-implant	interface	and	is	often	found	to	increase	over	time,	most	likely	because	
of	 the	osseointegration	process.	Nevertheless,	most	 studies	have	 failed	 to	 show	a	
correlation	between	the	actual	degree	of	implant–bone	contacts	and	RFA	measurements.	





















































dental implants entangles the comparison.
	 Implant	geometry	is	considered	to	influence	the	difference	in	ISQ	between	both	







losses	 in	 this	 investigation	 does	 not	 allow	 to	make	 any	 correlations	 between	 ISQ	
values	and	implant	failure	rates.	The	first	implant	loss	occurred	in	a	man	with	insulin	
dependent type 2 diabetes mellitus, a disease reported to be correlated with a higher 
risk of implant loss.21	The	second	implant	loss	was	an	elective	surgical	explantation	
because	of	chronic	pain	around	the	implant,	a	complication	reported	to	be	the	main	
reason	 for	 elective	 explantations.22 The implant survival rate in the present 
investigation	compares	positively	with	rates	reported	in	the	literature.	A	retrospective	
analysis	 of	 implants	 similar	 to	 the	 control	 implant	demonstrated	 survival	 of	 91.7%	
during	a	mean	follow-up	time	of	4.6	years	(range	0–22	years).4	Interestingly,	79.8%	 
of	all	 lost	 implants	were	lost	during	the	first	three	years	after	implantation.	As	the	
current	 study	 is	 the	 first	 long-term	 prospective	 study	 with	 a	 large	 population	
comparing	the	previous	generation	and	new	implant,	there	is	only	dental	literature	
for comparison. In dental research, advantages of using wide-diameter implants have 
been	reported,	such	as	providing	a	larger	surface	for	bone-implant	contact,	resulting	
in	 higher	 initial	 mechanical	 stability,	 and	 a	 reduction	 in	 stresses	 and	 strain.6 
Moderately roughened surfaces are the most applied surfaces in dental implants, as 
they have proven superior in terms of bone response to the implant compared to 
smoother and rougher surfaces.7
 Dun et al.5 proposed that the rounded shape of the test abutment might have a 
positive	effect	on	the	stabilization	of	the	peri-implant	soft	tissue,	which	is	thought	to	
be	a	key	parameter	for	good	soft	tissue	health.	Furthermore,	the	conical	connection	
between	 the	new	 implant	 and	abutment	provides	a	tighter	 seal	 than	 the	external	
hexagonal	coupling	of	the	control	implant.	This	is	believed	to	reduce	the	risk	of	biofilm	
formation	 in	 the	abutment/implant	 interface	and	within	 the	abutment,	which	has	
been	identified	as	a	risk	factor	for	persisting	soft	tissue	reactions.23	The	statistically	
significant	 differences	 in	 adverse	 skin	 reactions	 between	 the	 test	 and	 the	 control	
implant in the current three-year data further strengthen this theory. Similar low 
adverse	skin	reactions	have	been	reported	on	the	test	implant	in	a	study	propagating	
an earlier loading protocol.16
90
Conclusion
The current study presented three-year clinical follow-up on two osseointegrated 
implants	for	bone	conduction	hearing.	The	test	 implant	showed	higher	 ISQ	values,	
indicating	better	implant	stability.	Both	test	and	control	implants	showed	high	implant	
survival	 rates	compared	to	 long-term	retrospective	analyses.	The	test	 implant	was	
also	 superior	 to	 the	control	 implant	concerning	 soft	tissue	outcome.	Loading	both	
implants	 at	 six	weeks	after	 surgery	was	 secure.	As	 a	 consequence	of	 the	 superior	
clinical	 results	 of	 the	 test	 implant	 in	 the	 current	 study,	 it	might,	 speculatively,	 be	
advocated	for	use	in	patients	with	compromised	bone	quality	or	wound	healing.
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CHAPTER 2.3
LOADING OF OSSEOINTEGRATED 
IMPLANTS FOR BONE 
CONDUCTION HEARING AT 
THREE WEEKS




Objective | To ascertain the long-term safety of loading osseointegrated implants for 
bone	conduction	hearing	three	weeks	post-surgery.
Methods |	Thirty	consecutive	adult	patients	were	 implanted	with	 the	Baha	BI300	
(Cochlear	 Bone	 Anchored	 Solutions)	 in	 our	 tertiary	 referral	 center.	 Implants	were	
loaded	with	the	sound	processor	three	weeks	post-surgery.	Follow-up	examinations	





type of implants loaded from 6 weeks post-surgery as part of another study. 
Subjective	benefit	was	measured	by	means	of	the	Glasgow	Benefit	Inventory	(GBI).
Results |	After	an	initial	dip	in	ISQ	at	10	days	after	implantation,	a	gradually	increasing	
trend	 in	 ISQ	was	found	until	6	months	 in	both	populations,	after	which	 ISQ	values	
remained	above	baseline	values.	 Implant	survival	was	97%	in	the	study	population	
and	96%	in	the	comparison	population.	Clinically	relevant	soft	tissue	reactions	were	
found	 in	 0.9%	 (study	 population)	 and	 1.7%	 (comparison	 population)	 of	 all	 visits.	
Patients	reported	subjective	benefit;	the	mean	GBI	score	was	22.8.
Conclusion | Loading these implants at three weeks post-surgery is safe based on the 
current study, as long-term results show high ISQ values and good implant survival 
and tolerability.
PUBLISHED AS | Nelissen RC, den Besten CA, Faber HT, Dun CAJ, Mylanus EAM, Hol 
MKS.	Loading	of	osseointegrated	implants	for	bone	conduction	hearing	at	3	weeks:	










































Percutaneous	 osseointegrated	 titanium	 implants	 in	 the	 temporal	 bone	 have	 been	
used	 since	 1977	 to	 attach	 a	 vibrating	 sound	 processor	 to	 accomplish	 hearing	
amplification	for	several	indications.1,2	Obviously,	an	implant	needs	to	be	sufficiently	
fixated	 to	 the	 bone	 before	 loading	 it	with	 the	 sound	 processor	 is	 feasible.	 In	 the	
earliest days, implant surgery consisted of two stages, allowing a minimum of three 
months	of	osseointegration	time	before	the	percutaneous	abutment	was	connected	
to the implant, which allowed loading with the sound processor.1,3 Later on, clinical 
application	of	a	one-stage	surgical	technique	was	reported	with	a	healing	time	of	six	
to eight weeks before loading the implant.4
	 To	allow	patients	to	start	using	their	device	as	soon	as	possible,	yet	safely,	after	
implantation,	loading	times	have	gradually	decreased.	This	was	mostly	stimulated	by	
dental research where earlier (and even immediate) loading protocols are common 
practice.	A	recent	Cochrane	Review5 concluded that there was no convincing evidence 
of	a	clinically	important	difference	in	prosthesis	failure,	implant	failure,	or	bone	loss	
associated	with	different	 loading	times	of	dental	 implants.	However,	the	quality	of	
the evidence was assessed as very low due to risks of bias in primary studies and 




on expert opinion.2	 Subsequently,	 even	 earlier	 loading	 protocols	 have	 been	
reported.6,7 These results were all found using 3.75-mm-diameter implants. In 2010, 
a 4.5-mm-diameter implant with a moderately roughened surface was introduced. 
The larger implant diameter increases the bone-implant contact surface, which 
should	theoretically	result	in	a	larger	area	for	osseointegration,	while	the	moderately	
roughened	surface	 is	 thought	to	stimulate	the	 initial	healing	response	of	the	bone	
directly	after	implantation.	Promising	short-term	clinical	results	of	applying	a	loading	
time	of	six	weeks	after	implantation	with	this	implant	were	reported.8	Subsequently,	
even	shorter	loading	times	of	four,9 three,10 and two weeks11 were advocated when 
using this implant.
	 The	current	study	is	a	continuation	of	the	study	that	presented	the	clinical	results	
of loading at three weeks with a follow-up period of six months.10 Study outcomes 
concern	the	clinical	results	on	implant	stability	quotient	(ISQ),	implant	survival,	and	
soft	 tissue	 tolerability	 of	 this	 wide	 and	moderately	 roughened	 implant	 loaded	 at	
three weeks with a follow-up period of three years. This is considerably longer than 
all other early loading data published to date, which have been presented with a 
follow-up	of	one	year	or	less.	Additionally,	outcomes	were	compared	to	those	from	
another study of the same type of implant, which, however, had been loaded from six 
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implant	or	 implant	 loading	at	 three	weeks	had	been	 reported,	only	adult	patients	
with	 normal	 bone	 quality	 were	 considered	 for	 participation	 in	 the	 study.	 To	 be	





that	 compromises/will	 compromise	 the	 bone	 quality	 at	 the	 implant	 site,	 such	 as	
radiation	therapy	and	osteoporosis	(assessed	by	medical	history);	psychosocial	problems	
or	 psychiatric	 disease;	 and,	 finally,	 the	 inability	 to	 attend	 all	 scheduled	 follow-up	
visits.	 Furthermore,	 if	 patients	were	 assessed	during	 implantation	 to	 have	 a	 bone	
thickness at the implant site of less than 4 mm, they were excluded. All subjects were 
free	 to	 discontinue	 participation	 in	 the	 investigation	 at	 any	 time	without	 giving	 a	
reason and without prejudice regarding further treatment.
	 The	results	from	the	current	investigation	were	compared	to	those	of	52	patients	
(referred	 to	 as	 the	 “comparison	 population”),	 implanted	 with	 the	 same	 type	 of	
implant	 and	 abutment,	 reported	 on	 in	 a	 previous	 multicenter	 study	 with	 similar	
inclusion	and	exclusion	criteria	and	an	almost	identical	study	protocol,	however,	with	
implant	 loading	from	six	weeks	after	surgery.	Thus,	 this	population	 is	not	a	 formal	
control group. Therefore, methods and outcomes concerning this group will not be 



















































	 No	 sample	 size	 calculation	was	 conducted,	 as	 no	 differences	 between	 groups	
were	expected.	Thus,	the	study	population	size	was	chosen	empirically.
	 After	 inclusion	and	having	provided	written	 informed	 consent,	 patients	 in	 the	
current	investigation	underwent	one-stage	implant	surgery	with	subcutaneous	tissue	
reduction,	 according	 to	 the	 Nijmegen	 linear	 incision	 technique,14 in June and July 




means	of	 resonance	 frequency	analysis	 (RFA)	with	 the	Osstell	Mentor	 (Osstell	AB,	
Göteborg,	 Sweden),	 an	 objective	 and	 non-invasive	 technique.	 RFA	 provides	
information	about	the	stiffness	of	the	implant–bone	junction15 and produces two ISQ 
values: ISQ High and ISQ Low, usually obtained from perpendicular measurements 
and	 generally	 differing	 a	 few	 points.	 Both	 values	may	 be	 used	 for	 interpretation;	
however, as trends should be analyzed, it is important to use one of both values 
consistently.	 In	 the	 current	 study,	 the	 ISQ	High	 values	were	used	 in	 the	 statistical	
analyses. In cases where an abutment was replaced by a longer one during follow-up, 
ISQ values were no longer included in the analysis from that point on, as a change in 
length	of	the	abutment	affects	the	ISQ	values.	Soft	tissue	status	was	monitored	and	
graded	according	to	Holgers’	classification.16
 Implant loading occurred at three weeks, provided that the stability of the 
implant	(evaluated	clinically	and	not	based	on	an	absolute	ISQ	value)	and	soft	tissue	
status	 were	 judged	 to	 be	 satisfactory.	 Significant	 postoperative	 wound	 healing	
complications	or	a	soft	tissue	reaction	corresponding	to	a	Holgers	grade	3	or	higher	
would result in postponed implant loading.















was developed and validated in reference material by Osstell AB to transfer the ISQ 
values measured in the present study to corrected ISQ values to address the use of 
different	SmartPegs,	as	a	change	in	SmartPeg	type	was	advised	during	the	course	of	
the study. Only these corrected ISQ values (i.e., comparable to measurements with 
SmartPeg type 55) are presented throughout the study to make it possible to compare 
ISQ	values	between	the	present	study	and	the	comparison	population.	A	weighted	
average	of	ISQ	values	during	the	period	between	baseline	(time	of	implantation)	and	
the three-year follow-up was obtained by determining the mean area under the 
curve	(AUC)	using	the	trapezoid	rule.	The	mean	AUC	was	calculated	for	the	time	the	
implant	was	 functional.	 For	 patients	who	were	 lost	 to	 follow-up,	 last	 observation	
carried	forward	was	used	in	the	mean	AUC	calculations.	Comparisons	between	the	
study	and	comparison	populations	were	made	using	Fisher’s	exact	test	for	gender,	









to	be	comparable.	 In	both	groups,	 three	patients	were	excluded	during	 follow-up.	
The	reasons	for	exclusion	from	the	current	study	were:	implant	loss	(after	three	days),	
non-implant-related	death	(after	22	months),	and	lack	of	follow-up	(patient	left	out	of	



















































visit.	 After	 an	 initial	 dip	 in	 mean	 ISQ	 ten	 days	 after	 implantation,	 ISQ	 gradually	
increased	until	six	months	after	implantation.	A	dip	in	ISQ	was	found	at	two	years,	
after	which	mean	ISQ	increased	at	three	years	to	the	same	mean	value	as	found	at	
one year. From two years and onwards, the spread in ISQ values increases (as seen by 
an	 increase	 in	 95%	 confidence	 intervals	 of	 mean	 ISQ).	 Two	 patients	 required	 an	
abutment	replacement	to	a	longer	9-mm	abutment	due	to	soft-tissue	problems	with	




Table 1   Patient	characteristics	of	the	study	population	(3-week	loading)	and	 
the	comparison	population	(6-week	loading).	
3-week loading (n = 30) 6-week loading (n = 52) p-value
Sex, n	(%)
   Male






Age (years), mean (SD) 55.3 (± 12.3) 55.5 (± 13.8) 0.92
Indication	for	implant
   CMHL
   SSD









Figure 1  Box-and-whisker	plot	of	ISQ	High	values	for	the	study	population	(3-week	
loading).	Mean	(cross)	and	median	(horizontal	line)	are	defined	within	the	boxplot.	
Dots represent outlier values.
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no	statistically	significant	difference	(p = 0.22) between the study and comparison 
populations.	Within	the	comparison	population,	the	percentages	of	Holgers	grade	2	
soft	 tissue	 reactions	were	 comparable	 between	 the	 different	 centers,	which	 each	
applied	their	customary	soft	tissue	handling	technique.12














Red and slightly moist tissue (Holgers grade 2)




three-year	 follow-up	was	88.9%	 (n = 24). Of these responders, 18 used the sound 
processor daily, 4 sporadically, 2 stopped, and 2 had lost their sound processors. The 
daily users reported a mean GBI total score of 22.8, compared to 11.1 reported by the 





be safe and, thus, should not compromise implant stability and wound healing. The 
current	study	investigated	the	long-term	safety	of	reducing	the	loading	time	to	three	
weeks	 after	 implantation	 and	 provides	 a	 comparison	 to	 previously	 reported	 data	 




on	 the	 long-term	 safety	of	 this	 early	 loading	protocol.	 There	 is	 a	 limitation	 in	 the	
comparison	with	a	group	loaded	from	six	weeks	from	another	prospective	multicenter	
study,8,12	in	that	this	comparison	was	not	set	up	as	a	randomized	controlled	prospective	






implant stability, which was the primary analysis of the current and the former study. 
The inclusion and exclusion criteria of both studies were similar.
	 ISQ	 trends	over	time	were	not	 found	 to	be	 influenced	by	 loading	 the	 implant	 
at	three	weeks	compared	to	loading	from	six	weeks.	An	initial	dip	in	ISQ	during	the	
first	 follow-up	 examination	 after	 implantation	was	 found,	which	 is	 believed	 to	 be	
attributed	 to	normal	 bone	 remodeling	 characteristics.10 No decrease in ISQ values 
during	the	immediate	period	after	implant	loading	at	three	weeks	was	observed.	This	
suggests	that	the	level	of	stability	at	three	weeks	after	implantation	of	the	current	
implant	 is	 adequate	 to	 support	 the	 sound	 processor.	 As	 with	 the	 comparison	
population,	ISQ	values	remained	above	baseline	values,	as	measured	at	implantation,	








































Interestingly,	 in	the	study	population	there	 is	a	dip	 in	mean	ISQ	after	two	years	of	
follow-up,	 after	 which	 mean	 ISQ	 increases	 again	 at	 three	 years.	 We	 have	 no	
explanation	for	this	one-point	dip,	but	it	is	not	deemed	to	be	of	clinical	significance,	
as it did not result in implant loss and the ISQ values increased again at three years. It 





known to occur in dental implantology.17 However, in that case we do not understand 
why	there	is	a	difference	between	the	trends	for	these	two	groups.
 Despite slightly decreasing ISQ trends during some periods, implants remained 





studies using implants and abutment of the same type and size,9,11,12 ISQ in this type of 
implant rarely drops below a value of 55. However, it is not currently possible to 
determine strict ISQ values that indicate the point at which loading is safe; only ISQ 
trends	over	time	should	be	interpreted	for	clinical	use.	More	ISQ	data	will	be	needed	
in	 order	 to	 establish	 clinical	 relevance	 of	 specific	 values.	 Dental	 implantological	
studies	 have	 shown	 that	 high	 ISQ	 values	 are	 indicative	 of	 a	 successful	 implant	




demonstrate	 significant	 differences	 in	 implant	 survival.	 These	 figures	 compare	
positively	 to	 those	 reported	 on	 the	 previous	 3.75-mm-diameter	 as-machined	titanium	
implants	 in	 a	 long-term	 retrospective	 study	 (92%),	 which	 also	 demonstrated	 that	
implant	 loss	 occurred	 most	 frequently	 (79.8%	 of	 all	 lost	 implants	 in	 that	 study)	 
in	 the	 first	 three	 years	 after	 implantation.18 In dental implantology, wider implant 




healing	 negatively	 nor	 positively.	 The	 percentages	 of	 clinically	 relevant	 soft	tissue	
reactions	(Holgers	grade	2	or	higher)	are	favorable	for	both	the	study	and	comparison	
populations	 compared	 to	 those	 reported	 in	 retrospective	 studies.18,21 As these 
retrospective	studies	predominantly	report	on	the	previous	implant	with	a	conically	
104
shaped	 abutment,	 the	 positive	 soft	 tissue	 tolerability	 recorded	 in	 the	 current	
investigation	 can	most	 likely	 be	 attributed	 to	 the	 new	 rounded	 abutment	 design,	
possibly	in	combination	with	a	more	stable	implant.	This	is	confirmed	by	a	previous	
prospective	 randomized	 controlled	 clinical	 comparison	 of	 the	 rounded	 abutment	
design and a conically shaped abutment.12
	 To	date,	few	studies	have	reported	long-term	clinical	outcomes	from	prospective	
studies of the current implant. However, long-term stability and survival are crucial 
parameters	 for	 a	 successful	 implant.	 Therefore,	 in	 addition	 to	 the	 need	 for	more	
long-term data to be published, follow-up periods exceeding three years will be of 
great interest. 
	 Subjective	benefit	as	measured	by	 the	GBI	 in	 the	daily	users	group	 (22.8)	was	
comparable	 to	 the	 score	 measured	 at	 three	 months	 (20.9).	 Satisfaction	 with	 the	
implant	 and	 device	 did	 not	 change	 appreciably	 over	 time.	 As	 can	 be	 expected,	
patients	who	used	their	sound	processors	less	frequently	or	not	at	all	reported	lower	
scores.	Because	the	GBI	was	only	completed	by	the	study	population,	a	comparison	




The reported long-term results of an early loading protocol at three weeks post 
implantation	 indicate	 good	 ISQ	 values	 over	 time,	 implant	 survival,	 and	 soft	 tissue	
tolerability. These results were compared to those of the same implant type loaded 
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STABILITY, SURVIVAL,  
AND TOLERABILITY OF A 
4.5-MM-WIDE BONE-ANCHORED 
HEARING IMPLANT




Objective | To compare the stability, survival, and tolerability of two percutaneous 
osseointegrated	titanium	implants	for	bone	conduction	hearing:	a	4.5-mm-diameter	
implant (test) and a 3.75-mm-diameter implant (control).
Methods |	 Fifty-seven	adult	patients	were	 included	 in	 this	 randomized	 controlled	
clinical	trial.	Sixty	implants	were	allocated	in	a	2:1	(test–control)	ratio.	Follow-up	visits	
were scheduled at 7, 14, 21, and 28 days; 6 and 12 weeks; and 6 months. At every visit, 
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bone	conduction	devices	to	the	temporal	bone	since	1977.1 Both implants and devices, 
as	well	as	the	indications	for	application,	have	been	studied	extensively.2,3 The clinical 
outcomes	 of	 these	 implants	 have	 been	 reported	 in	 large	 populations:	 long-term	
implant	survival	rates	vary	between	81.5%	and	98.4%,	while	complications	generally	
involve	soft	tissue	inflammation.4-6	Severe	complications	are	rare.4,5
 Recently, the designs of these bone-anchored hearing implants have evolved to 
include	wider	diameters,	based	on	the	known	advantages	of	wider	implants	in	dentistry.7 
These 4.5-mm-diameter implants provide a larger contact surface between the 
implant and the bone compared to the 3.75-mm-diameter implants of the previous 
generation,	which	results	in	higher	reported	implant	stability	quotients	(ISQ)	and	high	










The test implant was the wide Ponto implant (diameter 4.5 mm, length 4 mm) and 
the	control	implant	was	the	previous	generation	Ponto	implant	(diameter	3.75	mm,	
length 4 mm). Both implants used the same 6-mm abutment. The implants and abutments 
are	 developed	 and	manufactured	 by	Oticon	Medical	 AB	 (Askim,	 Sweden)	 and	 are	
displayed in Figure 1.
 Out	 of	 all	 of	 the	 patients	 indicated	 for	 a	 percutaneous	 bone	 conduction	 device,	 
57	adult	patients	with	a	total	of	60	implants	were	consecutively	included.	Eligibility	
criteria	were	as	 follows:	 indication	 for	 a	percutaneous	 implant;	 age	of	 18	 years	or	
older;	bone	thickness	of	at	least	4	mm	at	the	implant	site;	written	informed	consent	




implant site (e.g., radiotherapy, osteoporosis, diabetes mellitus).
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Study design
The current study was designed as an open randomized controlled clinical trial in 
our	 tertiary	 referral	 center.	The	primary	outcome	parameter	was	 implant	 stability	





ISQ Low values during the six-month follow-up period was obtained by the mean 
area	 under	 the	 curve	 (AUC)	 calculation	 using	 the	 trapezoid	 rule	 with	 all	 ISQ	 low	
measurements	 over	 the	 first	 six	months.	 Data	 from	 a	 similarly	 designed	 previous	
study11	 were	 used	 for	 the	 sample	 size	 calculation.	 An	 expected	 difference	 of	 4.5	
in the mean AUC of the ISQ Low values of the test and the control groups, with 
unequal	 standard	 deviations	 (SDs)	 of	 ±	 2.8	 and	 ±	 5.5,	 respectively,	were	 used	 for	








feasible because the appearances of the implants and instruments used during surgery 
were	clearly	different.	Because	most	patients	were	operated	under	local	anesthesia,	
the	patients	were	also	not	blinded.	
 Implants and abutments were placed in a single-stage surgical procedure. The 
linear	 incision	 technique	 with	 subcutaneous	 tissue	 reduction	 was	 applied	 in	 all	
cases.12 Implants were alternately placed within or posterior to the incision line. In 


















































accordance with the study protocol, follow-up visits were scheduled at 7, 14, 21, and 
28	days,	6	and	12	weeks,	and	6	months.	At	each	visit,	resonance	frequency	analysis	
(RFA)	 was	 used	 to	 establish	 the	 ISQ.	 RFA	 uses	magnetic	 pulses	 generated	 by	 the	
Osstell ISQ device (Osstell AB, Göteborg, Sweden) to excite the SmartPeg (type 55) 
that	is	connected	to	the	abutment,	which	leads	to	vibration	of	the	implant-abutment	
system.	The	intensity	of	these	vibrations	is	analyzed	by	the	device	that	computes	the	
ISQ,	which	 is	an	 indication	of	 the	 rigidity	of	 the	 implant-bone	 link.13 Perpendicular 




Profile	 of	Hearing	Aid	Benefit	 (APHAB),15	 the	Glasgow	Benefit	 Inventory	 (GBI),	 and	
the Glasgow Health Status Inventory (GHSI).16 The APHAB and GHSI outcomes were 
only	included	in	the	analysis	when	both	the	baseline	screening	before	implantation	
and	 the	 six-month	 evaluation	 had	 been	 completed.	 In	 cases	where	 patients	 used	
hearing	aids	at	 the	baseline	evaluation,	 they	were	asked	 to	complete	 the	baseline	
questionnaire	both	for	the	aided	and	unaided	conditions.	The	unaided	condition	was	
used	as	the	baseline	measurement	for	analyzing	the	benefit	of	the	bone	conduction	





 For comparisons between the test and control groups, Mann-Whitney U tests were 

































(n	 =	 39)	 and	 59.3	 (SD	 ±	 2.1;	 range	 55.5–62.5)	 for	 the	 control	 population	 (n = 20). 
The	difference	between	groups	of	5.1	 ISQ	points	 (95%	CI	3.6–6.6;	p < 0.0001) was 
Table 1   Patient	demographics	and	baseline	characteristics.	
Variable Test (n = 39) Control (n = 20) p-value
Gender, n	(%)
Male 15 (38.5) 9 (45.0)
Female 24 (61.5) 11 (55.0) 0.8554
Age in years, mean (SD) 53.7 (± 12.0) 53.0 (± 16.4) 0.4950
Smoking at baseline, n	(%) 6 (15.4) 6 (30.0) 0.2750
Body mass index, mean (SD) 25.9 (± 4.2) 25.3 (± 4.1) 0.6029
Skin disease, n	(%) 4 (10.3) 3 (15.0) 0.8288
Indication	for	bone-anchored	hearing	
 implant, n	(%)
Acquired	conductive/mixed	hearing	loss 26 (66.7) 16 (80.0) 0.3657
Congenital	conductive	hearing	loss 1 (2.6) 1 (5.0) 1.0000


















































statistically	significant.	For	ISQ	High,	a	difference	of	3.3	(95%	CI	1.8–4.7;	p < 0.0001) 
was observed during the six-month follow-up, with a mean AUC of 65.8 (SD ± 2.7; 
range	57.0–70.5)	for	the	test	population	and	62.5	(SD	±	2.8;	range	56.9–66.8)	for	the	
control	population.	At	all	follow-up	visits,	statistically	significant	differences	in	mean	
ISQs between both groups were recorded. The results are displayed in Figure 2. The 
mean	increase	in	ISQ	from	baseline	is	statistically	significant	in	both	groups;	however,	
the	 increase	 in	 ISQ	 from	 baseline	 for	 the	 test	 implant	 is	 statistically	 significantly	
stronger compared to the increase for the control implant. The ISQ dip at 42 days for 




the test implant can be ascribed to a single implant that displayed a very low ISQ (ISQ 
Low 46, ISQ High 52) but remained clinically stable and presented with an ISQ within 
the normal range at the next follow-up appointment.
 No dip in mean ISQs was observed, as the ISQ High and ISQ Low values were 





± 4.6; range –4–29) was observed for the total group (n	=	59),	which	was	significantly	
different	 from	the	 ISQ	 low	at	the	time	of	surgery	(p < 0.0001). The mean increase 








and	 two	 implants	 (10.0%)	 in	 the	 control	 group	 developed	 adverse	 skin	 reactions	
(Holgers	 grade	 2–4).	 Results	 related	 to	 soft	 tissue	 reactions	 are	 displayed	 in	 Figure	 3.	 
The	analysis	of	soft	tissue	statuses	throughout	the	follow-up	period	revealed	findings	
of	Holgers	grade	0	in	87.1	%	(test)	and	88.4	%	(control)	of	visits,	Holgers	grade	1	 in	
11.8	%	 (test)	 and	9.5	%	 (control)	of	 visits,	Holgers	grade	2	 in	 1.1	%	 (test)	 and	 1.4	%	
(control)	of	visits,	Holgers	grade	3	 in	0.0	%	 (test)	and	0.7	%	 (control)	of	visits,	and	









the	 questionnaire	 outside	 of	 the	 defined	 visit	window	 (mean	of	 22	 days	 after	 the	
planned	visit	date).	These	results	were	still	included	in	the	final	analysis.	No	differences	
were observed in the outcomes between the test and control groups. The results are 


















































All	 patients	 completed	 the	 APHAB	 and	 GHSI	 questionnaires	 six	 months	 after	
surgery.	However,	five	patients	did	not	complete	baseline	questionnaires	and	were	
consequently	 excluded	 from	 the	 benefit	 analysis.	 One	 additional	 patient	 did	 not	
complete	 the	 baseline	 APHAB,	 while	 another	 three	 patients	 were	 excluded	 from	
the	 benefit	 analysis	 using	 the	GHSI	 because	 of	 incomplete	 data	 on	 the	 six-month	
questionnaire.	The	outcomes	of	these	questionnaires	are	displayed	in	Figure	4.	For	
the	GHSI,	 significant	 improvement	was	observed	 for	 the	 total	 and	 general	 scores,	
but not for the social and physical subscales. The APHAB indicated that there was 
statistically	 significant	 improvement	on	 all	 of	 the	 subscales	 in	 the	 aided	 condition	
compared	to	the	unaided	condition.
Figure 3  Soft	tissue	tolerability	for	both	test	and	control	groups	as	a	percentage	of	
all	visits	according	to	the	Holgers	classification.	Note	that	only	Holgers	grade	0	to	3	
are depicted, as no Holgers grade 4 was observed.
Table 2   Subjective	benefit	as	measured	by	the	GBI.	
Variable Test (n = 39) Control (n = 20) p-value
Total score (SD) 33.1 (± 20.0) 36.5 (± 14.1) 0.4889
General subscale (SD) 46.9 (± 25.5) 50.7 (± 21.2) 0.5715
Social subscale (SD) 11.0 (± 20.6) 10.0 (± 18.6) 0.9199
Physical subscale (SD) 1.28 (± 18.9) 6.67 (± 14.7) 0.0371
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Discussion
The current randomized controlled clinical trial compared outcomes of two percutaneous 
bone-anchored	 hearing	 implants	 for	 bone	 conduction	 devices	 with	 six	months	 of	
follow-up. These implants, a new 4.5-mm-diameter implant (test) and the 3.75-mm 
previous	generation	implant	(control),	were	both	loaded	with	the	bone	conduction	device	
at	three	weeks.	The	test	implant	exhibited	significantly	higher	ISQ	values	than	the	control	





















































implant. All other clinical outcomes were comparable between the implants. Quality of 
life	generally	improved	in	the	aided	condition	compared	to	before	implantation.
 The strengths of the current study include the absence of cases lost to follow-
up	and	the	conscientiously	followed	prospective	study	protocol.	The	tightly	spaced	
follow-up	 visits	 allow	 for	 a	 detailed	 analysis	 of	 the	 development	 of	 the	 implant’s	
stability.	Therefore,	the	study	design	yielded	useful	information	on	short-term	clinical	
results	for	both	implants.	The	study’s	strength	lies	also	in	the	fact	that	only	a	single	
parameter,	 the	 implant	width/design,	was	varied.	A	 limitation	of	 the	current	study	
was	the	non-blinded	follow-up	for	the	investigators	and	patients.
Both	implants	exhibited	positive	trends	in	ISQ	measurements	that	generally	increased	
from	baseline	until	 the	final	 follow-up	at	 six	months.	These	positive	 trends	are	an	
indication	of	a	progression	 in	 implant	stability	over	time.	RFA	application	 in	bone-
anchored hearing implants has gained increasing interest in recent years. However, 
to	date,	reporting	standards	vary	widely.	Therefore,	comparisons	between	different	
studies should be made very carefully. Foghsgaard and Caye-Thomasen8 also studied 
the	test	implant	and	found	an	increasing	trend	in	ISQ	in	the	first	year	after	surgery;	
however, they noted a slight decrease at the second follow-up visit (mean 7.3 weeks), 
when loading was applied. In our results, the ISQ was never lower than at surgery. 
It	is	worth	noting	not	only	that	the	test	implant	gave	higher	ISQ	values	on	average,	 
as	expected,	but	also	that	the	increase	in	ISQ	over	time	was	significantly	higher	for	
the	 test	 implant	 than	 the	 control	 implant.	Although	 the	present	 investigation	was	
limited	to	adult	patients	with	normal	bone	quality,	it	might	be	anticipated	that	the	
positive	outcomes	of	the	test	implant	could	improve	treatment	outcomes	in	pediatric	
patients	 and	 patients	with	 compromised	 bone	 quality.	 In	 comparable	 prospective	
studies	on	another	wide	implant	type,	increasing	ISQ	trends	were	reported	in	the	first	
six	months	as	well,	with	a	dip	in	the	ISQ	at	the	first	follow-up	visit	after	surgery	(ten	
days).10,11 A three-year follow-up on those implants revealed somewhat decreasing 
trends	in	ISQs	beginning	two	years	after	implantation.9	It	will	be	interesting	to	extend	
the follow-up period of the current study to observe ISQ trends in comparison.
	 At	 this	 moment,	 the	 clinical	 implications	 of	 absolute	 ISQ	 values	 are	 not	 yet	
understood,	so	only	trends	should	be	evaluated.	Additionally,	in	dental	implantology,	
there	 is	 still	 a	 lack	of	 studies	documenting	 clear	 clinical	benefits	 from	 therapeutic	






(range 12.1–25.2 months).17 These survival rates are slightly higher than those reported 
in	 two	other	prospective	 studies	on	a	different	wide	 implant	 type.10,11 Although all 
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of	these	are	short-term	results,	the	first	year	after	surgery	has	been	reported	to	be	




diameter	 flange	 fixtures	 with	 a	 design	 comparable	 to	 that	 of	 the	 current	 control	
implant).4-6
	 Soft	tissue	tolerability	was	comparably	good	in	both	the	test	and	control	implants,	
with	 incidental	 adverse	 Holgers	 grade	 2	 and	 3	 skin	 reactions.	 This	 was	 expected	
because	 the	 abutment,	 which	 is	 believed	 to	 mainly	 influence	 the	 skin	 outcomes,	
was	the	same	for	both	the	test	and	control	groups.	The	current	adverse	soft	tissue	
events	are	comparable	or	even	slightly	better	than	rates	reported	from	this	center	
in the studies of another type of wide implant,10,11 also installed with skin thinning 





	 As	 both	 implants	were	 loaded	 at	 three	weeks	 after	 implantation,	 the	 current	
study	established	that	early	loading	did	not	affect	the	positive	ISQ	trend	and	short-
term	 clinical	 outcomes.	 This	 is	 confirmed	by	 another	 study	 of	 the	 current	 control	
implant	that	reported	on	a	loading	time	as	early	as	two	weeks	after	implantation.21 
Early loading of two, three and four weeks has also been studied on another type of 
wide implant with promising short-term results.10,22,23
	 Hearing-related	quality	of	 life	 improved	due	to	the	system	as	a	whole,	as	patients	
reported	 improvements	 on	 both	 the	 APHAB	 and	 GHSI	 questionnaires	 from	 pre-
implantation	to	six	months	later.	The	aided	APHAB	outcome	is	comparable	to	a	similar-
sized	 population	with	 single-sided	 deafness	 fitted	with	 bone	 conduction	 devices24 
and	better	than	a	larger	population	of	elderly	patients	fitted	with	bone	conduction	
devices	for	mixed	indications.25	The	APHAB	outcome	can	be	strongly	 influenced	by	
the	 sound	 processor	 used,	 with	modern	 sound	 processors	 producing	 significantly	
better	aided	APHAB	scores	 than	older	 technologies.26 To our knowledge, the GHSI 
has	not	been	used	to	evaluate	quality	of	life	improvements	with	percutaneous	bone	
conduction	devices.	GBI	scores	were	also	positive	and	comparable	between	groups.	
The	 current	 GBI	 outcome	 compares	 positively	 to	 other	 studies	 that	 used	 the	 GBI	
to	 establish	 benefit	 from	 bone	 conduction	 systems	 (see	 Table	 3	 in	 Faber	 et	 al.10). 
It	should	be	emphasized	that	indications	and	patient	characteristics	influence	quality	





















































After	 six	 months	 of	 follow-up,	 outcomes	 of	 a	 new	 4.5-mm-diameter	 implant	 for	
bone	 conduction	devices	 compared	 to	 the	previous	generation	3.75-mm-diameter	
implant	exhibited	higher	 ISQ	values	and	similarly	promising	clinical	characteristics.	
No	implants	were	lost,	and	soft	tissue	tolerability	was	good.	Loading	both	implants	
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CLINICAL AND  
AUDIOLOGICAL ASPECTS OF  




COMPARISON BETWEEN  
A NEW IMPLANTABLE 
TRANSCUTANEOUS BONE 







Especially in children, adverse events with percutaneous BCDs might occur more 
frequently.	 Transcutaneous	BCDs,	 if	 powerful	 enough,	 can	 provide	 a	 solution	 that	
minimizes adverse events and implant loss. This study compares a new transcutaneous 




with the Sophono and 6 with the BAHA. Both clinical results and audiologic data were 
gathered.	For	an	objective	audiologic	comparison	between	both	systems,	we	used	a	
skull simulator.




and speech comprehension at 65 dB. The skull simulator demonstrated that the 
output of the BAHA was 10 to 15 dB higher compared to the Sophono.
Conclusion |	The	Sophono	offers	appealing	clinical	benefits	of	transcutaneous	bone	
conduction	hearing;	however,	the	audiologic	challenges	of	transcutaneous	application	
remain,	 as	 the	 Sophono	 does	 not	 exceed	 percutaneous	 application	 regarding	
audiological output.
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skull-bone is well-known. In 1977, Tjellström et al.1	were	the	first	 to	make	use	of	a	
percutaneous	 bone	 conduction	 device	 (BCD),	 termed	 bone-anchored	 hearing	 aid	
(BAHA),	 by	 combining	 BC	 hearing	 with	 the	 principle	 of	 osseointegrated	 titanium	
implants.	In	2005,	a	consensus	statement	has	been	formulated	on	indications	for	the	
use	 of	 these	 titanium	percutaneous	 temporal	 bone	 implants	 for	 BC	 hearing.2 The 
benefits	of	these	BCDs	on	percutaneous	implants	compared	with	conventional	BCDs	
that	are	mounted	in	spectacles	or	attached	to	steel	springs	have	been	recognized.2,3 
Although	 percutaneous	 application	 demonstrated	 its	 merits	 and	 successes,	 one	
should be aware of some drawbacks.4,5 First, the implant site for percutaneous 
coupling	requires	lifelong	care,	and	adverse	skin	reactions	can	be	observed.	Second,	
loss	of	the	implant	can	occur,	either	spontaneously,	due	to	infection,	or	as	a	result	of	





has	been	demonstrated,	 particularly	 in	 cases	of	 bilateral	 conductive	hearing	 loss.7 
The	application	of	BCDs	in	children	from	as	young	as	three	months	old	is	possible	by	
connecting	the	hearing	device	to	an	elastic	softband.8 From the age of four the skull 
is	thick	and	mature	enough	to	allow	safe	implantation	for	percutaneous	devices.2,9,10
Children with percutaneous implants are more prone to adverse events, e.g., skin 




transcutaneous BCDs is ongoing. In 1986, Hough et al.13	introduced	the	first	implantable	
transcutaneous	BCD,	the	temporal	bone	stimulator,	marketed	as	the	Xomed	Audiant.	
A magnet was implanted in the temporal bone and covered by a thin layer of skin. The 
implanted	magnet	was	 driven	 by	 an	 external	 coil	 that	was	 positioned	on	 the	 skin	
above	the	magnet	and	secured	by	a	coupling	magnet.	Consequently,	the	implanted	
magnet was part of the actuator of the Audiant. The external coil was powered by an 
amplifier	in	a	behind-the-ear	housing	or	in	a	larger,	body-worn	housing.	The	major	
disadvantage	 of	 this	 configuration	 was	 the	 relatively	 large	 distance	 between	 the	
implanted magnet and the external driving coil.14 Resultantly, gain and maximum 
output were low15	and	significantly	worse	compared	to	the	percutaneous	alternative.14 
Additionally,	the	clinical	outcomes	of	the	Audiant	were	less	favorable,16 and the device 
was withdrawn from the market.
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Magnetic	coupling	was	revitalized	by	the	Otomag	BCD,	on	which	Siegert	has	reported	








device as described by Siegert is nowadays known as the Sophono Alpha 1 (Sophono, 
Inc., Boulder, Colorado, USA).
	 The	current	paper	reports	on	the	first	results	of	six	patients	who	received	the	
Sophono Alpha 1 and discusses whether this new transcutaneous system is a valuable 






Between April 2010 and December 2011, six children aged 5–11 years (mean 7 years) 
were	implanted	with	the	Sophono	by	one	surgeon	(M.H.).	The	patient	characteristics	






external part. During a surgical procedure,5,18 subcutaneous implantable twin magnets 
that	are	encapsulated	in	a	titanium	case	are	fixated	to	the	bone	through	little	arms	
that have openings in which to place the screws (Figure 1). At 7 cm posterior and 
superior of the ear, an 8-cm curved incision is made, which reaches down to the 
skull-bone.	After	the	periost	is	cleared	from	the	bone,	the	locations	of	the	magnets	
are marked on the bone, in which the shallow bone beds are drilled out to a depth of 
2.5 mm, countersinking the implant in the skull, whereupon it can be secured with 
five	Champy	screws	(3	mm	length,	0.5	mm	diameter).	Finally,	the	skin	can	be	closed	










































































































































































































































































































































































































































































































































































































































































 The external part of the Sophono consists of an audio processor with a bone 
conduction	vibrator	which	is	mounted	on	an	acrylic	base	plate	on	which	two	external	
magnets are embedded. According to the manufacturer, the Sophono is designed for 
patients	 aged	 five	 years	 and	 older	 with	 conductive	 hearing	 loss	 or	 mixed	 loss	 if	




coupled.	 The	 sound	 preocessor	 generates	 vibrations	 that	 are	 transmitted	 via	 the	
percutaneous implant to the skull to provide BC hearing. All implant surgery was 
performed	according	to	the	Nijmegen	linear	incision	technique.20	Five	patients	in	the	


















































1, 2, and 4 kHz) and BC thresholds (at 0.5, 1, 2, and 4 kHz) were measured, both in 
unaided	condition	with	headphones	and	plugging	of	the	contra	lateral	side.	Also	speech	






(TU-1000; Nobelpharma Inc., Göteborg, Sweden). The BAHA can be coupled directly 
to the skull simulator; the output is expressed in dB output force level.
	 The	skull	simulator	has	also	previously	been	used	to	evaluate	the	Audiant.	Håkansson	
et al.22	constructed	a	rigid	connection	between	the	to-be-implanted	magnet	and	the	
skull simulator, so the BCD could be coupled to the magnet with in between a thin 
layer of skin. We used the same approach to couple the Sophono, which enabled us 
to compare it with the BAHA. The BAHA was directly coupled to the skull simulator. 
To apply the Sophono, magnets in a standard acrylic base plate were rigidly connected 
to a BAHA coupling unit and then connected to the skull simulator. To measure the 
damping of this extra coupling, we temporarily connected a BAHA abutment on the 
other	side	of	the	base	plate.	Assuming	that	this	abutment	was	tightly	coupled,	this	
enabled	us	to	compare	the	frequency	response	of,	firstly,	a	Divino	directly	coupled	to	
the skull simulator, and secondly, the Divion coupled with the Sophono magnet in 
between the BAHA and the skull simulator. Damping was less than 3 dB for all 
frequencies	up	to	2	kHz.	Above	2	kHz,	(anti)	resonances	occurred.	Next,	the	temporary	
abutment was removed, and the Sophono was connected to the adapted skull 
simulator in between a 3-mm piece of specially prepared pig skin. 
	 The	skull	simulator	was	mounted	in	the	TBS25	Test	Chamber,	part	of	the	Affinity	
2.0	Hearing	Aid	Analyzer	(Interacoustics	A/S,	Assens,	Denmark).	We	measured	frequency	
output curves by applying broadband noise as the input signal, presented at levels of 
50,	 60,	 70,	 75,	 80,	 85,	 and	 90	 dB	 SPL.	 From	 the	 set	 of	 frequency	 specific	 output	
curves, input-output curves were constructed. The Divino was used at a volume set 
at 2 and separately at 3, which was the maximum level. The Sophono was set at the 






Wound	 healing	 and	 skin	 reactions	were	monitored	 in	 the	 outpatient	 clinic	 during	
regular	visits	for	both	groups	similarly.	A	strict	follow-up	protocol	is	common	practice	




strength	 2,	 and	 one	 patient	 used	magnet	 strength	 4	 (1.9	 N).	 The	mean	 follow-up	
period was 325 days (range 145–740 days).
	 Retrospective	analysis	of	the	regular	follow-up	data	demonstrated	that	none	of	
the	BAHA	users	presented	with	adverse	skin	reactions	(Holgers	≥	2).	One	month	after	
the second phase surgery, one BAHA user presented with a loose implant. Thereupon, 





An overview of audiological outcomes of both hearing aids is provided in Table 1. Tone 
audiometry	(i.e.,	PTA:	mean	thresholds	at	0.5,	1,	2,	and	4	kHz)	data	of	the	atretic	side	
are presented in Figure 2. The unaided air and BC thresholds of the two groups of 
children	were	comparable.	The	aided	thresholds	were	similar	 in	 lower	 frequencies	
(i.e.,	500,	and	1000	Hz),	but	not	in	higher	frequencies,	where	the	BAHA	users	exhibited	
5–10	 dB	 better	 thresholds	 than	 the	 Sophono	 users.	 In	 accordance	 with	 this,	 the	




volume 2) is approximately 10 dB louder than the Sophono (at maximum volume). 


















































thresholds (measured with headphones with the good ear masked).
Figure 3  [A]	Frequency–output	curves.	A	comparison	of	the	data	of	the	Sophono	
and BAHA, obtained with the skull simulator. Broadband noise set at a  
65	dB	SPL	input	level	was	used.	The	x-axis	represents	the	frequency	in	kHz;	 
the y-axis presents the measured output, expressed in dB Fl (force level, reference 
1-μN).	[B] Input/output curves at 1.5 kHz comparison for the Sophono and BAHA. 





In	 the	 current	 study,	 we	 compared	 the	 first	 Dutch	 results	 of	 the	 Sophono	 in	 six	
patients	with	a	matched	group	of	patients	using	BAHA.	We	studied	clinical	follow-up	
data and audiometry, and performed measurements with the skull simulator.
	 Clinical	outcomes	of	the	percutaneous	application	for	BCDs	in	children	are	well-	
known	since	one	of	the	first	children	was	implanted	in	our	center	in	1993.	To	the	best	
of our knowledge, the only published data on the Sophono are presented by Siegert.5,17 
Some	 of	 his	 patients	 experienced	 pressure	 marks,	 for	 which	 force	 reduction	 by	
installing a less powerful magnet provided a remedy. Our experiences with the 






which is comparable to these data, but lower than the BAHA users. Sophono users 
demonstrated poorer aided thresholds, compared to the BAHA users, especially in 





is	 equal	 to	 the	 benefit	 of	 percutaneous	 coupling	 compared	 with	 transcutaneous	






than 10 years old, the surgical procedure implies a single-stage surgery in the case of 
the Sophono, though a two-stage procedure for the BAHA. Finally, the Sophono is 























































our clinic. Finally, the authors would like to thank Chris-Jan Beerendonk for his 
assistance on the skull simulator measurements and John Noten, Mieke Verbruggen, 
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Several studies have demonstrated delays in development and school performance 
in children with unilateral hearing loss (UHL) compared to children with normal 
hearing.1-3	A	specific	condition	of	UHL	 is	congenital	conductive	UHL,	which	 is	often	
caused by anatomical anomalies, such as aural atresia and/or ossicular chain anomalies. 
These	relatively	rare	abnormalities	affect	approximately	one	 in	10,000	live	births.4 
Depending	 on	 the	 severity	 of	 the	 anomaly,	 several	 treatment	 options	 are	 to	 be	
considered	in	children	presenting	with	such	altered	anatomy:	surgical	correction	of	
the	 anomaly	 if	 feasible,	 amplification	 by	 means	 of	 a	 conventional	 hearing	 aid	 if	
possible	 or	 a	 bone	 conduction	 device	 (BCD)	 in	 all	 other	 cases,	 or	 conservatively	
monitoring	the	child’s	development.	When	intervention	is	required,	amplification	of	
sound	 by	 means	 of	 a	 percutaneous	 BCD	 is	 associated	 with	 better	 audiological	
outcome	than	surgical	intervention,	especially	in	patients	with	considerable	anatomic	
deviations.5-7
 In 2011, a new passive transcutaneous BCD (Sophono Alpha 1) has been introduced.8 
The	Sophono	provides	hearing	amplification	through	an	intact	skin	due	to	magnetic	
coupling, in contrast to the well-known percutaneous bone-anchored hearing aids 
(BAHA;	Cochlear	Baha	and	Oticon	Medical	Ponto).	In	a	previous	study,9 six children 
with	congenital	conductive	UHL	who	used	the	Sophono	were	compared	with	matched	
controls who used a BAHA. The BAHA was more powerful; measurements with a skull 





Sophono.	This	 is	especially	 relevant	 for	 the	application	of	BCDs	 in	children,	as	 it	 is	
reported	that	children	using	a	BAHA	with	a	previous	generation	implant	experience	
more	complications	and	implant	losses	compared	to	adults.11 However, it should be 
noted	that,	owing	to	new	and	wider	implant	designs,	soft	tissue	reactions	of	BAHAs	











Assessment	 by	 the	 local	 ethics	 committee	was	 not	 required	 as	 the	 application	 of	
BCDs	is	a	regular	health	care	treatment	option	in	the	Netherlands.	Furthermore,	all	
testing	data	were	used	 in	retrospect	and	part	of	 regular	 follow-up	measurements,	
which	were	used	to	optimize	outcomes	with	the	respective	BCDs.
Patients and BCDs
Retrospectively,	 the	 follow-up	 data	 of	 the	 same	 six	 patients	 implanted	 with	 the	
Sophono	who	participated	in	a	previous	study9	were	gathered.	Five	patients	(patients	
1	 to	 5)	 suffered	 from	 high	 grade	 unilateral	 congenital	 aural	 atresia	 type	 IIb	 or	 III	







the same previous study.9
	 The	Sophono	Alpha	1	(Sophono,	Inc.,	Boulder,	CO,	USA;	recently	acquired	by	Medtronic,	
Inc.,	Fridley,	MN,	USA)	is	a	BCD	that	is	magnetically	coupled	to	surgically	implanted	
double	 magnets	 through	 an	 intact	 skin.	 The	 applied	 surgical	 technique	 has	 been	
described in detail.8 Recently, the sound processor was updated (Alpha 2) and aided 
thresholds with this new sound processor were tested in the current manuscript. The 
even	more	recent	Alpha	2	MPO	was	not	yet	made	available	to	the	study	population	at	
the	time	of	the	measurements.
	 All	 BAHA	 users	 were	 implanted	 with	 the	 Baha	 3.75-mm-diameter	 flange	 fixture	
(Cochlear	 Bone	 Anchored	 Solutions	 AB,	 Mölnlycke,	 Sweden).	 Implant	 surgery	 was	




During	 frequent	 follow-up	visits	of	 at	 least	one	 visit	 per	 year,	 the	 local	 soft	tissue	
status	 was	 monitored.	 Skin	 reactions	 were	 recorded	 according	 to	 Holgers’	




































The	 patients	 with	 the	 Sophono	 underwent	 audiometric	 evaluation	 for	 the	 aided	
condition	with	the	first-generation	(November	2012)	and	the	updated	sound	processor	
(May 2013). For the BAHA users there were no more recent data available compared 







and	with	a	localization	setup	described	by	Agterberg	et	al.19,20 The MAA test was used 
to examine the minimal angle at which two speakers could be discriminated. In this 
test	 the	patients	were	seated	comfortably	 in	a	chair	 in	a	sound-attenuated	booth,	
with	two	speakers	at	90°	azimuth	left	and	right.	A	broadband	noise	burst	of	0.3	s	with	
roved amplitudes was randomly presented from one of both speakers. If the subject 
identified	the	speaker	from	which	the	stimulus	was	presented,	the	angle	was	changed	




which provided a reference.
	 The	MAA	test	provides	information	about	the	ability	to	lateralize	sound.	To	measure	
the	 localization	abilities	of	 the	patients	we	applied	another	 test	 setup.	Broadband	
noise	 stimuli	 (0.5–20	 kHz;	 n	 =	 36)	 were	 presented	 in	 a	 completely	 dark,	 sound	
attenuated	 room,	 to	 ensure	 that	 patients	 could	 only	 use	 acoustic	 information	 to	
localize sounds. Sound levels ranged between 45–65 dB SPL in broadband and 
duration	of	all	stimuli	was	150	ms.	The	subjects	indicated	the	direction	of	the	sound	
(ranging	 from	 –85°	 to	 +85°	 in	 azimuth)	 by	 means	 of	 head	 movement	 (magnetic	
search-coil	induction	technique)	with	a	laser	pointer	mounted	on	eyeglasses	pointed	
on	a	small	plastic	frame	in	front	of	them.	The	test	setup21,22 and the processing of the 
data19,20 are described in detail in previous studies. Recently, this setup and the test 
protocol	were	also	used	for	testing	sound	localization	in	children.20 The outcome of 
this	test	is	defined	by	the	best	linear	fit	of	the	stimulus-response	relationship	on	the	
azimuth data, which is derived from the following formula:
146
in which a is the azimuth angle (in degree), b is the response bias (in degree), and g the 
response gain (dimensionless). Furthermore, the mean absolute error (MAE) was 





3.1–4.7	 years).	 Two	 of	 the	 six	 patients	 stopped	 using	 their	 device:	 patient	 2	 after	
approximately	1.5	years	because	of	cosmetics	and	patient	6	after	approximately	3	years	
because	she	experienced	too	little	audiological	benefit.	All	other	patients	reported	to	
use	 their	 device	 predominantly	 at	 school.	 Few	 skin	 complications	were	 reported.	









	 The	 mean	 follow-up	 of	 the	 patients	 implanted	 with	 the	 BAHA	 was	 4.7	 years	














































































































































































































































































































































































































































































































































































































The	MAA-results	 in	 Table	 2	 show	 better	 aided	 than	 unaided	 scores	 for	 both	 the	
Sophono users and the BAHA users. Three of the Sophono users already displayed 
good	unaided	MAA	scores,	which	did	not	improve	in	the	aided	condition.	All	BAHA	
users showed improvement from their poor unaided scores, although they did not all 
meet the scores of the Sophono users. All normal hearing children reached the 
smallest possible MAA of 5°.
Table 2   The outcomes of the minimum audible angle (MAA) test. Normal hearing 
children	all	scored	a	MAA	of	5	degrees.	Patient	numbers	correspond	to	



































































In the current study, we presented data obtained with at least three years of follow-up 
on	a	population	with	congenital	conductive	UHL	who	were	rehabilitated	with	either	a	
Sophono	 or	 a	 BAHA.	 The	 first	 audiological	 comparison	 between	 these	 BCDs	 was	
reported previously.9	Four	out	of	six	patients	implanted	with	the	Sophono	were	still	






































using	 their	device	after	a	mean	 follow-up	time	of	3.6	years,	mainly	at	 school.	 The	
same applies to the BAHA users at a mean follow-up of 4.7 years, although one 
patient’s	use	could	not	be	confirmed.	Soft	tissue	tolerability	with	the	Sophono	was	
favorable.	 Subjective	 appreciation	 of	 the	 users	 was	 comparably	 reasonable.	 The	






both	 conductive	 and	 mixed	 hearing	 loss23,24 while others provide only concise 
audiometry data.25,26	Case	series	that	consist	of	patients	with	conductive	hearing	loss,	
included	 both	 unilaterally	 and	 bilaterally	 affected	 patients.10,27-29 Because of these 
mixed	populations,	 it	 is	hard	to	substantially	objectify	or	compare	the	audiological	
outcomes.	Soft	tissue	outcomes	have	been	generally	reported	positive.




of BCDs. In contrast to the literature that has already been published on the Sophono, 
the	 current	 results	 are	 derived	 from	 a	 homogeneous	 population	 with	 matched	
controls	using	a	BAHA	over	a	relatively	long-term	follow-up	period.
 The clinical outcome of the current case-series with the Sophono is considered 
favorable to that of the BAHA when applied in children. It has been demonstrated 
that	15.2%	of	the	previous	generation	percutaneous	implants	are	lost	in	children	and	
adverse	skin	reaction	were	found	 in	7.8%	of	 follow-up	visits,	which	 is	considerably	
lower in adults.11	 Arguably,	 in	 adult	 patients,	 skin	 reactions	 with	 percutaneous	
implants are decreasing to such low values with updated implant designs,12,13 that no 
significant	difference	between	soft	tissue	tolerability	between	a	transcutaneous	and	
percutaneous BCD is to be expected. Furthermore, in children, implant survival is 
reported to increase with these new implants.14	In	contrary,	soft	tissue	problems	with	
the	Sophono	were	encountered	in	another	study,	with	5	of	14	implants	(36%)	having	
significant	enough	difficulties	to	discontinue	use	for	a	certain	period.26
	 Although	 subjective	 benefit	 with	 the	 BCDs	 was	 not	 measured	 by	 means	 of	
validated	questionnaires,	patients	who	used	either	device	 reported	 to	be	satisfied	
with it, yet all reported to use their BCD only in school. Furthermore, only four of the 
original	six	implanted	patients	in	either	group	were	still	using	their	BCD.	It	has	recently	
been found that long-term compliance with a BCD (although percutaneously applied 







of	 another	 study	 with	 a	 comparable	 population.29 We consider these thresholds 
unsatisfactory;	 in	 patients	with	 normal	 cochlear	 function	 aided	 thresholds	with	 a	
properly	functioning	BCD	should	ideally	be	around	10-20	dB	HL.6,31 As a result, the use 
of	head	shadow,	binaural	squelch,	and	binaural	summation	might	be	below	expected	
values.






congenital	 conductive	 UHL	 perform	 well	 on	 different	 sound	 localization	 tests.33,34 
Possibly,	 patients	with	 congenital	 conductive	UHL	have	developed	a	different	 strategy	 
for	directional	hearing,	as	they	have	coped	with	unilateral	hearing	all	their	life.	Good	
MAA scores with unilateral input have also been reported for children with bilateral 
conductive	hearing	loss	by	Dun	et	al.18 Despite fair to good improvement found in the 
MAA	and	sound	 localization	 test	 in	 the	current	population,	 localization	abilities	of	




implanted with a Sophono compared to a BAHA. Aided thresholds with the Sophono 
were	 unsatisfactory,	 also	 with	 the	 updated	 second-generation	 sound	 processor.	
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LONG-TERM FOLLOW-UP ON 
PATIENTS WITH A PERCUTANEOUS 





CONDUCTION DEVICES IN 
SINGLE-SIDED DEAFNESS PATIENTS




patients	with	 single-sided	 deafness	 (SSD)	who	 underwent	 bone-anchored	 hearing	
implant	surgery	to	be	able	to	use	a	percutaneous	bone	conduction	device	(BCD)	as	a	
contralateral	routing	of	sound	(CROS)	hearing	aid.
Methods |	 In	 this	 retrospective	 case-control	 study,	 all	 (n	 =	 145)	 consecutive	 SSD	
patients	fitted	with	a	BCD	between	January	2001	and	October	2011	were	asked	to	
complete	a	questionnaire	consisting	of	the	Abbreviated	Profile	of	Hearing	Aid	Benefit	



















































Since	 1977,	 titanium	 temporal	 bone-anchored	hearing	 implants	 (BAHIs)	 have	 been	
used	for	hearing	rehabilitation	via	bone	conduction	devices	(BCDs).	The	indications	
for their use have been established for a variety of unilateral and bilateral types of 
hearing	 loss,	 including	 conductive	 hearing	 loss,	mixed	 hearing	 loss,	 and	 profound	
unilateral	sensorineural	hearing	loss.	The	latter	is	also	known	as	single-sided	deafness	













in	 assessing	 the	degree	of	disability	 and	 the	benefits	of	 rehabilitating	SSD	using	a	
percutaneous BCD as a CROS device.
	 Distinct	outcomes	for	assessing	the	perceived	benefits	of	a	percutaneous	BCD	in	
SSD	patients	are	not	well	defined.4	Satisfaction	with	a	hearing	solution	can	vary	over	
time	and	might	be	gender-related.5	 To	create	 realistic	expectations,	a	one	 to	 two-
week	trial	of	a	headband	version	of	the	BCD	 is	recommended	before	the	 implantation	 
with the BAHI.6,7	In	patients	with	SSD	who	have	had	BAHI	surgery,	there	is	a	tendency	




clinic to be able to use a percutaneous BCD.
Methods
All	of	the	consecutive	SSD	patients	fitted	with	a	percutaneous	BCD	between	January	
2001	and	October	2011	were	 identified.	Patients	 that	had	passed	away	or	had	 the	




assessing 1) hearing disability, 2) coping with hearing disability, and 3) the daily use 
of	and	satisfaction	with	the	BCD.	The	questionnaire	was	sent	in	November	2011,	and	
all	patients	who	did	not	 return	 the	questionnaire	were	contacted	by	 telephone	to	
evaluate	whether	they	were	still	using	their	BCD.
	 The	 Abbreviated	 Profile	 of	 Hearing	 Aid	 Benefit	 (APHAB)	 was	 used	 to	 assess	
disability.	 The	APHAB	 inventory	 is	 a	 self-report	questionnaire	 that	 can	be	used	 to	
qualify	 the	 impact	 of	 a	 hearing	 problem	 on	 an	 individual’s	 daily	 life.13	 Multiple	





















includes	 eight	 questions	 regarding	 the	 amount	 of	 daily	 use,	 satisfaction	 under	




	 A	subanalysis	of	 the	APHAB	scores	of	 the	first	29	patients	 implanted	between	
2001 and 2003 was performed, as previously described by Hol et al.8. That study 
reported	 the	 APHAB	 scores	 obtained	 12	 weeks	 after	 BCD	 fitting	 and	 at	 one-year	
follow-up. These data were compared with the recent ones, which were obtained at 



































Corp., Armonk, NY, USA). The long-term outcomes were described using the mean 
values	and	standard	deviation	(SD)	for	the	numerical	(subscales	of	the)	questionnaires	
and	using	percentages	for	the	categorical	(subscales	of	the)	questionnaires.	Comparisons	
between	male	 and	 female	 patients	were	performed	using	 the	 t-test	 or	 χ2 test for 
numerical	 or	 categorical	 outcomes,	 respectively.	Because	 the	aim	of	 study	was	 to	
investigate	 in	which	directions	 the	possible	differences	between	men	and	women	
exist	and	what	the	long-term	effects	were	for	a	variety	of	outcomes,	no	adjustment	
for	multiple	 testing	was	 considered	 necessary.	 The	 level	 of	 statistical	 significance	




The	questionnaire	was	 sent	 to	 145	 patients,	 including	 all	 the	 consecutive	patients	
within	the	study	period.	Of	the	145	patients,	102	(70.3%)	returned	the	questionnaire,	
and	we	were	able	to	contact	33	of	the	remaining	43	by	telephone.	(See	the	flowchart	





















































using	 their	BCD.	The	reason	 for	discontinued	use	 that	most	patients	 reported	was	
limited	benefit	in	addition	to	their	normal	hearing	ear.
	 The	group	of	users	 that	 responded	 to	 the	questionnaires	consisted	of	41	men	
(44.1%)	and	52	women	(55.9%).	The	mean	age	in	this	group	was	56	years	(SD	±	10),	and	
the	average	time	of	follow-up	was	62	months	(SD	±	39	months;	range	2–129	months).	
Table 2 provides an overview of some of the data pertaining to the nonusers. The 
distribution	 of	 gender	 in	 the	 population	 of	 nonusers	 was	 56.5%	male	 and	 43.5%	
female. The mean age in the group of nonusers was 59 years (SD ± 16).
Abbreviated Profile of Hearing Aid Benefit
The	 APHAB	 was	 used	 to	 quantify	 hearing	 disability.	 Lower	 scores	 indicate	 less	
disability	(frequency	of	problems).	The	mean	score	was	19	(SD	±	14)	for	EC,	57	(SD	±	21)	
for BN, 46 (SD ± 23) for RV, and 40 (SD ± 25) for AV. The global APHAB score (mean of 
the EC, BN and RV scores) was 41 (SD ± 16).
Communication Profile for the Hearing Impaired
The	scores	for	the	CPHI	(on	a	scale	from	0	to	5)	were	4.1	(SD	±	0.7)	for	maladaptive	
behaviors, 2.8 (SD ± 0.6) or verbal strategies, 4.1 (SD ± 0.7) for nonverbal strategies, 
3.9 (SD ± 0.9) for self-acceptance, 3.4 (SD ± 1.0) for acceptance of loss, and 3.1 (SD 
± 0.9) for stress and withdrawal. Table 3 presents these data, as well as published 
data	obtained	in	other	groups	of	patients	with	hearing	impairment.	The	etiology	of	
hearing loss in these comparison studies varied widely.
Single-Sided Deafness questionnaire
The	 responders	 to	 the	 questionnaire	who	were	 still	 using	 the	 BCD	 used	 it	 for	 an	
average of 44 hours (SD ±	23)	per	week,	which	equates	to	a	mean	of	6.3	hours	of	use	
per	day.	Half	of	the	patients	(53.8%)	used	the	BCD	for	63	hours	or	more	in	a	week.



























































	 More	 than	 half	 of	 the	 patients	 (61.3%)	 experienced	 improved	 quality	 of	 life.	




of 6.8 (SD ±	1.5)	on	a	scale	from	0	to	10.	Handling	the	device	was	easy	(52.7%)	or	very	
easy	(32.3%)	for	the	majority	of	patients.	Fourteen	patients	(15.1%)	rated	handling	of	
the	device	as	acceptable,	and	no	patients	found	it	very	hard	to	handle.
Gender in usage group
The average age of the men was 58 years (SD = 11), and the average age of the women 
was 54 years (SD = 9). The mean weekly BCD use in men was 44 hours and 45 hours 
in	women.	 There	was	 no	 significant	 difference	 in	 the	 improvement	 in	 the	 quality	
of	life,	with	26	of	the	41	men	(45.6%)	versus	31	of	the	52	women	(54.4%)	reporting	
improvement.	The	appreciation	of	the	BCD	was	scored	on	a	scale	of	0	to	10,	yielding	





 No	 significant	 differences	 in	 disability	 between	men	 and	women	were	 found,	
according	 to	 the	 APHAB	 (Figure	 2).	 More	 specifically,	 the	 EC	 score	 for	 the	 aided	
Table 3   Mean CPHI subscale scores obtained in our study and in other studies. 
Demorest et al.22, a 
(n = 1,226)
Erdman et al.23, a 
(n = 1,008)




MB 4.0 4.0 4.0 4.1
VS 3.0 2.9 2.8 2.8
NVS 3.7 3.5 3.6 4.1
SA 3.5 3.5 4.0 3.9
AoL 3.7 3.7 3.3 3.4
ST 3.1 3.2 2.9c 3.1c
WD 3.3 3.3
a		English	language	questionnaire,	b	Dutch	language	questionnaire,	c The combined results of the Stress 
and Withdrawal Scale.
MB:	Maladaptive	Behaviours,	VS:	Verbal	Strategies,	and	NVS:	Non-verbal	Strategies.	SA:	Self-Acceptance,	
AoL: Acceptance of Loss, ST: Stress and WD: Withdrawal.
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situation	was	 18	 for	men	 and	 19	 for	women,	 the	BN	 score	 for	 the	 aided	 situation	
was	54	for	men	and	59	for	women,	and	the	RV	score	for	the	aided	situation	was	42	
for men and 49 for women. The mean global APHAB score for the three domains 
indicated slightly less disability in the men, which was 38 for men and 42 for women; 
none	of	the	differences	between	men	and	women	were	significantly	different.
	 Men	and	women	with	a	BCD	for	SSD	appeared	to	cope	equally	well,	according	



















































Figure 2  Distribution	of	the	Abbreviated	Profile	of	Hearing	Aid	Benefit’s	 
global	disability	score,	as	obtained	recently.	A	higher	score	relates	to	more	often	
experienced disability.
Figure 3  Coping	with	hearing	after	BCD	application	by	means	of	the	CPHI.	Mean	
values are presented as bars with a standard error of the mean. High CPHI scores 
indicate	adequate	coping	behavior.	AoL:	acceptance	of	loss,	CPHI:	Communication	
Profile	for	the	Hearing	Impaired,	MB:	maladaptive	behaviors,	NV:	nonverbal	
strategies, SA: self-acceptance, STWD: stress and withdrawal, VS: verbal strategies.
168










BCD use among men and women with SSD who underwent BAHI surgery in the period 
between January 2001 and October 2011.
	 We	found	no	statistically	significant	differences	with	regard	to	gender	 in	 reported	
disability or coping behavior. Similarly, although men appeared to be more prone 
to	 discontinuation,	 no	 significant	 difference	with	 regard	 to	 gender	 was	 found	 for	
discontinuation	of	BCD	use.	The	data	presented	here	are	unique	because	data	were	
Figure 4  Disability	over	time,	according	to	the	APHAB	questionnaire	in	a	subgroup	
of patients with a follow-up of 10 years (22 patients, of which 4 were lost to 
follow-up; n = 18 at 1 year and at 10 years of follow-up). Mean scores are presented 
as bars with standard error of the mean. A higher score relates to more disability. 








































results were reported by Desmet et al.20,	with	diminished	satisfaction	over	an	extended	
period	of	use.	Possible	explanations	for	this	increase	in	perceived	disability	might	be	
adaptation	 to	 the	benefits	of	 the	new	hearing	 situation.	Deterioration	of	hearing	 in	
time	might	be	another	factor	to	dampen	the	positive	effect	of	a	hearing	device.
	 The	mean	 APHAB	 norm	 scores	 for	 adult	 conventional	 hearing	 aid	 users	 with	
symmetrical sensorineural hearing loss were 23 for EC, 37 for RV, 40 for BN, and 38 
for AV.21	In	our	study,	the	patients	experienced	less	disability	in	the	EC	domain	(18.6)	
and more disability in the RV (46.3), BN (57.2), and AV (39.6) domains. It is logical 
that scores for listening in the presence of back-ground noise and in reverberant 
surroundings	suggested	greater	disability	in	the	present	patient	group	because	they	
have	problems	with	spatial	hearing	that	are	not	resolved	by	using	a	CROS	device.
 The CPHI results were compared to those of other studies,16,22,23 as shown 
in	Table	3.	The	Dutch	 translation	of	 the	CPHI	was	previously	applied	 in	a	different	
clinical sample, adults with symmetric hearing impairment.16 Demorest et al.22 and 
Erdman et al.23	also	conducted	large	multicenter	studies	using	the	CPHI	to	investigate	












period of follow-up (mean almost 10 years). Desmet et al.20	reported	a	discontinuation	
with	BCD	use	of	14%	 in	an	SSD	population	over	a	period	of	50	months,	attributing	
to	 about	 3%	per	 year.	 Considering	 the	 10-year	 follow-up	 in	 the	 current	 study,	 the	
discontinuation	seems	on	par	with	the	study	of	Desmet	et	al.	The	group	of	patients	






and	preconceptions	of	 a	 CROS	device	before	 surgery,	 particularly	 in	 patients	with	
SSD.	The	difference	in	discontinuation	rate	over	time	might	be	due	to	our	developed	
insights,	 and	 therefore	 perhaps	 altered	 preoperative	 counseling.	We	 believe	 that	
this	 counseling	 (habits,	 work/social	 environment,	 expectations)	 and	 an	 extensive	
preoperative	 trial	 of	 a	 BCD	 on	 a	 headband	 helped	 our	 patients	 to	 shape	 their	
expectations	as	we	pay	much	attention	 to	 this.	A	comparison	of	 the	 initial	APHAB	








noisy environments as long as the speech source is located near the deaf ear. However, 
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LONG-TERM COMPLIANCE  
AND SATISFACTION WITH 
PERCUTANEOUS BONE 
CONDUCTION DEVICES IN 





Objective |	Patients	with	congenital	unilateral	 conductive	hearing	 loss	 (UCHL)	can	
either	be	watchful	monitored	or	treated	surgically	through	the	fitting	of	a	percutaneous	




percutaneous	 BCD	 in	 our	 tertiary	 referral	 center	 between	 1998	 and	 2011	 were	











improvement	 in	 the	 aided	 condition	 compared	with	 the	 unaided	 condition	 in	 the	
users, in contrast to the nonusers.
Conclusion |	 The	 current	 disappointing	 long-term	 compliance	figures	 indicate	 the	
need for an even more careful and individualized approach with life-long follow-up 
when	fitting	BCDs	in	this	specific	population,	especially	in	children.
PUBLISHED AS | Nelissen RC, Mylanus, EAM, Cremers CWRJ, Hol MKS, Snik AFM. 
Long-term	compliance	and	satisfaction	with	percutaneous	bone	conduction	devices	














































Impairments brought about by unilateral hearing loss (UHL), either sensorineural or 
conductive,	have	traditionally	been	underestimated.	However,	in	recent	years	it	has	
been demonstrated that UHL in children might be associated with delayed speech-lan-
guage development.1	 Moreover,	 behavioral	 and	 educational	 problems	 have	 been	
reported	 to	 occur	 more	 often	 in	 children	 with	 UHL	 than	 in	 children	 with	 normal	
hearing.2,3	Children,	parents,	and	teachers	reported	significant	benefits	from	the	use	
of hearing aids to restore bilateral hearing at home and at school.4
	 Congenital	unilateral	conductive	hearing	 loss	 (UCHL)	 is	a	specific	 form	of	UHL,	
usually caused by aberrant aural anatomy. Generally, this involves atresia of the ear 
canal,	often	combined	with	a	malformed	pinna	and/or	middle	ear	anomalies.	Surgical	
options	 to	 restore	hearing	 to	a	 sufficient	 level	 are	quite	 limited.	 Furthermore,	 the	
higher	 the	 grade	 of	 the	 anomaly,	 the	 less	 the	 hearing	 benefit	 a	 patient	 might	
experience	after	surgery.	Therefore,	only	mild	to	moderate	cases	of	atresia	(classes	I	
and IIA) might be considered suitable candidates for surgical repairs that result in 
adequate	hearing.5
	 The	restoration	of	binaural	hearing	in	children	with	congenital	UCHL	is	of	great	
importance. Kunst et al.6,7	 reported	 audiometric	 benefits	 in	 20	 patients	 with	
congenital	 UCHL	 (10	 adults	 and	 10	 children)	 using	 percutaneous	 bone	 conduction	
devices	(BCDs).	These	patients	showed	promising	subjective	benefits	and	compliance	
with	the	BCD	after	a	mean	follow-up	period	of	25.4	months.	Reviewing	the	Kunst	et	
al. data in more detail, Agterberg et al.8	found	that,	in	contrast	to	acquired	UCHL,	the	
patients	 with	 congenital	 UCHL	 benefited	 less	 from	 BCD	 usage.	 Priwin	 et	 al.9 also 




few	 studies	 on	 this	 specific	 subject.	 A	 systematic	 review	 showed	 that	 there	 was	
limited	evidence	for	a	strong	recommendation	supporting	the	use	of	percutaneous	
BCDs	 in	 patients	 with	 unilateral	 aural	 atresia.10 Several other studies reported 
favorable	 hearing	 outcomes	 in	 patients	 with	 both	 unilateral	 and	 bilateral	 atresia	



































placement	 of	 the	 percutaneous	 titanium	 temporal	 bone	 implant.	 After	 a	 healing	
period,	the	patients	were	fitted	with	the	BCD.	At	that	time,	audiological	benefit	was	
objectively	 established.	 Aided	 thresholds	 were	 measured	 with	 warble	 tones	 in	 a	
sound	field,	as	described	elsewhere.16,17 During these measurements, the contralateral 
ear	with	normal	hearing	was	blocked	with	an	ear	plug	and	earmuff,	resulting	in	an	
attenuation	of	approximately	40	dB.17	The	fit	of	the	BCD	was	only	considered	to	be	
adequate	when	 either	 the	 aided	 speech	 perception	 threshold	 or	 the	mean	 aided	
sound	field	threshold	was	25	dB	or	better.6 In children, yearly follow-up visits were 
arranged	to	evaluate	device	use.	If	they	did	not	use	the	BCD	or	were	dissatisfied	with	














































To	 gather	 data	 on	 device	 use,	 all	 patients	 were	 contacted	 by	 telephone	 and	
interviewed	 about	 their	 daily	 use.	 Specifically,	 the	 hours	 of	 use	 per	 day	 and	 the	
reasons	for	not	using	the	BCD	when	it	went	unused	were	assessed.	The	patients	were	
divided into three groups based on their BCD use: users (with days per week and 
hours	per	day	of	use	specified),	sporadic	users	(used	only	in	very	specific	conditions,	
generally less than one day per week), and non-users.
	 If	the	patients	still	used	their	BCD	or	stopped	using	it	within	the	previous	year,	
they	were	asked	to	complete	the	validated	Dutch	translation	(by	ExpORL,	KU	Leuven,	
Belgium)	of	the	Speech,	Spatial	and	Qualities	of	Hearing	Scale	(SSQ),18 both for aided 
and	unaided	conditions.	Children	were	asked	to	complete	the	questionnaire	together	
with	 their	parents.	 The	SSQ	questionnaire	was	also	used	 in	 the	previous	 study	by	
Kunst et al.7	Furthermore,	all	the	patients	who	had	completed	the	Glasgow	Children’s	












device usage data were available in their hospital records; accordingly, those data 
were	included.	Table	1	provides	an	overview	of	the	patient	characteristics.	The	mean	age	
at	the	time	of	surgery	was	17	years	old	(range	4–61	years).	The	mean	follow-up	period	
was 6.8 years (range 1–15 years). The mean hearing loss (pure tone average (PTA); 0.5, 







10	years.	This	difference	is	statistically	significant	(p = 0.003, see Table 2). The mean 
180
Table 1   Patient	characteristics	with	baseline	audiometric	data.	




Anomaly Side PTA NE PTA IE ABG IE
1 61 72 CA IIB/III AD 9 68 50
2 40 55 CA IIB/III AD 19 61 41
3 31 43 CA IIB/III AD 5 76 59
4 22 34 OCA AS 13 54 30
5 23 34 CA IIB/III AD 9 88 53
6 18 31 CA IIB/III AS 4 69 60
7 18 31 CA IIB/III AD 6 68 54
8 18 28 CA IIB/III AD 4 70 49
9 20 28 CA I AS 13 48 45
10 13 24 CA IIB/III AD 11 73 59
11 6 18 CA IIA AD 8 53 49
12 6 16 CA IIB AD 6 60 50
13 10 20 CA IIB/III AD 6 66 53
14 14 24 CA IIB/III AD 4 55 51
15 6 16 CA IIA AD 5 56 49
16 10 21 CA IIA AS 15 65 49
17 5 16 CA IIB/III AD 9 53 40
18 6 15 CA IIB/III AD 30 89 58
19 12 20 OCA AS 8 61 40
20 6 14 CA III AD 8 74 59
21 30 39 CA IIB AD 18 85 60
22 5 14 CA IIB/III AD 0 44 50
23 9 18 CA IIB/III AS 16 64 61
24 12 20 CA IIB/III AS 4 63 50
25 6 13 CA III AD 6 70 48
26 11 18 CA IIA AS 10 55 60
27 41 47 CA IIB AD 8 74 53
28 12 18 CA IIA AS -1 58 53
29 4 10 CA III AD 9 69 63
30 5 11 CA IIB/III AS 19 63 63
31 9 14 CA IIB/III AS 15 84 46
32 5 10 CA IIB/III AD 13 65 50
33 7 12 CA IIA AD 5 56 49
34 7 12 OCA AD 9 50 49
35 9 14 CA IIB/III AD 3 38 41












































age at which non-users stopped using their BCDs was 15 years (median 14), which 
results	in	a	mean	time	of	BCD	usage	before	stopping	of	4.8	years.	In	the	user	group,	
the	mean	time	of	device	usage	at	the	evaluation	was	6.2	years.	This	prompted	us	to	
analyze the children who stopped using their BCDs in more detail (see Figure 2). All 
children who were implanted younger than 18 years old (mean age 8 years; median 7 
years) and who stopped using their BCDs did so at a mean age of 13 years (median 14). 
Children	who	were	younger	than	12	years	old	at	 implantation	(mean	and	median	6	
years)	stopped	at	a	mean	age	of	12	years	(median	11).	In	addition,	children	who	had	





non-user group, but the air-bone gap was comparable between both groups. PTAs in 
the	 contralateral	 normal	 ears	 were	 also	 different	 between	 both	 groups,	 but	 this	
Table 1   Continued.	




Anomaly Side PTA NE PTA IE ABG IE
37 6 10 CA III AD 8 65 55
38 28 32 CA IIB/III AD 18 66 60
39 58 62 CA IIA AD 19 79 41
40 9 12 CA III AD 5 74 60
41 7 11 CA III AS 19 74 55
42 11 15 CA IIB AD 9 50 54
43 38 41 CA IIB/III AD 8 64 56
44 33 36 OCA AD 16 58 40
45 7 10 CA I AS 6 60 51
46 9 11 CA IIB/III AS 5 68 59
47 39 41 CA III AD 10 95 46
48 11 13 CA III AS 5 74 60
49 9 11 CA III AS 4 66 54
50 48 50 CA III AD 9 94 56
51 7 8 CA IIB AS 14 78 58
52 8 9 CA III AS 9 63 55
53 8 9 CA III AD 13 61 54






undergone	elaborate	 audiological	 evaluations	 as	 reported	earlier	 (see	 Tables	4,	 5,	
Figure 1  Timelines	for	BCD	usage.	The	patient	numbers	in	the	bars	correspond	to	
those in Table 1. [A]:	Timelines	for	BCD	usage	per	individual	patient.	Patients	marked	
with	#	have	used	the	BCD	on	a	softband	for	at	least	several	months	before	receiving	
percutaneous implants. [B]:	Timelines	for	BCD	usage	per	individual	patient	sorted	 
by	their	age	at	implantation.	The	bars	indicate	the	current	status	of	BCD	usage	by	

















































in any of the earlier reported results were allocated rather arbitrarily as being worth 
1	 point	 and	 statistically	 significant	 deteriorations	were	 considered	 to	 be	worth	 –1	
point	 (Table	 3).	 Non-significant	 improvements	 or	 deteriorations,	 or	 cases	 without	
changes, were graded 0 points. A total score of at least 2 (out of 5 and 3, the maximum 
scores	for	adults	and	children,	respectively)	or	higher	was	considered	to	represent	a	
beneficial	result.	These	scores	were	compared	and	correlated	to	the	current	usage	of	




Figure 2  Distribution	of	age	at	implantation	and	age	at	discontinuing	use	for	all	
children who stopped using their BCD.
Table 2   Comparison	of	patient	characteristics	between	users	and	non-users.	
Variable Users Non-users p-value
Age, mean (SD) 28.3 (± 18.4) 18.4 (± 8.3) 0.011a
Age	at	implantation,	mean	(SD) 22.0 (± 17.3) 10.7 (± 7.8) 0.003a
Years of use, mean (SD) 6.2 (± 4.4) 4.8 (± 2.6) 0.153a
Anomaly, n	(%)   0.437b
 Ossicular chain anomaly 2 (6.7) 2 (± 8.7)  
 Atresia grade I 0 (0) 2 (± 8.7)  
 Atresia grade IIA 3 (10.0) 5 (± 21.7)  
 Atresia grade IIB 3 (10.0) 2 (± 8.7)  
 Atresia grade IIB/III 14 (46.7) 8 (± 34.8)  
 Atresia grade III 8 (26.7) 4 (± 17.4)  
PTA IE, mean (SD) 70.5 (± 12.0) 60.6 (± 9.8) 0.002c
PTA BC IE, mean (SD) 19.2 (± 11.6) 9.1 (± 7.9) 0.001c
ABG IE, mean (SD) 52.2 (± 7.9) 51.8 (± 5.9) 0.819c
SRT IE aid, mean (SD) 21.0 (± 5.9) 19.6 (± 8.5) 0.546c
PTA NE, mean (SD) 11.0 (± 6.2) 8.1 (± 4.9) 0.069c
PTA improvement, mean (SD) 41.2 (± 13.0) 36.5 (± 11.3) 0.332c
SRT improvement, mean (SD) 43.8 (± 15.3) 42.3 (± 12.4) 0.831c
a  Independent t-test	with	equal	variances	not	assumed
b  χ2 test














































higher than in the non- or sporadic users group: 1.9 versus 0.4 (p = 0.016, independent 
t-test).	 Furthermore,	 scores	 were	 found	 to	 correlate	 significantly	 with	 device	 use	 
(p	=	0.019,	two-sided	Fisher’s	exact	test).
	 The	reasons	for	no	longer	using	the	BCDs	were	inquired	about.	Most	non-users	
indicated audiological reasons for not using their BCDs. The majority of non-users 
(52%)	found	the	BCD	disruptive	due	to	background	and	interfering	noises	that	were	
felt	 to	 be	 overly	 amplified,	 causing	 them	 to	 hear	 too	many	 sounds.	 Another	 30%	
claimed	 to	 experience	 no	 benefit	 from	 their	 BCDs	 compared	 to	 being	 unaided.	
Table 3   Audiological	results	of	20	patients	in	the	aided	condition,	as	described	by	
Kunst et al.6,	with	a	first-order	approximation	score	and	their	current	status	
of BCD use. 
Patient Speech perception Sound localization Score Current BCD use per 
week (daily use)
SRT S/N NE S/N IE 500 Hz 3000 Hz
1 – – – – – 0 7 days (4–8 hours)
2 + = – SD – –1 Sporadic
3 SI – + SI SI 3 7 days (> 8 hours)
4 – SI + SI = 2 7 days (> 8 hours)
5 SI – + + + 1 Sporadic
6 SI SI + – – 2 7 days (> 8 hours)
7 + SI + + SI 2 5 days (4–8 hours)
8 = + SI SI SI 3 None
9 SI SI = – – 2 None
10 – + SD SD + –2 None
11 n.a. SI n.a. SD SI 1 None
12 n.a. + n.a. + + 0 None
13 n.a. + n.a. SI – 1 7days (> 8 hours)
14 n.a. + n.a. + – 0 None
15 n.a. SI n.a. – – 1 None
16 n.a. n.a. n.a. – – 0 None
17 n.a. SI n.a. SI SI 3 7 days (> 8 hours)
18 n.a. SI n.a. SI – 2 7 days (> 8 hours)
19 n.a. n.a. n.a. – + 0 None
20 n.a. SI n.a. SD – 0 None
SRT:	speech	perception	threshold;	speech	in	front,	without	noise.	S/N	NE:	signal-to-noise;	speech	in	
front, noise near normal hearing ear. S/N IE: signal-to-noise; speech in front, noise near impaired ear. 
SI:	significant	improvement.	SD	=	significant	deterioration.	N.a.:	data	not	available.
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Table 4   Audiological	results	of	33	newly	described	patients	and	their	current	 
status of BCD use. 
 Baseline Aided Improvement  BCD use per week 
(daily use)Patient PTA SRT PTA SRT PTA SRT
21 85 n.a. 48 42 38 n.a. Sporadic
22 44 48 n.a. 10 n.a. 38 None
23 64 80 16 22 48 58 None
24 63 n.a. 31 20 31 n.a. None
25 70 57 20 17 50 40 7 days (> 8 hours)
26 55 53 38 25 18 28 None
27 74 n.a. n.a. 20 n.a. n.a. None
28 58 60 n.a. 0 n.a. 60 None
29 69 60 20 17 49 43 None
30 63 n.a. n.a. n.a. n.a. n.a. Sporadic
31 84 n.a. 16 13 68 n.a. 2 days (4–8 hours)
32 65 n.a. 24 20 41 n.a. None
33 56 60 18 12 39 48 5 days (4–8 hours)
34 50 45 n.a. 13 n.a. 32 None
35 38 n.a. 16 22 21 n.a. None
36 76 n.a. 44 26 33 n.a. 7 days (> 8 hours)
37 65 60 n.a. 23 n.a. 37 None
38 66 n.a. 24 18 43 n.a. 4 days (4–8 hours)
39 79 n.a. 40 23 39 n.a. 6 days (> 8 hours)
40 74 70 n.a. 20 n.a. 50 Sporadic
41 74 n.a. 25 10 49 n.a. None
42 50 n.a. 29 18 21 n.a. Sporadic
43 64 70 24 18 40 52 4 days (> 8 hours)
44 58 45 39 30 19 15 7 days (> 8 hours)
45 60 n.a. 18 22 43 n.a. None
46 68 65 38 30 30 35 5 days (4–8 hours)
47 95 93 28 23 68 70 Sporadic
48 74 n.a. 24 23 50 n.a. 5 days (> 8 hours)
49 66 63 39 30 28 33 5 days (4–8 hours)
50 94 n.a. 33 28 61 n.a. 2 days (4–8 hours)
51 78 70 35 12 43 58 5 days (4–8 hours)
52 63 n.a. 24 18 39 n.a. 5 days (4–8 hours)
53 61 60 28 23 34 37 5 days (4–8 hours)
PTA	(pure	tone	average)	in	dB	HL	at	0.5,	1,	2,	and	4	kHz.	SRT:	speech	recognition	threshold	in	dB.	



















































The SSQ was sent to the 34	patients	still	using	their	BCDs	(n = 23 users, n = 7 sporadic 
users) or who stopped using them in the year before they were interviewed (n = 4). 
Twenty-six	questionnaires	were	returned,	resulting	in	a	response	rate	of	76.5%.	BCD	
users	reported	significant	improvements	in	the	speech	(5.4	unaided,	6.6	aided)	and	













group is 16 points (9 versus –7 points). In comparison to the Kunst et al. data, the 













a	 mean	 follow-up	 period	 of	 seven	 years.	 The	 mean	 age	 at	 implantation	 was	
significantly	different	between	users	and	non-users	in	the	current	study:	22	versus	10	
years	 old.	 We	 found	 that	 the	 group	 of	 compliant	 patients	 (i.e.,	 users)	 showed	
approximately	10	dB	worse	air	and	bone	conduction	PTAs	in	the	impaired	ear	than	the	
non-users; thus, they presented with similar air-bone gaps. It is unlikely that that 
played	a	role,	as	aided	SRTs	of	the	two	groups	were	comparable.	Interestingly,	there	
was	a	significant	correlation	between	short-term	binaural	benefit	(using	the	results	of	
directional	 hearing	 assessments	 and	 elaborate	 speech	 audiometry	 from	 previous	
research by Kunst et al.6)	and	device	use.	Most	of	the	patients	who	quit	using	the	BCD	
claimed	 to	 experience	 no	 benefit	 from	 their	 BCD:	 generally,	 they	 reported	 that	
background noise was too loud and/or that they could hear well enough with their 
normal-hearing	ear.	Subjective	benefits	measured	by	the	SSQ	questionnaire	generally	
showed improvements. The outcomes of the SSQ in the non-users did not provide an 
indication	of	hindrance	due	 to	 the	BCD.	The	 remarkable	higher	aided	score	 in	 the	
spatial	hearing	domain	reported	by	the	non-users	was	most	likely	influenced	by	the	
small n-size. The GCBI scores were much lower than those reported by Kunst et al.7
We	consider	these	compliance	figures	to	be	disappointing.	The	current	results	are	in	
contrast	 with	 recent	 data	 from	 Birmingham,	 United	 Kingdom,	 reporting	 100%	
compliance	with	BCDs	in	12	children	(mean	and	median	age	at	implantation:	9	years	
old)	with	 congenital	UCHL	after	an	estimated	mean	3	 to	4	years	of	 follow-up.20 In 
accordance with our data, poor acceptance of wearing BCDs is reported in children 
with	UCHL,	especially	those	with	malformations	of	the	ears.21
	 One	theory	to	explain	the	difference	in	non-use	between	the	children	and	the	
adults in the current study might be that the choice of treatment with a BCD is made 
by	 parents	 when	 children	 are	 young.	 Parents	 might	 overestimate	 their	 child’s	
problems, as reported by Kopun and Stelmachowicz.22 When children grow up, they 
might stop using the BCD because they experience only a limited handicap or because 
they	 want	 to	 fit	 in	 with	 their	 peers.	 It	 could	 also	 be	 possible	 that	 children	 have	
experienced	 benefits	 of	 the	 BCD	 in	 the	 crucial	 phase	 of	 speech	 and	 language	
development and have successfully surpassed this. This is supported by the fact that 
even	 though	 a	majority	 of	 children	 quit	 using	 the	 BCD,	 they	 used	 it	 for	 4.8	 years	
before	quitting.	Patients	implanted	at	an	adult	age	are	most	likely	a	selected	group	




















































adults reported that they had been teased and that the amount of teasing they 




given by the children.
	 We	found	that	binaural	processing	capabilities	are	highly	variable	between	patients 
and	that	those	capabilities	are	predictive	for	compliance	with	the	BCD.	Agterberg	et	
al.8	 reported	 that	 the	 binaural	 benefit	 of	 a	 BCD	 in	 congenital	 UCHL	 was	 hard	 to	
objectify	 and	 that	 these	 patients	 were	 remarkably	 capable	 of	 using	 directional	
hearing	 in	 the	 unaided	 condition.	 They	 argued	 that	 the	 poor	 binaural	 scores	 that	
were	found,	in	contrast	to	patients	with	acquired	UCHL,	might	have	been	caused	by	a	
lack	of	binaural	input	in	the	past.	The	sensitive	period	for	learning	to	process	bilateral	
input	 effectively	most	 likely	 plays	 a	 role.	 It	 should	 be	 noted	 that	 normal	 hearing	
children	of	five	years	old	have	already	developed	binaural	processing	skills	that	are	
comparable to those of adults.24 Whether the absence of bilateral cues before age 
four leads to a permanent immature neural system is not known. What argues against 
the	 effect	 of	 early	 deprivation	 is	 that	 several	 of	 Kunst	 et	 al.’s	 patients	 who	were	
implanted at an adult age showed obvious binaural processing. Looking at Table 3, 












it	 would	 have	 been	 interesting	 to	 investigate	 more	 objective	 parameters	 in	 the	
current	study	population.	The	effects	of	early	intervention	and,	eventually,	the	use	of	
dedicated	training	programs	aimed	at	binaural	hearing	should	be	investigated.	Longer	
follow-ups	on	 the	current	study	population	will	provide	more	 insights.	 It	might	be	
possible	that	the	patients	who	quit	using	the	BCDs	will	use	them	again	later	in	life	or,	
alternatively,	 they	 might	 arrange	 their	 lives	 and	 careers	 in	 ways	 that	 make	 their	
hearing	handicaps	less	significant.	
190
 The present results suggest that only providing the BCD to children with congenital 
UCHL	might	not	be	enough.	Adults	seem	to	be	a	more	self-selected	population	and	
seek help when needed, which is supported by their good compliance. Importantly, 
the	pediatric	congenital	UCHL	population	is	diverse	and	requires	more	individualized	
care. This is in agreement with the main conclusion by The Pediatric Working Group 
on	 Amplification	 for	 Infants	 and	 Children	 with	 Hearing	 Loss,25 who stated that 
provision of a hearing aid for children with unilateral hearing loss should be based on 
case-by-case	evaluations.	Ideally,	benefits	should	be	established	in	a	prolonged	trial	
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Since	 the	 implantation	 of	 the	 first	 bone-anchored	 hearing	 implant	 (BAHI)	 in	 1977,	
there have been numerous developments. The implants and abutments have evolved 
to	improve	stability,	reduce	implant	loss,	and	diminish	soft	tissue	inflammation.	The	




inflammation	 and	 implant	 loss,	 and	 studied	 new	 implant	 designs	 (Cochlear	 Baha	
BI300	and	Oticon	Medical	Ponto	wide	 implant),	as	well	 as	 the	 loading	moment	of	
these implants. Furthermore, a transcutaneous BCD with an implantable magnet for 
coupling (Sophono Alpha 1 and Alpha 2) was compared to the percutaneous BCD 
(Cochlear	 Baha).	 Finally,	 the	 long-term	 compliance	 and	 subjective	 benefit	 for	 two	
extended	 indications	 for	 percutaneous	 BCDs	 were	 studied:	 single-sided	 deafness	
(SSD)	and	congenital	unilateral	conductive	hearing	loss	(UCHL).
Following	the	general	introduction	in	chapter	1.1,	chapter	1.2	discussed	the	application	
and	 interpretation	of	 resonance	 frequency	analysis	 (RFA)	application	 in	BAHI.	 This	
technique	has	recently	been	introduced	in	the	field	of	BAHI,	but	is	well	known	from	
dental	implantology	research.	The	outcome	of	RFA	is	the	implant	stability	quotient	
(ISQ),	 which	 provides	 information	 about	 implant	 stability.	 As	 this	 is	 an	 objective	
measuring	 technique,	 it	 could	 be	 an	 interesting	 outcome	 of	 BAHI	 research	 and,	
possibly,	 also	 become	 an	 additional	 tool	 in	 routine	 clinical	 follow-up.	 Up	 to	 date,	
however,	presentation	and	interpretation	of	RFA	outcome	varied	between	studies.	To	
realize comparability between future studies and increase the clinical relevance of 
ISQ measurements, guidelines were proposed in this chapter. The most important 
consideration	is	that	ISQ	should	be	interpreted	as	a	trend;	no	conclusions	should	be	
drawn from absolute stand-alone values.
In	chapter	2.1,	a	retrospective	analysis	of	581	adult	patients	with	a	total	number	of	
669	BAHIs	(3.75-mm	diameter	implants)	was	conducted	to	identify	the	influence	of	
comorbidity	 factors	on	soft	tissue	reactions,	revision	surgery,	and	 implant	 loss.	An	
adverse	soft	tissue	reaction	(Holgers	grade	2	or	higher)	was	noticed	at	least	once	in	





high body mass index (BMI).2	Revision	surgery	was	performed	in	11.8%	of	all	implants.	




implants.	 Smoking	was	 identified	 as	 the	only	 statistically	 significant	 risk	 factor	 for	
implant	 loss.	 In	other	studies,	 radiation	 therapy4 and diabetes mellitus5 have been 
reported	 to	 present	 with	 statistically	 significantly	 higher	 rates	 of	 implant	 loss.	
Diabetes	mellitus	and	cardiovascular	diseases	were	identified	as	comorbidity	factors	
that showed trends towards higher implant loss in the current study. The current 
findings	 should	 be	 included	 in	 patient	 counseling	 and	 selection	 of	 surgical	 and	
postoperative	procedures.	Moreover,	the	current	results	could	be	used	as	a	reference	
for upcoming clinical results of new types of BAHI (e.g., wider diameters or surface 
modifications)	and	advances	in	surgical	techniques.
	 Chapter	2.2,	2.3,	and	2.4	presented	prospective	studies	on	wide	BAHIs	with	a	
diameter of 4.5 mm. In chapter 2.2, a BAHI with moderately roughened surface and a 
rounded, apically converging abutment (Cochlear Baha BI300, test implant) was 
compared to the previous 3.75-mm-diameter BAHI with a machined surface and 
conically	shaped	abutment	(Cochlear	Baha	flange	fixture,	control	implant).	This	study	
was	set	up	as	a	three-year	multicenter	randomized	controlled	clinical	trial	including	
52 test implants and 25 control implants. Implants were loaded with the sound 
processor	from	six	weeks	after	surgery.	Both	implants	presented	an	increasing	ISQ	






implant seemed feasible. Therefore, this was studied in chapter 2.3, where the same 
implant as test implant from chapter 2.2 was loaded with the sound processor at 
three	weeks	post	implantation	in	30	patients.	This	study	was	designed	as	a	three-year	
single-center	 prospective	 case	 series.	 The	 outcome	 was	 compared	 to	 the	 test	
population	of	the	study	 in	chapter	2.2.	Because	no	notable	differences	 in	terms	of	
ISQ,	 implant	 survival,	 and	 soft	 tissue	 tolerability	 were	 observed,	 loading	 the	 test	
implant	 at	 three	 weeks	 after	 surgery	 seemed	 safe.	 This	 was	 confirmed	 by	 other	
studies,	 although	 with	 shorter	 follow-up,	 that	 studied	 loading	 times	 of	 the	 same	
implant at four6 and two weeks.7
 Chapter 2.4 presented the six-months results of a single-center randomized 
controlled clinical trial that compared a 4.5-mm-diameter BAHI with a machined 
surface	(Oticon	Medical	Ponto	wide	implant,	test	implant,	n = 39) with the previous 
generation	3.75-mm-diameter	BAHI	(Oticon	Medical	Ponto	implant,	control	implant,	
n = 20). Both implants had the same shoulder-shaped abutment and were loaded at 
three weeks. Therefore, the strength of this study is in the fact that only one 

















both study groups. Both implants presented an increasing trend in ISQ from baseline, 
with	 a	 statistically	 significantly	 higher	 mean	 ISQ	 and	 a	 statistically	 significantly	
stronger	increase	in	ISQ	in	the	test	implant	group.	No	implants	were	lost.	Soft	tissue	
tolerability	was	comparably	good:	Holgers	grade	2	 in	 1.1%	(test	 implants)	and	1.4%	
(control	implants)	of	visits,	Holgers	grade	3	in	0.0%	(test	implants)	and	0.7%	(control)	
implants of visits, and no Holgers grade 4 cases over all of the visits. Hearing-related 
quality	 of	 life	 was	measured	 by	means	 of	 the	 Abbreviated	 Profile	 of	 Hearing	 Aid	
Benefit	(APHAB),	the	Glasgow	Benefit	Inventory	(GBI),	and	the	Glasgow	Health	Status	
Inventory	 (GHSI).	 The	 outcomes	 of	 these	 questionnaires	 indicated	 benefit	 of	 the	
system.	 These	 positive	 short-term	 results	 indicate	 that	 both	 implants	 and	 its	
corresponding	sound	processors	loaded	at	three	weeks	are	a	safe	option	for	hearing	
rehabilitation.
 The outcomes of chapter 2.2, 2.3, and 2.4 indicated that wider implants provide 
higher ISQ. This suggests improved implant stability compared to the previous 
generation	3.75-mm-diameter	implants.	There	seems	to	be	a	difference	between	the	
mean absolute ISQ of both types of 4.5-mm-diameter implants. Possibly, this is 
described to the moderately rough surface compared to the machined surface. If this 
difference	in	mean	ISQ	is	clinically	significant	is	not	yet	understood.	The	exact	value	
of	surface	modification	of	BAHIs	is	not	yet	demonstrated.	A	randomized	controlled	
clinical trial comparing both types of 4.5-mm-diameter implants would be suited to 
investigate	such	a	difference.	Although	follow-up	on	both	implant	types	is	still	relatively	
short,	 implant	 losses	 seem	diminished	compared	 to	previous	generation	 implants,	






was proposed with promising outcome.8	 It	 will	 be	 interesting	 to	 compare	 this	
technique	 to	 the	 conventional	 Nijmegen	 linear	 incision	 technique	with	 soft	 tissue	
reduction	 in	 a	 prospective	 and	 randomized	 setting.	 Besides	 abutment	 length,	 the	
recently	introduced	hydroxyapatite	coated	abutments	are	suggested	to	increase	soft	
tissue	tolerability	even	more,	which	is	not	yet	obvious	from	the	first	case-series	that	
reports outcome of these abutments.9
The	concept	of	transcutaneous	BCDs	was	recently	revived	with	the	introduction	of	a	
magnetically	 coupled	 device	 (Sophono	 Alpha	 1).	 This	 device	 consists	 of	 double	
implanted	magnets	in	titanium	housing	under	closed	skin.	Conceivably,	implant	loss	
and	soft	tissue	infection	should	be	reduced	to	a	minimum	due	to	the	closed	skin.	On	
the other hand, previous transcutaneous BCDs have been reported inferior in terms 
200
of	 audiological	 outcome,	 due	 to	 damping	 characteristics	 of	 the	 skin	 between	 the	




device. In terms of audiological outcome, however, aided thresholds and speech 
perception	were	 better	 in	 the	 patients	 with	 the	 percutaneous	 BCD.	 To	 study	 any	
differences	between	the	devices	and	their	coupling,	objective	output	measurements	
were conducted on a skull simulator. The transcutaneous device was found to be 
around 10 dB less powerful than the percutaneous device, which is in compliance 
with other comparisons between transcutaneous and percutaneous devices.10,11 The 
follow-up of the children with the transcutaneous BCD was extended in chapter 3.2. 
It	was	found	that	two	out	of	the	six	patients	(33%)	stopped	using	the	device	after	a	
follow-up	 of	 three	 years.	 This	 relatively	 high	 figure	 of	 non-compliance	 is	 in	
correspondence	with	another	study	(chapter	4.2)	that	found	disappointing	compliance	
after	 long-term	 follow-up	 with	 percutaneous	 BCDs	 in	 another	 congenital	 UCHL	
population.	Soft	tissue	tolerability	of	the	transcutaneous	device	was	good.	Also,	the	
new sound processor (Alpha 2) was tested and found to provide similar hearing 
results	 as	 the	 Alpha	 1.	 Finally,	 sound	 localization	 with	 the	 device	 was	 tested	 and	
compared	to	sound	localization	with	a	percutaneous	BCD.	Both	devices	yielded	slight	
mean	improvement	in	directional	hearing,	however,	results	varied	within	both	study	
groups	and	no	firm	conclusions	could	be	drawn.	Possibly,	 this	 limited	effect	of	 the	
device	could	also	partially	be	described	to	the	specific	handicap	that	congenital	UCHL	
is,	as	it	has	been	reported	before	that	sound	localization	capabilities	and	the	success	









In accordance with our conclusion, several authors underline the importance of a 
preoperative	headband	trial	period	with	the	BCD,	before	implantation	is	considered	
in	 patients	 with	 SSD.14,15	 Patients	with	 SSD	 should	 have	 realistic	 expectations	 of	 a	
percutaneous	BCD,	as	it	is	known	to	provide	limited	benefit	in	challenging	listening	
conditions.	Binaural	hearing	will	not	be	accomplished,	as	these	patients	have	only	a	

















environments is greatest when the speech source is located near the deaf ear. 
However,	 in	case	the	noise	source	 is	 located	on	the	deaf	ear,	the	benefit	becomes	
negative.
	 Chapter	4.2	reported	compliance	and	satisfaction	with	percutaneous	BCDs	in	a	




hearing	 results	 in	 several	 publications.16-18	 Nevertheless,	 compliance	was	 just	 57%	
after	 a	 mean	 follow-up	 time	 of	 6.8	 years	 (range	 1–15	 years).	 The	 mean	 age	 at	
implantation	of	the	users	(22	years)	was	significantly	higher	than	that	of	the	non-users	
(10	 years).	 The	 primary	 reasons	 mentioned	 for	 quitting	 usage	 of	 the	 BCD	 were	
experiencing	 excess	 background	 noise	 and/or	 subjectively	 not	 receiving	 enough	
benefit.	 Long-term	 use	 figures	 were	 found	 to	 correlate	 with	 the	 improvement	 of	
binaural processing skills yielded by the BCD, as reported in another study.19 In 
accordance,	 the	 patients	who	 still	 used	 the	 BCD	 reported	 subjective	 benefit.	 The	
current results suggest that only providing the BCD to children with congenital UCHL 











In the recent past research and developments in BAHIs and BCDs have gained 
momentum,	which	is	expected	to	continue	in	the	near	future.	It	will	be	interesting	to	










retrospective	 studies	 with	 mixed	 populations	 are	 reviewed,	 severe	 complications	
(i.e., revision surgery and implant loss) in percutaneous implants are rare. Table 1 
presents	that	severe	complications	occur	once	in	30	to	60	years	of	follow-up	in	the	
previous	 generation	 implants.	 Moreover,	 with	 the	 currently	 used	 4.5-mm	 wide	
implants	 and	 the	updated	abutment	designs,	 severe	 complications	are	even	more	
rare, occurring once in 115 years. It remains to be seen whether transcutaneous 
application	will	provide	similar	long-term	clinical	outcome.	Skin	ulceration	due	to	the	
magnetic	 coupling	 has	 been	 reported	 in	 transcutaneous	 devices.20	 Ultimately,	 the	
argument that transcutaneous BCDs are needed because of stability or tolerability 









the head in the MRI scan being unable to be assessed. The larger the implanted parts, 
the	more	scattering	will	be	produced.
 Besides stability and tolerability of the implants, the audiological performance of 
these	different	types	of	BCDs	should	be	considered.	So	far,	the	Sophono	Alpha	1	and	
Alpha 2, as studied in the current thesis, seem less powerful, compared to the 
percutaneously applied Baha and Ponto devices. The recently introduced transcutaneous 
Baha	 Attract	 system	 has	 not	 yet	 been	 studied	 extensively	 enough	 to	 draw	 firm	
conclusions.25 Nevertheless, these passive transcutaneous BCDs will always lose 
some	output	due	to	the	damping	characteristics	of	the	skin	en	subcutaneous	tissue	
between	 the	 actuator	 of	 the	 sound	 processor	 and	 the	 implant.	 Active	 implanted	
BCDs, such as the MED-EL BoneBridge26	and	the	Bone	Conduction	Implant	(developed	
by	Håkansson	and	co-workers),27,28	are	suggested	to	have	better	hearing	results	than	
passive transcutaneous BCDs especially due to the fact that they can be located more 
closely to the cochlea. The maximum power output might be comparable to 
percutaneous BCDs.29	 Future	 research	 is	however	needed	 to	 compare	all	different	
aspects	of	these	rather	new	types	of	BCDs	to	what	still	remains	the	golden	standard	
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hearing	 implants,	 BAHIs)	 is	 a	 well-established	 treatment	 option	 for	 patients	 with	
various types of hearing loss. The system consists of a screw-shaped implant and a 
tightly	 connected	 percutaneous	 abutment	 to	which	 the	 vibrating	 BCD	 is	 coupled,	
which	provides	stimulation	of	the	cochlea	through	bone	conduction.
	 Since	 the	 first	 patients	were	 implanted	with	 the	 implant-abutment	 system	 in	
1977, numerous developments in implants, abutments, and devices have been 
realized. Important hallmarks of the success of the system were, i.a., decreasing 
figures	of	implant	loss,	better	soft	tissue	tolerability,	and	greater	audiological	benefit.	
The	 indications	 for	 the	 application	 of	 BCDs	 have	 been	 extended	 over	 the	 recent	
decades.	 Initially,	 the	 indications	 for	 application	of	 the	 system	were	patients	who	
could	not	use	conventional	hearing	aids	due	to	ear	infections	or	patients	with	bilateral	
conductive	hearing	 loss.	Over	time,	 the	 system	also	proved	 its	 success	 in	patients	
with	(congenital	or	acquired)	unilateral	conductive	hearing	loss	(UCHL),	mixed	hearing	
loss and single-sided sensorineural deafness (SSD).
Resonance	frequency	analysis	(RFA)	is	a	technique	to	evaluate	implant	stability	that	has	
recently	been	applied	to	BAHI,	originating	from	dental	implantology.	RFA	is	essentially	




measures	 the	 resulting	 resonance	 frequency	 (in	Hz)	 and	 translates	 it	 into	 the	more	
clinically	useful	implant	stability	quotient	(ISQ),	which	ranges	from	1	to	100.

















RFA at surgery should be established as a baseline. Depending on the research 
question,	follow-up	moments	may	vary.
4.	 After	 abutment	 replacement,	 individual	 ISQ	 trends	 from	 baseline	 cannot	 be	
interpreted	anymore	if	abutments	differ	in	length.	A	new	baseline	ISQ	value	should	 
be	established	after	replacement.
5. It is encouraged to present case-series of clinically unstable implants with 
baseline and event related ISQ values. With a large pool of such data, an individual 
absolute	 ISQ	value	 for	a	specific	 implant	might	be	of	clinical	use	to	predict	 its	
clinical behavior.
 
Implant survival and tolerability of BAHIs should be as high as possible to provide 
optimal	 benefit	 of	 the	 system.	 Survival	 and	 tolerability	 are	 largely	 attributed	 to	
implant	and	abutment	features,	but	are	also	affected	by	the	individual	patient’s	char-




18.4%	 of	 all	 implants.	 The	 only	 statistically	 significant	 risk	 factor	 for	 adverse	 soft	
tissue	reactions	that	could	be	identified	in	the	current	population	was	skin	disease.	
Revision	surgery	was	performed	 in	11.8%	of	all	 implants.	No	statistically	significant	
risk factors for revision surgery were detected, however, female gender and, 
remarkably,	 cardiovascular	 diseases	 were	 identified	 as	 protective	 factors	 with	 a	
negative	risk	for	revision	surgery.	Implant	loss	was	observed	in	7.5%	of	implants	and	
the	only	statistically	significant	risk	factor	for	implant	loss	was	smoking.
 The results above were found in a cohort of implants that have been replaced 
recently, as novel designs of wider diameter implants and reshaped abutments have 
been	introduced.	However,	these	findings	are	a	valuable	reference	for	research	on	
novel implants. These wider diameter implants should provide higher stability and 
survival,	 while	 the	 abutments	 should	 result	 in	 better	 soft	 tissue	 tolerability.	 Two	
recently	 introduced	 implants	 were	 studied	 in	 comparison	 to	 previous	 generation	
implants.
	 In	 a	 three-year	 multicenter	 randomized	 controlled	 trial,	 a	 4.5-mm-diameter	
implant with a moderately rough surface and a rounded, apically rounded converging 
abutment (Cochlear Baha BI300, test implant, n = 52) was compared to a 3.75-mm-
diameter implant with a machined surface and conically shaped abutment (Cochlear 
Baha	 flange	 fixture,	 control	 implant,	 n = 25) in terms of stability, survival, and 
tolerability.	The	 implants	were	 loaded	from	six	weeks	after	 implantation.	For	both	













whereupon	 ISQ	values	decreased	between	 two	and	 three	 years	 after	 surgery,	 but	
remained	above	baseline	values.	The	test	 implant	showed	a	statistically	significant	
higher mean ISQ over the whole follow-up period (ISQ High: 71.5 versus 66.4, ISQ Low: 
69.8	versus	64.4).	Implant	survival	was	comparably	high	for	both	implants:	96.2%	for	
the	test	implants	and	100%	for	control	implants.	Soft	tissue	tolerability	was	better	for	
the	 test	 implant,	 as	 15.4%	 of	 the	 patients	 with	 a	 test	 implant	 presented	 with	 an	
adverse	soft	tissue	reaction	compared	to	48.0%	of	the	patients	with	a	control	implant.	




 Early loading of these 4.5-mm-diameter implants with a moderately rough 





survival	was	 97%	 in	 the	 study	population	 and	96%	 in	 the	 comparison	population.	
Clinically	 relevant	 soft	tissue	 reactions	were	 found	 in	0.9%	 (study	population)	and	
1.7%	(comparison	population)	of	all	visits.
 In a six-month randomized controlled trial, another 4.5-mm-diameter implant 
(Oticon	Medical	Ponto	wide	implant,	test	implant,	n = 39) was compared to a 3.75-
mm-diameter	implant	(Oticon	Medical	Ponto	implant,	n = 20). Both implants had a 









of visits, and no Holgers grade 4 cases over all of the visits in these six months.
As	an	alternative	to	the	percutaneous	BAHI,	the	concept	of	transcutaneous	coupling	
of BCDs to the skull has been revived recently. The Sophono system consists of double 
implanted	 magnets	 in	 titanium	 housing	 under	 closed	 skin	 to	 which	 the	 sound	
processor	 (Alpha	 1)	 can	be	coupled	magnetically.	 In	concept,	 implant	 loss	and	soft	
tissue	 infection	 should	be	 reduced	 to	 a	minimum	due	 to	 the	 closed	 skin	 over	 the	
implant.	 This	 was	 investigated	 in	 six	 children	 with	 congenital	 UCHL	 compared	 to	
212
matched	 controls	 using	 a	 BCD	 coupled	 to	 a	 BAHI.	 Implant	 loss	 and	 soft	 tissue	
tolerability were indeed favorable for the transcutaneous BCD. However, aided 
thresholds	and	speech	perception	were	better	in	the	patients	with	the	percutaneous	
BCD.	Objective	output	measurements	were	 conducted	on	a	 skull	 simulator,	which	
revealed the transcutaneous BCD to be around 10 dB less powerful than the 
percutaneous BCD.
	 The	Alpha	2	was	introduced	recently	and	studied	in	the	same	six	patients	together	
with long-term clinical outcome of at least three years with the system was studied in 




localization	 abilities	 generally	 improved	 with	 either	 the	 transcutaneous	 or	
percutaneous	 BCD,	 although	 in	 these	 patients	 with	 congenital	 UCHL	 the	 sound	













usage	 before	 the	 patients	 stopped	 using	 the	 BCD	was	 five	 years.	 Users	 reported	
significant	improvement	in	the	aided	condition	compared	with	the	unaided	condition,	
in contrast to the nonusers.
Summarizing	the	current	thesis,	positive	clinical	results	with	the	new	generation	of	
wider	BAHIs	were	found.	Transcutaneous	application	of	BCDs	in	children	demonstrated	
positive	 tolerability,	 however,	 audiological	 outcomes	 of	 percutaneous	 application	
were	measured	 to	be	superior.	The	compliance	of	patients	with	SSD	or	congenital	
















































uiteenlopende soorten slechthorendheid. Via dit chirurgisch geïmplanteerde schroef - 













Resonance	 frequency	 analysis	 (RFA)	 is	 een	 techniek	 om	 implantaatstabiliteit	 te	
bepalen. Deze techniek stamt uit de tandheelkundige implantologie en is sinds enkele 
jaren	ook	beschikbaar	voor	BAHI’s.	In	essentie	is	RFA	een	test	van	de	buigzaamheid	
van	 een	 implantaat	 in	 bot.	Magnetische	pulsen	 stimuleren	 een	 aan	het	 abutment	
gekoppelde	SmartPeg,	waardoor	deze	een	uitslag	binnen	het	bot	maakt.	De	resonantie	
frequentie	van	deze	uitslag	wordt	vervolgens	gemeten	door	hetzelfde	apparaat	dat	




een meta-analyse onmogelijk maakte. Er bleken heterogeniteit en beperkingen te zijn 
in het rapporteren van de type implantaten en abutments, de gebruikte SmartPegs, 
de	grootte	van	de	studiepopulaties,	de	duur	van	de	follow-up	en	de	manier	waarop	
ISQ gerapporteerd werd. Daarom werden er aanbevelingen voor gebruik en rapportage 
vastgelegd, zoals hieronder opgesomd.
1.	 Veranderingen	in	ISQ	vanaf	implantatie	over	tijd	geven	de	trend	van	de	stabiliteit	
het beste weer.
2. Op dit moment hebben op zichzelf staande ISQ waarden nog weinig waarde; 
trends	 in	 individuele	 patiënten	 of	 een	 groep	 geven	meer	 informatie.	 Daarom	
kunnen	er	nog	geen	klinische	consequenties	worden	verbonden	aan	specifieke	
ISQ	waarden.	Het	 is	aanbevolen	RFA	minstens	 te	verrichten	bij	 implantatie	en	
daarna waarna mogelijk of noodzakelijk.
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3. Wanneer RFA wordt gebruikt in wetenschappelijk onderzoek dienen de meet - 
momenten	prospectief	 te	worden	vastgelegd.	Deze	momenten	zijn	afhankelijk	
van de onderzoeksvragen.
4. Na het vervangen van een abutment voor een langer type kan de ISQ trend niet 
meer	 vanaf	 implantatie	 beschouwd	worden;	 op	 het	moment	 van	 vervangend	
dient	er	een	nieuwe	uitgangsmeting	verricht	te	worden.
5.	 Het	 wordt	 aanbevolen	 ISQ	 waarden	 van	 BAHI	 waarbij	 complicaties	 optreden	
tijdens	de	follow-up	te	rapporteren.	Indien	er	voldoende	van	zulke	data	verzameld	




techniek, het implantaat en het abutment, maar ook van de eigenschappen van de 
patiënt	 in	 combinatie	 met	 zijn/haar	 persoonlijke	 verzorging.	 Daarom	 werden	
risicofactoren	voor	huidirritatie,	revisiechirurgie	(heroperaties)	en	implantaatverlies	
onderzocht	 in	 een	 retrospectief	 cohort	 van	 581	 patiënten	 (669	 vorige	 generatie	






tot revisiechirurgie, echter bleken vrouwelijk geslacht en cardiovasculaire aandoeningen 
beschermende factoren hiervoor te zijn. Implantaatverlies werd geobserveerd in 
7,5%	van	alle	implantaten,	waarvoor	roken	als	enige	risicofactor	kon	worden	ontdekt.
	 De	BAHI’s	waarmee	de	hierboven	beschreven	resultaten	zijn	geobserveerd,	zijn	




Twee	 verschillende	 types	 van	 de	 nieuwe	BAHI’s	met	 grotere	 diameters	werden	 in	
onderstaande studies vergeleken met hun voorganger.
	 Een	BAHI	met	een	diameter	van	4,5	mm,	een	matig	geruwd	oppervlak	en	een	
apicaal afgerond convergerend abutment (Cochlear Baha BI300, test implantaat, 
n = 52) werd vergeleken met zijn voorganger, welke een diameter van 3,75 mm, een 
glad	 oppervlak	 en	 een	 conisch	 abutment	 (Cochlear	 Baha	 flange	 fixture,	 controle	



































twee jaar zelfs een daling waargenomen, echter niet tot onder de waarden gemeten 
bij	implantatie.	Gedurende	de	gehele	follow-up	periode	was	het	gemiddelde	ISQ	van	
het	test	implantaat	statistisch	significant	hoger	dan	die	van	het	controle	implantaat	
(ISQ High: 71,5 versus 66,4; ISQ Low: 69,8 versus 64,4). Implantaatverlies was 
zeldzaam:	96,2%	van	de	test	implantaten	en	100%	van	de	controle	implantaten	waren	
na	 drie	 jaar	 nog	 in	 situ.	 Het	 test	 implantaat	werd	 beter	 verdragen:	 15,4%	 van	 de	
patiënten	met	een	test	implantaat	vertoonde	op	enig	moment	tijdens	de	follow-up	
een	huidirritatie	van	Holgers	graad	2	of	hoger	ten	opzichte	van	48,0%	van	de	patiënten	





geruwd	oppervlak	werd	onderzocht	in	een	prospectief	cohort	(n = 30) met drie jaar 
follow-up.	 De	 aanvankelijke	 drie	 maanden	 wachttijd	 voor	 belasting	 van	 een	
implantaat,	is	al	enige	tijd	teruggeschroefd	naar	zes	weken.	In	de	huidige	studie	was	
dit	 verder	 teruggebracht	 tot	 drie	 weken.	 De	 uitkomsten	 van	 deze	 test	 populatie	
werden	vergeleken	met	een	populatie,	bestaand	uit	de	test	patiënten	uit	de	hiervoor	
beschreven studie, waarbij de implantaten vanaf zes weken na plaatsing werden 





geobserveerd	 in	 0,9%	 (test	 populatie)	 en	 1,7%	 (vergelijkbare	 populatie);	 hogere	
Holgers graden werden niet waargenomen.
	 Een	ander	 type	4,5	mm	brede	BAHI	 (Oticon	Medical	Ponto	wide	 implant,	 test	
implantaat, n	 =	 39)	 werd	 vergeleken	met	 zijn	 3,75	mm	 brede	 voorganger	 (Oticon	
Medical Ponto implant, controle implantaat, n = 20) met een follow-up van zes 




populatie.	 Ook	 was	 het	 gemiddelde	 ISQ	 over	 de	 gehele	 periode	 hoger	 in	 de	 test	
populatie	 dan	 in	 de	 controle	 populatie	 (ISQ	 high:	 65,8	 versus	 62,5;	 ISQ	 low:	 64,4	
versus	 59,3).	 Er	 trad	 in	 beide	 groepen	 geen	 implantaatverlies	 op.	 Huidirritaties	






geïntroduceerd	 met	 als	 idee	 huidreacties	 en	 implantaatverliezen	 nog	 verder	 te	
verlagen. Deze Sophono bestaat uit geïmplanteerde dubbele magneten in een 
titanium	behuizing	waar	de	huid	overheen	gesloten	wordt,	zodat	het	toestel	(Alpha	1)	
magnetisch	op	zijn	plek	wordt	gehouden.	Theoretisch	zou	deze	gesloten	huid	moeten	
leiden	 tot	 minder	 implantaatverlies	 en	 huidirritatie.	 Dit	 werd	 onderzocht	 in	 zes	
kinderen met congenitaal eenzijdig geleidingsgehoorverlies in vergelijking tot zes 
kinderen met een BAHI als behandeling van hetzelfde soort gehoorverlies. Er trad 
inderdaad	 minder	 implantaatverlies	 en	 huidirritatie	 op	 bij	 de	 patiëntjes	 met	 het	
transcutane BCD, echter bleken de audiologische uitkomsten beter met een BAHI. De 
output	van	beide	toestellen	en	koppelingen	werd	objectief	gemeten	met	een	skull	
simulator, hetgeen een verschil van 10 dB aantoonde in het voordeel van het 
percutane BCD.
 De uitkomsten met de opvolger van het transcutane BCD (Alpha 2) werden in 
dezelfde	populatie	bestudeerd.	De	follow-up	was	nu	minimaal	drie	jaar	en	toonde	de	
klinische veiligheid van het systeem op langere termijn aan. De audiologische 
resultaten met de Alpha 2 waren vergelijkbaar met die gemeten met de Alpha 1. Ge-
luidslokalisatie	 met	 zowel	 het	 transcutane	 als	 het	 percutane	 BCD	 verbeterde	
gemiddeld genomen, echter bereikten ze niet het niveau van normaal horende 
kinderen, wat waarschijnlijk ook voor een groot deel aan het type gehoorverlies toe 
te schrijven was.
Het	gebruik	van	hun	BCD	werd	onderzocht	in	een	retrospectief	cohort	opeenvolgende	
patiënten	 met	 SSD	 die	 geïmplanteerd	 waren	 met	 een	 BAHI	 (n = 145). Na een 
gemiddelde	follow-up	van	62	maanden	(range	2–129	maanden)	bleek	83%	van	hen	
het toestel nog te gebruiken, echter bleek naarmate de follow-up langer werd, het 
gebruik	af	te	nemen.	In	verschillende	vragenlijsten	gaven	de	patiënten	aan	tevreden	
te zijn over het toestel, waarbij hun geslacht geen rol bleek te spelen.
	 In	een	andere	studie	werd	het	gebruik	van	hun	BCD	in	een	retrospectief	cohort	
van	 53	 opeenvolgende	 patiënten	 die	 een	 BAHI	 hadden	 gekregen	 in	 verband	met	
congenitaal eenzijdig geleidingsgehoorverlies onderzocht. Na gemiddeld zeven jaar 
follow-up	bleek	57%	het	toestel	nog	te	gebruiken.	De	gemiddelde	 leeftijd	ten	tijde	
van	 implantatie	was	significant	hoger	onder	de	gebruikers	dan	 in	de	patiënten	die	
waren gestopt met het toestel te dragen (22 versus 10 jaar). De gemiddelde 
gebruiksduur	voordat	de	patiënten	stopten	met	het	gebruik	van	hun	BCD	was	vijf	jaar.	



































beter verdragen te worden dan de percutane koppeling door kinderen, echter was de 
percutane	 koppeling	 superieur	 op	 audiologisch	 vlak.	 Patiënten	 met	 een	 BCD	 in	
verband met SSD of congenitaal eenzijdig geleidingsgehoorverlies bleken naarmate 


























revalidatie	bezighoudt.	Met	een	kritische	blik	houd	 je	de	 laatste	ontwikkelingen	 in	 
de	gaten	en	probeer	je	de	kwaliteit	hiervan	zelf	te	objectiveren,	terwijl	je	het	belang	
van	de	patiënt	centraal	stelt.	Daarnaast	ben	je	laagdrempelig	te	benaderen	en	weet	





op	mijn	 vragen	 en	 revisies	 van	mijn	manuscripten;	 altijd	met	 positieve	 feedback.	
Zonder	 jou	 had	 ik	waarschijnlijk	 een	 stuk	 langer	 over	 dit	 promotietraject	 gedaan.	
Bovendien	bleef	er	ook	nog	genoeg	tijd	over	voor	gezelligheid	buiten	het	werk.	Enorm	
bedankt!
prof. dr. Mylanus. Beste Emmanuel, ondanks jouw drukke agenda wist je meestal toch 
tijd	te	vinden	om	met	een	kritische	blik	naar	mijn	manuscripten	te	kijken	en	hierover	
persoonlijk van gedachten te wisselen. Als kroon op jouw indrukwekkende klinische 
en	wetenschappelijke	prestaties	ben	je	recent	benoemd	tot	professor,	waarvoor	hier	
nogmaals	mijn	 felicitaties.	Dank	 voor	de	fijne	 samenwerking,	maar	ook	 voor	 jouw	
enthousiaste	bijdrage	aan	activiteiten	buiten	het	ziekenhuis.	
prof. dr. Cremers. Geachte professor Cremers, aangezien u inmiddels enige jaren met 
emeritaat	bent,	is	dit	het	eerste	Nijmeegse	proefschrift	over	BCD’s	waarbij	u	niet	als	
(co-)promotor	 betrokken	 bent.	 Desalniettemin	 heeft	 u	 een	 waardevolle	 bijdrage	
geleverd	aan	enkele	manuscripten	in	dit	proefschrift	en	was	u	altijd	bereikbaar	voor	







de onderzoeken waar ik door de start van de KNO-opleiding niet meer toe in staat 
was. Allen bedankt voor jullie bijdragen aan verschillende manuscripten van dit 
proefschrift.	Beste	Ivo,	succes	met	het	opstarten	van	je	promotietraject.
Alle	 collega’s	 die	 op	 hun	 eigen	 wijze	 belangrijke	 bijdragen	 hebben	 geleverd	 aan	
verschillende	aspecten	van	dit	proefschrift.	Martijn	Agterberg,	dank	voor	je	bijdragen	
aan	meerdere	onderzoeken	en	met	name	je	expertise	op	het	gebied	van	richtinghoren.	
Alle betrokkenen op het Audiologisch Centrum (in het bijzonder Herman, John, Mieki 
en	Teja),	bedankt	voor	alle	essentiële	audiometrie	die	 jullie	hebben	verricht	en	de	
flexibiliteit	 voor	 alle	 patiënten	 die	 ‘er	 even	 tussendoor’	 gepland	 konden	 worden.	
Daarnaast hebben de dames van de opnameplanning mij enorm geholpen met de 
planning	 van	de	 klinische	 trials,	 net	 als	 Eefke	en	 Sylvia	 op	de	operatiekamers,	 die	
ervoor zorgden dat de juiste materialen beschikbaar waren. Als laatste, maar zeker 
niet als minste, dank ik de stafsecretaresses van de afdeling KNO (in het bijzonder 








bijzonder de opleiders prof. dr. Henri Marres en dr. Frank van den Hoogen. Dank voor 
het vertrouwen dat in mij gesteld is door mij aan te nemen voor het gecombineerde 
promotie-	en	opleidingstraject	tot	KNO-arts.	Het	inhoudelijk	zeer	sterke	en	positieve	
opleidingsklimaat met daarnaast voldoende ruimte voor gezelligheid op en buiten de 
werkvloer is prijzenswaardig.
De leden van de maatschap Keel-, Neus- en Oorheelkunde in het VieCuri Medisch 


















Al mijn vrienden. Omdat ik als een van de weinigen niet naar de Randstad ben 
verhuisd na ons afstuderen, zien we elkaar niet meer dagelijks of wekelijks. Gelukkig 
zorgden	jullie	de	afgelopen	jaren	toch	voor	de	broodnodige	afleiding	in	de	weekenden,	
vooral	in	de	Randstad,	maar	ook	in	het	Nijmeegse.	Daarnaast	zijn	de	(mini-)vakanties	







het	doorzettingsvermogen	dat	 jullie	de	afgelopen	 jaren	 in	 lastige	periodes	hebben	
laten zien. Blijkbaar hebben jullie ook een klein deel hiervan op mij overgebracht. 
Gelukkig is er nu weer de mogelijkheid en gelegenheid voor een feestje.
Lieve	Maeke,	traditiegetrouw	zijn	de	laatste	woorden	van	het	dankwoord	gericht	aan	
de belangrijkste persoon in het leven van de promovendus. Terwijl ik dit dankwoord 
aan het schrijven was, gaf je aan dat ik jou vooral dankbaar moet zijn voor het feit dat 
je me af en toe achter mijn laptop vandaan wist te lokken om te ontspannen of samen 
iets leuks te doen. Daarmee zou ik je natuurlijk tekort doen. Aan de andere kant zou 
alles opschrijven waarvoor ik jou dankbaar ben of wat ik zo geweldig aan jou vind dit 
dankwoord wel erg lang maken. Daarom hou ik het kort: ik ben enorm gelukkig met 
jou	 en	 ben	blij	 dat	 nu	 dit	 proefschrift	 afgerond	 is,	we	weer	meer	tijd	 hebben	om	






















Maastricht, begon hij met de studie Geneeskunde in diezelfde stad. Tijdens zijn 
studenten	tijd	was	hij	actief	lid	van	Studentenvereniging	Circumflex.	De	eerste	kennis	-	
making	met	de	Keel-,	Neus-	en	Oorheelkunde	volgde	tijdens	het	reguliere	coschap	in	
het	Maastricht	 UMC+.	 Na	 buitenlandse	 ervaringen	 tijdens	 coschappen	 in	 Pretoria	
(Zuid-Afrika)	en	Brussel	(België),	volgde	een	keuzecoschap	KNO	in	het	Atrium	Medisch	
Centrum te Heerlen. Hier werd ook een start gemaakt met wetenschappelijk onder - 
zoek, wat leidde tot een wetenschappelijke stage bij de afdelingen Moleculaire 
Celbiologie en KNO in het Maastricht UMC+. Na het afronden van de laatste stage als 




begon hij in augustus 2013 met de opleiding tot KNO-arts. Het tweede jaar van de 
opleiding werd in het VieCuri Medisch Centrum te Venlo doorlopen. Op het moment 
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